<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia - Fabes, J - 2018 | Cochrane Library</title> <meta content="Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia - Fabes, J - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010649.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia - Fabes, J - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010649.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010649.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia" name="citation_title"/> <meta content="Jez Fabes" name="citation_author"/> <meta content="John Radcliffe Hospital" name="citation_author_institution"/> <meta content="Susan J Brunskill" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="susan.brunskill@nhsbt.nhs.uk" name="citation_author_email"/> <meta content="Nicola Curry" name="citation_author"/> <meta content="Churchill Hospital" name="citation_author_institution"/> <meta content="Carolyn Doree" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Simon J Stanworth" name="citation_author"/> <meta content="Oxford University Hospitals NHS Foundation Trust and University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010649.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/12/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010649.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010649.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010649.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Blood Coagulation Factors [*therapeutic use]; Cause of Death; Factor XIII [*therapeutic use]; Fibrinogen [*therapeutic use]; Hemorrhage [mortality, prevention &amp; control, *therapy]; Hemostatics [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010649.pub2&amp;doi=10.1002/14651858.CD010649.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="PMzGcYGP";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010649\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010649\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pl","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010649.pub2",title:"Pro\\u2010coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia",firstPublishedDate:"Dec 24, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010649.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010649.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010649.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010649.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010649.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010649.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010649.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010649.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010649.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010649.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7889 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010649.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0176"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-sec-0162"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/appendices#CD010649-sec-0181"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/table_n/CD010649StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/table_n/CD010649StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#CD010649-cr-0002">Jez Fabes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#CD010649-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Susan J Brunskill</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#CD010649-cr-0004">Nicola Curry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#CD010649-cr-0005">Carolyn Doree</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information#CD010649-cr-0006">Simon J Stanworth</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information/en#CD010649-sec-0184">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 December 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010649.pub2">https://doi.org/10.1002/14651858.CD010649.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010649-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010649-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010649-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010649-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010649-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010649-abs-0001" lang="en"> <section id="CD010649-sec-0001"> <h3 class="title" id="CD010649-sec-0001">Background</h3> <p>Some hospital patients may be at risk of or may present with major bleeding. Abnormalities of clotting (coagulation) are often recorded in these people, and the traditional management has been with transfusions of blood components, either to prevent bleeding (prophylactic) or to treat bleeding (therapeutic). There is growing interest in the use of targeted therapies with specific pro‐coagulant haemostatic (causing bleeding to stop and to keep blood within a damaged blood vessel) factor concentrates in place of plasma. </p> </section> <section id="CD010649-sec-0002"> <h3 class="title" id="CD010649-sec-0002">Objectives</h3> <p>To assess the effects and safety of pro‐coagulant haemostatic factors and factor concentrates in the prevention and treatment of bleeding in people without haemophilia. </p> </section> <section id="CD010649-sec-0003"> <h3 class="title" id="CD010649-sec-0003">Search methods</h3> <p>We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (2018, issue 3), MEDLINE (from 1948), Embase (from 1974), CINAHL (from 1938), PubMed (publications in process to 18 April 2018), PROSPERO, Transfusion Evidence Library (from 1950), LILACS (from 1980), IndMED (from 1985), KoreaMed (from 1934), Web of Science Conference Proceedings Citation Index (from 1990) and ongoing trial databases to 18 April 2018. </p> </section> <section id="CD010649-sec-0004"> <h3 class="title" id="CD010649-sec-0004">Selection criteria</h3> <p>We included RCTs that compared intravenous administration of a pro‐coagulant haemostatic factor concentrate, either with placebo, current best or standard treatment, or another pro‐coagulant haemostatic factor concentrate for prevention or treatment of bleeding. There was no restriction on the types of participants. We excluded studies of desmopressin, tranexamic acid and aminocaproic acid and use of pro‐coagulant haemostatic factors for vitamin K over‐anticoagulation. </p> </section> <section id="CD010649-sec-0005"> <h3 class="title" id="CD010649-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodological procedures.</p> </section> <section id="CD010649-sec-0006"> <h3 class="title" id="CD010649-sec-0006">Main results</h3> <p>We identified 31 RCTs with 2392 participants and 22 ongoing trials. There were 13 therapeutic RCTs that randomised 1057 participants (range from 20 to 249 participants) and 18 prophylactic trials that randomised 1335 participants (range 20 to 479 participants). The pro‐coagulant haemostatic factor concentrate was fibrinogen in 23 trials, Factor XIII in seven trials and pro‐thrombin complex concentrates (PCC) in one trial. </p> <p>Seventeen trials had industrial funding or support, eight studies either did not declare their funding or were unclear about their source of funding and six studies declared non‐industrial funding sources. </p> <p>Certainty in the evidence and included study bias </p> <p>Our certainty in the evidence, using GRADE criteria, ranged from very low to high across all outcomes. We assessed most outcomes as being of low certainty. Risks of bias were a concern in many of the RCTs; randomisation methodology was unclear in 15 RCTs, with allocation concealment unclear in 14 RCTs and at high risk of bias in five RCTs. The blinding status of outcome assessors was unclear in 13 RCTs and at high risk of bias in five RCTs, although most outcomes in these trials were objective and not prone to observer bias. Study personnel were often unblinded or insufficient information was available to assess their level of blinding (five RCTs were at unclear risk and seven at high risk of bias). </p> <p>Primary outcomes </p> <p>All‐cause mortality was reported by 21 RCTs, arterial thromboembolic events by 22 RCTs, and venous thromboembolic events by 21 RCTs. </p> <p><i>Fibrinogen concentrate: prophylactic trials with inactive comparator (nine RCTs)</i> </p> <p>The trials had heterogeneous clinical settings and outcome time points, so we did not pool the data. Compared to placebo, there was no evidence that prophylactic fibrinogen concentrate reduced all‐cause mortality (4 RCTs; 248 participants). Compared to inactive comparators there was low‐ to moderate‐quality evidence that prophylactic fibrinogen concentrate did not increase the risk of arterial or venous thromboembolic complications (7 RCTs; 398 participants). </p> <p><i>Fibrinogen concentrate: prophylactic trials with active comparator (two RCTs)</i> </p> <p>There was no mortality or incidence of thromboembolic events in these two RCTs (with 57 participants). </p> <p><i>Fibrinogen concentrate: therapeutic trials with inactive comparator (eight RCTs)</i> </p> <p>The trials had heterogeneous surgical settings and outcome time points, so we pooled data for subgroups only. Compared to an inactive comparator, there was no evidence (quality ranging from low to high) that fibrinogen concentrate reduced all‐cause mortality in actively bleeding participants (7 RCTs; 724 participants). Compared to inactive comparators there was no evidence that the use of fibrinogen concentrate in active bleeding increased arterial (7 RCTs; 607 participants) or venous (6 RCTs; 562 participants) thromboembolic events. </p> <p><i>Fibrinogen concentrate: therapeutic trials with active comparator (four RCTs)</i> </p> <p>We did not pool the outcome data, as they were not measured at comparable time points. Compared to other active pro‐coagulant agents, there was no evidence (very low to moderate quality) that fibrinogen concentrate reduced all‐cause mortality in actively bleeding participants (4 RCTs; 220 participants). There was no evidence that fibrinogen concentrate increased the risk of arterial (3 RCTs; 126 participants) or venous (4 RCTs; 220 participants) thromboembolic events. </p> <p>Factor<i>XIII: Prophylactic trials with inactive comparator (six trials)</i> </p> <p>The trials were heterogeneous in their surgical settings and time points for outcome analysis, so we pooled data for subgroups only. Compared to an inactive comparator, there was no evidence that prophylactic Factor XIII reduced all‐cause mortality (5 RCTs; 414 participants). There was no evidence (very low to low quality) of a difference in the arterial or venous event rate between Factor XIII and inactive comparators (4 trials; 354 participants). </p> <p>Factor<i>XIII: therapeutic trials with inactive comparator (one trial)</i> </p> <p>There was no mortality or incidence of thromboembolic events in this trial.</p> <p><i>Prothrombin complex concentrate</i> (<i>PCC</i> )<i>: prophylactic trials with inactive comparator (one trial)</i> </p> <p>There was no evidence (moderate quality) that PCC reduced all‐cause mortality (1 trial; 78 participants). No thromboembolic complications were reported in this trial. </p> </section> <section id="CD010649-sec-0007"> <h3 class="title" id="CD010649-sec-0007">Authors' conclusions</h3> <p>The paucity of good‐quality comparable evidence precludes the drawing of conclusions for clinical practice. Further research is required to determine the risk‐to‐benefit ratio of these interventions. The sample sizes of future RCTs would need to be greatly increased to detect a reduction in mortality or thromboembolic events between treatment arms. To improve consistency in outcome reporting, the development of core outcome sets is essential and may help address a number of the limitations identified in this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010649-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010649-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010649-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010649-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010649-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010649-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010649-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010649-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010649-abs-0004" lang="en"> <h3>The effectiveness of drugs to help blood clot in the prevention and treatment of bleeding in people without haemophilia </h3> <p><b>Review question</b> </p> <p>Do medicines that help in the prevention and treatment of bleeding reduce the risk of death, the risk of experiencing a blood clot and reduce the amount of blood lost in people who do not suffer from haemophilia (a bleeding disorder), who are bleeding, or at risk of bleeding? </p> <p><b>Background</b> </p> <p>Coagulopathy, defined as a failure of normal blood clotting, is common in severe illness, trauma and major surgery. This can make bleeding worse and may cause death. Medicines are available that are blood clotting factors that can be given into the vein to treat coagulopathy and bleeding. However, we lack enough information about how effective and safe they are. </p> <p>This review combines all the data available on these medicines to assess their effectiveness and safety. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature up to 18 April 2018 for randomised controlled trials (RCTs), as these provide the most reliable evidence. We identified 31 relevant RCTs that contained results from 2392 participants and compared these medicines either against placebo (inactive treatment) or another medicine or blood product. The RCTs focused on three types of factors that may improve blood clotting: fibrinogen (a clotting factor that increases clot strength), clotting factor XIII (important for holding clots together) and prothrombin complex concentrate (a combination of four precursor clotting factors). </p> <p>The trials either gave these medicines before bleeding occurred (prophylactically) or to treat existing bleeding (therapeutically). Most trials focused on surgery, especially heart surgery, trauma, and bleeding after childbirth. </p> <p>Seventeen of the RCTs we identified had industrial support, eight had unclear funding sources and six declared non‐industrial funding. </p> <p><b>Key results</b> </p> <p>No medicine had any effect on the risk of dying, regardless of clinical setting or how the medicine was used. However, our certainty in the results is low and this finding may change in the future when new studies are published. </p> <p>No medicine increased the risk of harmful clots in the veins or arteries, but our certainty in these findings is low. </p> <p>Prophylactic fibrinogen reduced bleeding after heart and orthopaedic surgery compared to placebo. Prophylactic fibrinogen, compared to placebo, almost halved the need for blood transfusion following heart surgery, and reduced the need by three‐quarters in other surgery. Fibrinogen reduced the need for blood transfusion when used to treat bleeding. </p> <p>Prophylactic factor XIII reduced bleeding after heart surgery.</p> <p>Sample sizes in future randomised trials need to be greatly increased in order to show any differences in overall survival and death due to bleeding. </p> <p><b>Certainty of the evidence</b> </p> <p>Our certainty in the evidence is low, but future research may change the findings of this review. </p> <p><b>Conclusion</b> </p> <p>The low certainty of the evidence makes it difficult to draw conclusions about how well these medicines work and whether they should be used in current health care. Further research is required in larger‐scale RCTs to determine the benefit and costs of these treatments and whether this outweighs their risks. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010649-sec-0176" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010649-sec-0176"></div> <h3 class="title" id="CD010649-sec-0177">Implications for practice</h3> <section id="CD010649-sec-0177"> <p>The inadequate quality of evidence in most of the studies included in this review means that we cannot draw conclusions for clinical practice or the use of these interventions outside controlled trials. Further research is required in larger‐scale randomised controlled trials to determine the risk‐to‐benefit ratio of these interventions. We anticipate that data from the identified ongoing trials, some of which are larger studies, will provide much higher‐quality evidence around clinical outcomes and efficacy. </p> <p>At present we lack a clear picture of the cost effectiveness of these interventions, due to a lack of health economic data. It is likely that many pro‐haemostatic agents are more costly than blood components, including plasma. Most studies co‐administer the pro‐coagulant agents with a broad range of other haemostatic interventions as part of the clinical setting or routine management of haemorrhage. Additionally, the progression towards viscoelastic testing and algorithmic clotting factor approaches to transfusion means that these agents are often administered in combination. However, at present we lack the data required to assess how these interventions interact or work together. </p> </section> <h3 class="title" id="CD010649-sec-0178">Implications for research</h3> <section id="CD010649-sec-0178"> <p>The main implication for this review is to direct the need for further research. Whilst at one level the numbers of trials represents a body of data to inform clinical practice, the limitations preclude the drawing of robust conclusions without additional studies. There is considerable current clinical interest in the use of these agents (we identified 22 ongoing trials), which is likely to expand in the coming years. Sample sizes in future randomised trials powered for clinical outcomes of mortality (or even preferably mortality due to bleeding) would need to be greatly increased. Analogous examples for power calculations would be CRASH‐2 (<a href="./references#CD010649-bbs2-0077" title="CRASH‐2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial. Lancet2010;376:23‐32. [DOI: 10.1016/S0140‐6736(10)60835‐5] ">CRASH‐2 2010</a>), WOMAN (<a href="./references#CD010649-bbs2-0104" title="WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised, double‐blind, placebo‐controlled trial. Lancet 389;10084:2105‐16. [DOI: 10.1016/S0140‐6736(17)30638‐4] ">WOMAN 2017</a>) and HALT IT (<a href="./references#CD010649-bbs2-0073" title="BrennerA , ArribasM , CuzickJ , JairathV , StanworthS , KerK , et al. Outcome measures in clinical trials of treatments for acute severe haemorrhage. Trials2018;19(1):533‐9. ">Brenner 2018</a>; <a href="./references#CD010649-bbs2-0093" title="RobertsI , CoatsT , EdwardsP , GilmoreI , JairathV , KerK , et al. HALT‐IT ‐ tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. Trials2014;15:450‐63. ">Roberts 2014</a>), which recruited between 15,000 and 20,000 participants each. </p> <p>To improve consistency in outcome reporting, the use of core outcome sets (COS) are increasingly advocated by both the CONSORT and SPIRIT statements (<a href="./references#CD010649-bbs2-0091" title="MoherD , HopewellS , SchulzKF , MontoriV , GotzschePC , DevereauxPJ , et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c869. ">Moher 2010</a>; <a href="./references#CD010649-bbs2-0075" title="ChanAW , TetzlaffJM , GøtzschePC , AltmanDG , MannH , BerlinJA , et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;8(346):e7586. ">Chan 2013</a>), and may help address a number of the limitations in reporting identified in this review. A COS is defined as a “minimum (number of outcomes) that should be measured and reported in all clinical trials of a specific condition” (<a href="./references#CD010649-bbs2-0081" title="GargonE , WilliamsonPR , YoungB . Improving core outcome set development: qualitative interviews with developers provided pointers to inform guidance. Journal of Clinical Epidemiology2017;86:140‐52. ">Gargon 2017</a>). The Core Outcome Measures in Effectiveness Trials (COMET) database has assisted in driving international collaboration amongst clinical researchers across a plethora of clinical conditions, such as critical care and rheumatological diseases, and it may be timely to look at this methodology for outcomes of bleeding. In particular, consideration of how to combine clinically meaningful endpoints (such as achievement of haemostasis) with reliable laboratory data must be a focus for future studies, in order to improve the quality of the available evidence for laboratory thresholds to guide clinicians about when to administer haemostatic therapy. Future updates of this review may need to be split by interventions used as treatment versus prophylaxis. </p> <p>Researchers may also consider the lessons from previous research in the management of coagulopathy and bleeding. Firstly, the extensive trial programmes undertaken to evaluate recombinant factor VIIa consisted initially of poor‐quality studies with small participant numbers in a heterogeneous range of clinical settings which demonstrated variable degrees of clinical efficacy that overestimated the benefit while concealing the underlying harm. It is essential that this process is not repeated. Secondly, there were two large studies of tranexamic acid (TXA) that demonstrated a positive impact on death from bleeding. CRASH‐2 was a study of just over 20,000 participants that showed that the administration of TXA reduced overall mortality and death from bleeding at a statistically significant level (<a href="./references#CD010649-bbs2-0077" title="CRASH‐2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial. Lancet2010;376:23‐32. [DOI: 10.1016/S0140‐6736(10)60835‐5] ">CRASH‐2 2010</a>). Subsequent analysis of the data, in combination with data from over 20,000 participants in the WOMAN study of TXA in postpartum haemorrhage (<a href="./references#CD010649-bbs2-0104" title="WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised, double‐blind, placebo‐controlled trial. Lancet 389;10084:2105‐16. [DOI: 10.1016/S0140‐6736(17)30638‐4] ">WOMAN 2017</a>), found that administration of an early dose of TXA improved outcomes. The multicentre and multi‐national design, the pragmatic approach and large participant numbers of these studies permitted statistically robust and clinically useful conclusions to be drawn about practice in a real‐world setting. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010649-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010649-sec-0022"></div> <div class="table" id="CD010649-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FIBRINOGEN: Therapeutic trials: intervention compared to inactive Control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Therapeutic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN in therapeutic trials<br/> <b>Comparison:</b> Inactive control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactive control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fibrinogen in therapeutic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 28 days following admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/> (0.71 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>97<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000<br/> (130 to 549) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>In‐hospital mortality up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/> (0.25 to 102.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 6 weeks post‐natally</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>294<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 46 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/> (0.05 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>213<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (4 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level as neither study was designed to measure mortality.<br/> <sup>b</sup>We downgraded by one level, due to low event rate. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010649-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN in therapeutic trials<br/> <b>Comparison:</b> Haemostatically active control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haemostatically active control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FIBRINOGEN in therapeutic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 7 days post‐operatively or hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 28 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.06 to 14.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (3 to 681) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.20<br/> (0.45 to 10.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/> (20 to 490) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level due to low event rate.<br/> <sup>b</sup>We downgraded by one level due to concerns about risks of bias both in the way that allocation of treatment was concealed at randomisation and whether blinding to treatment could be maintained for the duration of the trial in this "open‐label trial where adequacy of surgical field haemostasis reported as a subjective outcome".<br/> <sup>c</sup>We downgraded by one level as the study did not measure mortality as an outcome.<br/> <sup>d</sup>We downgraded by one level due to concerns about risks of bias in how blinding to treatment intervention could be maintained for the duration of the trial in this "open‐label trial where adequacy of surgical field haemostasis reported as a subjective outcome", and the non‐reporting of all outcomes that the investigators said they would measure (selective outcome reporting). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010649-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN: prophylactic trials<br/> <b>Comparison:</b> inactive control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactive control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FIBRINOGEN in prophylactic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events in one trial</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thrombotic events</p> <p>Up to 4 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thrombotic events</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 8.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 138) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thrombotic events ‐ up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thrombotic events</p> <p>Up to 4 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level due to low event rate.<br/> <sup>b</sup>We downgraded by one level due to concerns about risks of bias in the non‐reporting of all outcomes that the investigators said they would measure (selective outcome reporting).<br/> <sup>c</sup>We downgraded by one level due to concerns about risks of bias in the way that allocation of the treatment was concealed at the time of randomisation. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010649-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN: prophylactic trials<br/> <b>Comparison:</b> Haemostatically active control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haemostatically active control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FIBRINOGEN in prophylactic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events ‐ Duration of hospital stay (whole population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events Duration of hospital stay (whole population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level as the thromboembolic events (arterial or venous) in these participants given fibrinogen prophylactically were not an outcome of interest.<br/> <sup>b</sup>We downgraded by one level due to the small number of participants available for this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010649-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FXIII: prophylactic trials<br/> <b>Comparison:</b> inactive control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactive control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FXIII in prophylactic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> <p>Up to 5 to 7 weeks post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/> (0.28 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>282<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (23 to 131) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.14 to 66.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> <p>Post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/> (0.01 to 3.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (1 to 318) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events ‐ Up to 5 to 7 weeks post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.06 to 14.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>282<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (0 to 108) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events<br/> Up to 30 days post‐operatively </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.14 to 66.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events</p> <p>Post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level due to concerns about attrition, reporting and selection bias across these trials.<br/> <sup>b</sup>We downgraded by one level as thromboembolic events (arterial or venous) in these participants given factor XIII prophylactically were not an outcome of interest.<br/> <sup>c</sup>We downgraded by one level due to low event rates.<br/> <sup>d</sup>We downgraded by one level due to risks of bias concerns in how concealment of treatment intervention was attempted (unsealed envelopes in the patients notes) and the subsequent impact this had on the level of blinding to treatment intervention that could be maintained for the duration of the trial. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010649-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010649-sec-0023"></div> <p>A term which we use frequently throughout this review is 'haemostatic'. Haemostatic means to cause bleeding to stop, keeping blood within a damaged blood vessel or tissue. </p> <section id="CD010649-sec-0024"> <h3 class="title" id="CD010649-sec-0024">Description of the condition</h3> <p>Coagulopathy (a dysfunctional clotting response) is common in critically‐ill people, both in those with and without bleeding, because of the nature of their illness. Coagulopathy is typically defined by abnormalities of standard coagulation tests performed in haematology laboratories, most commonly defined by prolongation of the prothrombin time or the activated partial thromboplastin time. These are in vitro tests of the time taken for a plasma sample to start to form a fibrin clot. Notably, the prothrombin time or the activated partial thromboplastin time or both are poor predictors of bleeding and there are no clear definitions of a threshold that defines a clinically significant prolongation of either test (<a href="./references#CD010649-bbs2-0100" title="TripodiA , ChantarangkulV , MannucciPM . Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. British Journal of Haematology2009;147(1):77‐82. [PUBMED: 19659548] ">Tripodi 2009</a>). </p> <p>In a recent, multi‐centre, prospective, observational trial in adult critical care, which evaluated just under 2000 intensive‐treatment‐unit (ITU) admissions, one‐third of patients without active bleeding were shown to develop coagulopathy during their ITU admission (<a href="./references#CD010649-bbs2-0102" title="WalshCE , ValentinoLA . Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia2009;15(5):1014‐21. [PUBMED: 19493018] ">Walsh 2009</a>). </p> <p>The most common current treatment for people with coagulopathy remains the transfusion of plasma. Plasma is the liquid component of blood in which different cellular elements and macromolecules are suspended. Plasma contains pro‐coagulant haemostatic proteins which are a key component of the haemostatic system. These pro‐coagulant haemostatic proteins, known as blood clotting factors, interact with each other, with platelets and tissues to form stable blood clots. Around one‐third of people with coagulopathy received transfusions of plasma (termed fresh frozen plasma (FFP) in the UK), with around half of all FFP transfusions given to reduce a perceived risk of bleeding or prior to invasive procedures (<a href="./references#CD010649-bbs2-0099" title="StanworthSJ , Grant‐CaseyJ , LoweD , LaffanM , NewH , MurphyMF , et al. The use of fresh‐frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion2011;51(1):62‐70. [PUBMED: 20804532] ">Stanworth 2011</a>; <a href="./references#CD010649-bbs2-0102" title="WalshCE , ValentinoLA . Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia2009;15(5):1014‐21. [PUBMED: 19493018] ">Walsh 2009</a>). </p> <p>However, there is uncertainty around the effectiveness of plasma transfusion in clinical practice, and the risk‐benefit profile of FFP remains unknown (<a href="./references#CD010649-bbs2-0105" title="YangL , StanworthS , HopewellS , DoreeC , MurphyM . Is fresh‐frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion2012;52(8):1673‐86. [PUBMED: 22257164] ">Yang 2012</a>). The recognised risks associated with its use include fluid overload, transfusion‐related acute lung injury, along with the generic risks associated with transfusion of allogeneic blood products (<a href="./references#CD010649-bbs2-0096" title="Serious Hazards of Transfusion(SHOT) . Annual SHOT Report 2011. http://www.shotuk.org/shot‐reports/shot‐annual‐report‐summary‐2011 (accessed 1/4/2013). ">SHOT 2011</a>). A national audit of 5000 FFP transfusion episodes to consecutive patients from 196 hospitals across England indicated little efficacy for plasma transfusion, with very small median change in duration of prothrombin time following FFP transfusion (<a href="./references#CD010649-bbs2-0098" title="StanworthSJ , MorrisTP , GaarderC , GoslingsJC , MaegeleM , CohenMJ , et al. Reappraising the concept of massive transfusion in trauma. Critical Care (London, England)2010;14(6):R239. [PUBMED: 21192812] ">Stanworth 2010</a>). </p> </section> <section id="CD010649-sec-0025"> <h3 class="title" id="CD010649-sec-0025">Description of the intervention</h3> <p>Given concerns about the effectiveness of plasma transfusion, there is increasing interest in the targeted use of specific or purified intravenous pro‐coagulant haemostatic factors. Many different intravenous pro‐coagulant haemostatic factors exist, including those derived from plasma as concentrates, or those developed as specific recombinant factors. The advantages of plasma‐derived coagulation factor concentrates include greater standardisation (whether at the stage of production or during manufacture) and reduced infective and compatibility complications when compared with blood transfusions through the application of techniques such as pasteurisation, nanofiltration and adsorption to remove viruses. The advantages of recombinant‐derived factors include potentially unlimited supply, with reduced reliance on the availability of blood donors, as well as negligible infective risk. Finally, both recombinant and plasma‐derived intravenous concentrates offer the potential advantage of providing specific pro‐coagulant haemostatic factors more rapidly and at higher concentrations than is possible with the use of traditional plasma transfusion. </p> <p>Some of the plasma‐derived coagulation factor concentrates contain multiple pro‐coagulant haemostatic factors. Prothrombin complex concentrates are plasma‐derived coagulation factor concentrates that contain three or four (vitamin K‐dependent) factors at high concentration. </p> <p>Two observational cohort studies have examined the use of prothrombin complex concentrates as an adjunct to fibrinogen concentrate in the management of bleeding following trauma. Whilst neither of these studies demonstrated reduced mortality in those receiving prothrombin complex concentrates, one of the studies demonstrated an association between receiving prothrombin complex concentrates and a reduced transfusion requirement (<a href="./references#CD010649-bbs2-0083" title="GörlingerK , DirkmannD , HankeAA , KamlerM , KottenbergE , ThielmannM , et al. First‐line therapy with coagulation factor concentrates combined with point‐of‐care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single‐center cohort study. Anesthesiology2011;115(6):1179‐91. ">Görlinger 2011</a>). Safety data on the use of prothrombin complex concentrates are limited. In particular, rates of thrombosis, both arterial and venous, and disseminated intravascular coagulation need to be fully assessed (<a href="./references#CD010649-bbs2-0082" title="GrottkeO , BraunschweigT , SpronkHM , EschS , RiegAD , vanOerleR , et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood2011;118(7):1943‐51. [PUBMED: 21670472] ">Grottke 2011</a>). </p> <p>In contrast to concentrates containing multiple factors, single pro‐coagulant haemostatic factors allow the treatment of individual clotting factor deficiencies to be specifically targeted. A specific concentrate of the key pro‐coagulant haemostatic factor fibrinogen (or factor I) is available, although currently only licensed for use in many countries for people with inherited disorders of fibrinogen. The observation that normal‐to‐high levels of fibrinogen (in the range 1.5 to 4.0 g/L) prior to the onset of major obstetric haemorrhage are associated with improved outcomes (<a href="./references#CD010649-bbs2-0076" title="CharbitB , MandelbrotL , SamainE , BaronG , HaddaouiB , KeitaH , et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. Journal of Thrombosis and Haemostasis2007;5(2):266‐73. [PUBMED: 17087729] ">Charbit 2007</a>; <a href="./references#CD010649-bbs2-0078" title="deLloydL , BovingtonR , KayeA , CollisRE , RaymentR , SandersJ , et al. Standard haemostatic tests following major obstetric haemorrhage. International Journal of Obstetric Anesthesia2011;20(2):135‐41. [PUBMED: 21439811] ">de Lloyd 2011</a>), has led clinicians to consider targeted therapy with concentrates of fibrinogen in this cohort of women, rather than the more traditional use of FFP. </p> </section> <section id="CD010649-sec-0026"> <h3 class="title" id="CD010649-sec-0026">How the intervention might work</h3> <p>Specific coagulation factor concentrates are presumed to stop or prevent bleeding by providing a source of pro‐coagulant haemostatic factor(s) which, alongside contributions from platelets and the endothelium, interact to produce a stronger fibrin clot. The rationale for their use is based on either restoring or increasing levels of pro‐coagulant haemostatic factors, or activating clotting systems by infusing recombinant activated complexes to initiate coagulation. </p> <p>It is hypothesised that pro‐coagulant haemostatic factors administered intravenously might work more effectively than plasma (either FFP or cryoprecipitate) to deliver a more concentrated source of factors which will raise factor levels more effectively and predictably using a standardised product. Given that the current processes for thawing plasma would not apply to pro‐coagulant haemostatic factors, it is also likely that these agents would be more rapidly available for use in emergency situations. </p> <p>However, as for all pro‐coagulant haemostatic agents, adverse events are recognised. In particular, use of these agents might be expected to be associated with a greater rate of thromboembolic events. This has been clearly demonstrated in meta‐analyses of RCTs of recombinant factor VIIa in people without haemophilia (<a href="./references#CD010649-bbs2-0089" title="LeviM , LevyJH , AndersenHF , TruloffD . Safety of recombinant activated factor VII in randomized clinical trials. New England Journal of Medicine2010;363(19):1791‐800. [PUBMED: 21047223] ">Levi 2010</a>; <a href="./references#CD010649-bbs2-0097" title="SimpsonE , LinY , StanworthS , BirchallJ , DoreeC , HydeC . Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD005011.pub4; PUBMED: 21328270] ">Simpson 2012</a>). </p> </section> <section id="CD010649-sec-0027"> <h3 class="title" id="CD010649-sec-0027">Why it is important to do this review</h3> <p>In a short period there has been a rapid shift in the clinician's approach to the management of coagulopathy and bleeding, with increasing interest in the use of specific intravenous pro‐coagulant haemostatic factors instead of the current standard plasma transfusion. Because of the real uncertainties about the effectiveness and safety of FFP, wider use of the pro‐coagulant haemostatic factors and evaluation in clinical trials are anticipated, not least to understand their benefits given their increased cost in comparison to plasma transfusion. There is increasing understanding of the complex changes that occur in people with acquired major bleeding, particularly after trauma and parturition, and it is clear that many clotting factor levels change during active bleeding. </p> <p>This review explores both the use of single clotting factor concentrate therapy (at the time of publication these were fibrinogen, factor XIII and a prothrombin complex concentrate composite) but we also anticipate that clotting factor concentrates will be evaluated in combination to treat the complexity of clotting changes that occurs in major haemorrhage. Lessons should also be learned from the story of rFVIIa, which was 'marketed' as a universal haemostatic agent in people without haemophilia but was then found, as new randomised trials were published, to have uncertain benefit with harm (increased arterial thromboembolic events; <a href="./references#CD010649-bbs2-0089" title="LeviM , LevyJH , AndersenHF , TruloffD . Safety of recombinant activated factor VII in randomized clinical trials. New England Journal of Medicine2010;363(19):1791‐800. [PUBMED: 21047223] ">Levi 2010</a>; <a href="./references#CD010649-bbs2-0097" title="SimpsonE , LinY , StanworthS , BirchallJ , DoreeC , HydeC . Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD005011.pub4; PUBMED: 21328270] ">Simpson 2012</a>), emphasising the importance of a systematic review to identify and appraise the RCT literature as it evolves. This Cochrane Review builds on the experience gained from the rFVIIa Cochrane Review (<a href="./references#CD010649-bbs2-0097" title="SimpsonE , LinY , StanworthS , BirchallJ , DoreeC , HydeC . Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD005011.pub4; PUBMED: 21328270] ">Simpson 2012</a>), and comprehensively identifies and critically appraises all the RCT evidence assessing the use of intravenous pro‐coagulant haemostatic factors. </p> <p>This systematic review differs from two other 'clotting factor concentrate' Cochrane Reviews (<a href="./references#CD010649-bbs2-0103" title="WikkelsøA , LundeJ , JohansenM , StensballeJ , WetterslevJ , MøllerAM , et al. Fibrinogen concentrate in bleeding patients. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008864] ">Wikkelso 2013</a>; <a href="./references#CD010649-bbs2-0086" title="JohansenM , WikkesoA , LundeJ , WetterslevJ , AfshariA . Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non‐bleeding patients. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010555] ">Johansen 2015</a>). Our review did not assess the use of pro‐coagulant haemostatic factors and factor concentrates for the reversal of vitamin K antagonist treatment in bleeding and non‐bleeding people, which is the focus of <a href="./references#CD010649-bbs2-0086" title="JohansenM , WikkesoA , LundeJ , WetterslevJ , AfshariA . Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non‐bleeding patients. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD010555] ">Johansen 2015</a>. Our review does not include trials where the intervention was recombinant factor VIIa, antifibrinolytic therapy or desmopressin, as is the case in <a href="./references#CD010649-bbs2-0103" title="WikkelsøA , LundeJ , JohansenM , StensballeJ , WetterslevJ , MøllerAM , et al. Fibrinogen concentrate in bleeding patients. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008864] ">Wikkelso 2013</a>. Our review includes trials in which the participant group were neonates, unlike <a href="./references#CD010649-bbs2-0103" title="WikkelsøA , LundeJ , JohansenM , StensballeJ , WetterslevJ , MøllerAM , et al. Fibrinogen concentrate in bleeding patients. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008864] ">Wikkelso 2013</a> which excluded them. </p> <p>This systematic review indicates where high‐quality evidence is lacking, so informing healthcare professionals where more evidence is required before these expensive drugs are widely accepted into clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010649-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010649-sec-0028"></div> <p>To assess the effects and safety of pro‐coagulant haemostatic factors and factor concentrates in the prevention and treatment of bleeding in people without haemophilia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010649-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010649-sec-0029"></div> <section id="CD010649-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010649-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs), regardless of language, date or place of publication. We included open‐label and unblinded studies. </p> </section> <section id="CD010649-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included adults and children (with no age restriction) either at risk of bleeding or already bleeding due to any cause. We excluded people with known inherited bleeding disorders (e.g. haemophilia) unless any data were separately available for the participants without the inherited condition. We excluded studies of healthy volunteers. </p> </section> <section id="CD010649-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We assessed separately whether a pro‐coagulant haemostatic factor concentrate was administered as a treatment or in a prophylactic manner for the following comparisons: </p> <p> <ul id="CD010649-list-0001"> <li> <p>a pro‐coagulant haemostatic factor concentrate (either alone or in combination with another pro‐coagulant haemostatic factor concentrate) versus either placebo or current best/standard treatment (e.g. plasma/FFP). </p> </li> <li> <p>one pro‐coagulant haemostatic factor concentrate (either alone or in combination with another pro‐coagulant haemostatic factor concentrate) versus another different pro‐coagulant haemostatic factor concentrate (either alone or in combination with another pro‐coagulant haemostatic factor concentrate). </p> </li> </ul> </p> <p>Each of the above combinations could be given in any dose and for any duration of treatment. </p> <p>We included RCTs of the administration of prothrombin complex concentrates if used for conditions other than reversal of vitamin K antagonist therapy. </p> <p>We only included studies where pro‐coagulant haemostatic factors were administered intravenously. </p> <p>We excluded:</p> <p> <ul id="CD010649-list-0002"> <li> <p>pro‐coagulant haemostatic factors administered topically, e.g. thrombin or fibrin glue, as they are the subject of a previous Cochrane Review (<a href="./references#CD010649-bbs2-0074" title="CarlessPA , HenryDA , AnthonyDM . Fibrin sealant use for minimising peri‐operative allogeneic blood transfusion. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD004171; PUBMED: 12804501] ">Carless 2009</a>). </p> </li> <li> <p>RCTs of desmopressin, tranexamic acid and aminocaproic acid, due to their different mechanisms of action from other pro‐coagulant haemostatic agents. We also excluded RCTs in which a pro‐coagulant haemostatic agent was used exclusively to reverse warfarin (or a similar agent), but after the review had been started. </p> </li> <li> <p>Studies exclusively administering rFVIIa, as they have been the subject of a previous Cochrane Review (<a href="./references#CD010649-bbs2-0097" title="SimpsonE , LinY , StanworthS , BirchallJ , DoreeC , HydeC . Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD005011.pub4; PUBMED: 21328270] ">Simpson 2012</a>). However, studies in which rFVIIa was a co‐intervention with other intravenous pro‐coagulant haemostatic factors (i.e. in separate comparator arms or co‐administration of rFVIIa and another factor/reagent) were eligible for inclusion. </p> </li> </ul> </p> <p>We are aware that studies of fibrinogen concentrate in bleeding have been the focus of a previous Cochrane Review (<a href="./references#CD010649-bbs2-0103" title="WikkelsøA , LundeJ , JohansenM , StensballeJ , WetterslevJ , MøllerAM , et al. Fibrinogen concentrate in bleeding patients. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008864] ">Wikkelso 2013</a>), but as this is a rapidly expanding field with a significant number of new studies published since the <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> review, and as we have presented the analysis from an alternative perspective, we have included the fibrinogen concentrate studies in this review, </p> </section> <section id="CD010649-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We presented outcome data from all identified RCTs by prophylactic and therapeutic indications for use. In prophylactic use, the agent was given to prevent bleeding which may be anticipated prior to or during a surgical operation; in therapeutic use, the agent was given to treat bleeding which is established and ongoing. </p> <p>There was variation in the time points at which each outcome was measured, due to the nature of the participants and conditions across the trials; we took this into account when reporting and analysing the outcome data for the included trials. Most of the trials reported outcomes acutely postpartum and in the 24 hours following any given intervention or procedure, when compared to baseline measures for outcomes such as blood loss and transfusion requirement. These formed our main time point comparators for these outcomes. In addition,where outcome data were reported for other time points we have also included these data. For mortality, arterial and venous thromboembolic events, bleeding and adverse events, data were presented at different time points in each trial, making it difficult to generate a cohesive picture. </p> <section id="CD010649-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010649-list-0003"> <li> <p>Mortality (all causes) (principal primary outcome for therapeutic intervention usage)</p> </li> <li> <p>The number of participants suffering arterial and/or venous thromboembolic events (principal primary outcome for prophylactic intervention usage) </p> </li> </ul> </p> </section> <section id="CD010649-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010649-list-0004"> <li> <p>Mortality due to bleeding</p> </li> <li> <p>Red blood cell transfusion requirement (both volume of transfusion and the receipt of a transfusion) </p> </li> <li> <p>Blood loss</p> </li> <li> <p>Allergic reaction</p> </li> <li> <p>Change to laboratory measures of coagulation, both standard laboratory tests and global measurements of coagulation (such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM), or thrombin generation) </p> </li> </ul> </p> </section> </section> </section> <section id="CD010649-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>The Systematic Review Initative's Information Specialist (CD) formulated the search strategies used, in collaboration with the Cochrane Injuries Group. </p> <section id="CD010649-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched for RCTs in the following electronic databases between the dates listed below. There were no restrictions by language or publication status. All searches were undertaken on 18 April 2018 and the search strategies for all sources are detailed in <a href="./appendices#CD010649-sec-0182">Appendix 1</a>. </p> <p> <ul id="CD010649-list-0005"> <li> <p>Cochrane Central Register of Controlled Studies (CENTRAL) (the Cochrane Library 2018, Issue 3) on 18 April 2018; </p> </li> <li> <p>MEDLINE (OvidSP, 1948 to 18 April 2018);</p> </li> <li> <p>Embase (OvidSP, 1974 to 18 April 2018);</p> </li> <li> <p>CINAHL (EBSCOHOST, 1938 to 18 April 2018);</p> </li> <li> <p>PubMed, in process and epublications ahead of print only, on 18 April 2018;</p> </li> <li> <p>PROSPERO on 18 April 2018;</p> </li> <li> <p>Transfusion Evidence Library (<a href="http://www.transfusionevidencelibrary.com" target="_blank">www.transfusionevidencelibrary.com</a>, 1950 to 18 April 2018); </p> </li> <li> <p>LILACS (from 1980 to 18 April 2018);</p> </li> <li> <p>IndMed (from 1985 to 18 April 2018);</p> </li> <li> <p>KoreaMed (from 1934 to 18 April 2018);</p> </li> <li> <p>Web of Science Conference Proceedings Citation Index ‐ Science (CPCI‐S, from 1990 to 18 April 2018). </p> </li> </ul> </p> <p>We also searched for ongoing trials in the following databases. We undertook all searches on 18 April 2018 and the search strategies are detailed in <a href="./appendices#CD010649-sec-0182">Appendix 1</a>. </p> <p> <ul id="CD010649-list-0006"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>EU Clinical Trials Register (EUDRACT, <a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP, <a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>) </p> </li> <li> <p>ISRCTN Register (<a href="https://www.isrctn.com/" target="_blank">www.isrctn.com/</a>) </p> </li> </ul> </p> <p>We combined searches in MEDLINE, Embase and CINAHL with adaptations of the Cochrane RCT search filter, as detailed in Chapter 6 of the<i>Cochrane Handbook for Systematic Reviews of interventions</i> (<a href="./references#CD010649-bbs2-0085" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD010649-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We augmented database searching by:</p> <p> <ul id="CD010649-list-0007"> <li> <p>Handsearching of reference lists; we checked references of all identified trials and relevant review articles for further literature. We limited these searches to 'first generation' reference lists; </p> </li> <li> <p>Personal contacts; we contacted authors of relevant trials, trial groups and experts worldwide who are known to be active in the field for unpublished material or further information on ongoing trials. </p> </li> </ul> </p> </section> </section> <section id="CD010649-sec-0040"> <h3 class="title" id="CD010649-sec-0040">Data collection and analysis</h3> <section id="CD010649-sec-0041"> <h4 class="title">Selection of studies</h4> <p>One author (CD) initially screened all search results for relevance against the eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, three review authors (JF, NC, YL) independently screened all the remaining results (titles, abstracts and full text) for relevance against the full eligibility criteria. We retrieved full‐text papers for all references for which a decision of eligibility was not made from the title and abstract alone. We resolved differences of opinion through discussion and consensus, where necessary, with recourse to a fourth review author (SB). Trials that did not meet our eligibility criteria are detailed in the <a href="./references#CD010649-sec-0191" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD010649-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Five review authors (JF, NC, SB, YL, GS) independently extracted data onto standardised forms. Two of the review authors (JF, GS) piloted these forms on two included RCTs and made changes that were agreed upon as needed. Throughout the data extraction process, we resolved disagreements by consensus, with recourse to a third review author (SS) as needed. The review authors were not blinded to the names of study authors, institutions, journals or the outcomes of the trials. We extracted data on the setting of the trial, the methods and statistical assumptions made, the characteristics of participants and interventions and details of the outcomes measured and the timing of the outcome assessments. </p> <p>Where studies describe red blood cell transfusion in units (<a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>), we converted these to millilitres to permit comparison with other studies reporting millilitres of red blood cells transfused. We have used a conversion ratio of one unit of red blood cells equivalent to 300 millilitres. </p> </section> <section id="CD010649-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (JF, SB, NC) independently assessed all included trials for possible risks of bias, as described in Chapter 8 of the <i>Cochrane Handbook</i> (<a href="./references#CD010649-bbs2-0085" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We classified trials as being at low, high or unclear risk of bias. To assess risks of bias, the authors included the following questions in the 'Risk of bias' table for each included trial. </p> <p> <ul id="CD010649-list-0008"> <li> <p>Was the allocation sequence adequately generated?</p> </li> <li> <p>Was allocation adequately concealed?</p> </li> <li> <p>Was knowledge of the allocated intervention adequately prevented (i.e. blinded) throughout the trial for participants, trial personnel and outcome assessors? </p> </li> <li> <p>Were incomplete outcome data adequately addressed for the main outcome?</p> </li> <li> <p>Are reports of the trial free of selective outcome reporting?</p> </li> <li> <p>Was the trial apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> <p>We anticipated that knowledge of the allocated intervention would be difficult to blind from clinicians and participants. However we felt that it would be possible to blind knowledge of the allocated intervention from outcome assessors. We bore these considerations in mind when making an assessment of the risk of bias for the adequacy of blinding of participants, trial personnel and outcome assessors. </p> </section> <section id="CD010649-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We present dichotomous outcomes as relative risks (RRs) with 95% confidence intervals (CIs). We present continuous outcomes as mean differences (MDs) with 95% confidence intervals. Where data are not presented in this way, but we were able to make adjustments from the data given, we did this for the following studies: </p> <p> <ul id="CD010649-list-0009"> <li> <p><a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; we present the data in tabular form without quoting numeric values. We extracted these data quantitatively using digital measurement of the relevant table data and axes. </p> </li> </ul> </p> <p>A number of studies reported outcome data for blood loss and transfusion requirement using median values with interquartile ranges (IQRs) (12 and 17 studies, respectively); we have commented on these values in the text and tabulated them in <a href="#CD010649-tbl-0006">Table 1</a> and <a href="#CD010649-tbl-0007">Table 2</a>. </p> <div class="table" id="CD010649-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Red blood cell transfusion requirement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>intervention / comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Transfusion Protocol?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>When was transfusion requirement measured</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>How were findings reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Findings: Intervention/ Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Cui-2010" target="_blank">Cui 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>17/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During ICU stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 0)/0 (0 ‐ 1.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) total red blood cell usage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1.5)/1.5 (0 ‐ 2.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Fenger-Erikson-2009" target="_blank">Fenger Erikson 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Surgery (E): radical cystectomy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0 ‐ 5) /</p> <p>2.5 (0 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 2)/1.5 (0 ‐ 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total transfused</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 (0 ‐ 5)/4.0 (0 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within 48 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) patients requiring a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (20%)/8 (80%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Karlsson-2011" target="_blank">Karlsson 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within 12 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 (0.13)/0.7 (0.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Najafi-2014" target="_blank">Najafi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): total hip replacement arthroplasty</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Perioperative period"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) "sum of transfused packed cells" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (1.01)/1.06 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): posterior spinal fusion</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> (%) patients transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)/6 (30%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Ranucci-2015" target="_blank">Ranucci 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>58/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Duration of hospital stay until 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (33%)/32 (55%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/1 (0 ‐ 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within 24 hours of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL of red blood cells infused for transfused patients only </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (178)/356 (488)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>From 24 to 48 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL of red blood cells infused for transfused patients only </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420 (760)/218 (552)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>48/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Surgery (E): liver transplantation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/0 (0 ‐ 0.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (52.9%)/11 (42.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During and up to 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0 ‐ 6)/3 (0 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (68.8%)/30 (68.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Sadeghi-2014" target="_blank">Sadeghi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>30/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Within first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell infusions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (1.8)/2 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (50)/21 (70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): transurethral resection of the prostate.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (3.2%)/5 (17.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Haas-2015" target="_blank">Haas 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>10/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): scoliosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Over 24 hours from the start of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 15.3)/18.4 (0 ‐ 23.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7 (6.2)/7.2 (8.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (40%)/6 (67%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>17/ 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): craniosynostosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Over 24 hours from the start of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.2 (21.2‐ 49.9)/55.5 (27.5 ‐ 61.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.1 (17.9)/41.8 (18.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (100%)/13 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>58/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Between study intervention and chest closure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)/3 (5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Between study intervention and 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (17%)/20 (33%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/0 (0 ‐ 4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>28/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>From study intervention to discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0 – 2)/1 (0 – 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number (%) of patients who received a red blood cell transfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (46.6%)/13 (48.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number of red blood cell transfusions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>24/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Trauma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3hrs following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2 ‐ 6)/2 (2 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (91.3%)/20 (87.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6hrs following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2 ‐ 6)/2 (2 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (90.5%)/19 (86.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24hrs following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2 ‐ 8)/2 (2 ‐ 5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (95.0%)/18 (85.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) units of red blood cell s transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (1.17)/1.33 (3.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/0 (0 ‐ 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2 ‐ 5)/3 (2 ‐ 4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Rahe_x002d_Meyer-2013" target="_blank">Rahe‐Meyer 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>29/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): aortic valve replacement</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24 hours after receipt of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (55)/32 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 3)/2 (2‐5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): complex cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours after receipt of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0 ‐ 3)/0 (0 ‐ 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Wikkelso-2015" target="_blank">Wikkelso 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>123/121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for a red blood cell transfusion up to 4 hours post study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3)/10 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for a red blood cell transfusion up to 24 hours post study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (11)/19 (16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for a red blood cell transfusion up to 7 days post study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (20)/26 (21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the 6 week period postpartum"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (20)/26 (21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time‐point not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients who received a transfusion of &gt; 4 units of red blood cells. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (7)/3 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Galas-2014" target="_blank">Galas 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐operative day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 ( 83)/32 (97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Tanaka-2014" target="_blank">Tanaka 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): valve replacement or repair</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (90)/9 (90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiovascular, abdominal or spinal column</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Following study intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.98 (3.01)/5.38 (2.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Trauma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>At 24 hours after injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (90%)/39 (89%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2 ‐ 7)/6 (4 ‐ 11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Godje-2006" target="_blank">Godje 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (1.875)/3.3 (1.397)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Karkouti-2013" target="_blank">Karkouti 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>138/128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Until post‐operative day 7 or hospital discharge (whichever occurred first)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0‐1)/0 (0‐1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (33)/43 (34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Korte-2009" target="_blank">Korte 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): gastrointestinal cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150 (0‐700)/200 (0‐800)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Levy-2009" target="_blank">Levy 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Until post‐operative day 7 or hospital discharge (whichever occurred first)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number of patients requiring allogeneic blood products </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data was reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Percentage</b> of patients avoiding a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data was reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Rasche-1982" target="_blank">Rasche 1982</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute leukaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (0 ‐ 34)/6 (0 ‐ 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PCC: prophylactic trials with inactive comparator</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>(E) = elective surgery; ICU = intensive care unit, IQR = inter quartile range; SD = standard deviation. </p> </div> </div> <div class="table" id="CD010649-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood loss</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses intervention/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Transfusion Protocol?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>How the outcome was measured</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Findings: intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Findings: Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Cui-2010" target="_blank">Cui 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>17/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL/kg/h) of chest drainage at 1 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 (2.0) mL/kg/h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 (1.6) mL/kg/h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (ml/kg/h) of chest drainage at 6 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.1) mL/kg/h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.6) mL/kg/h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity ( mL/kg/h) of chest drainage at </p> <p>24 h post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6 (0.4 to 0.8) mL/kg/h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 (0.6 to 0.9) mL/kg/h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Fenger-Erikson-2009" target="_blank">Fenger Erikson 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): radical cystectomy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) blood loss at time of intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2682 (962) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2933 (1320) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Karlsson-2011" target="_blank">Karlsson 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD): "post‐operative bleeding" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>565 (150) mL/12 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>830 (268) mL/12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Najafi-2014" target="_blank">Najafi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): total hip replacement arthroplasty</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of intraoperative blood loss </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>744.6 (337) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>870 (498) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of post‐ operative bleeding to 24 hours post surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231.6 (67) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236.6 (81) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): posterior spinal fusion</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL blood loss up to 24 hours post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>533.3 (157.9) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>679 (130) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Ranucci-2015" target="_blank">Ranucci 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) lost from chest drain in first 12 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (200 to 400) mL/12 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355 (250 to 600) mL/12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Sadeghi-2014" target="_blank">Sadeghi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of blood lost in chest drain in first 12 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>477 (143) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>703 (179) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>31/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): transurethral resection of the prostate.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of blood lost intraoperatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>521 (290) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557 (411) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of blood lost post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291 (270) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>341 (314) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Haas-2015" target="_blank">Haas 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): scoliosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) "calculated total blood loss (%)" by 24 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.5 (14.9 to 54.3) %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.0 (38.5 to 69.2) %</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/ 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): craniosynostosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) "calculated total blood loss (%)" by 24 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.7 (77.7 to 112.9) %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156.9 (110..5 to 187.3) %</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>58/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss from study intervention to chest closure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (29 ‐ 100) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (33 ‐ 145) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss from ICU arrival to 1hr </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (35 ‐ 130) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (46 ‐ 149) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 1hr to 3h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (50 ‐ 156) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (40 ‐ 220) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 3h to 6h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (54 ‐ 169) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (60 ‐ 208) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 6h to 12h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (80 ‐ 160) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125 (83 ‐ 224) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 12h to 24h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 (80 ‐ 180) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160 (90 ‐ 270) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) cumulative mL blood loss in 24 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570 (390 ‐ 730) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>690 (400 ‐ 1090) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss within 24h of study intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>225 (100 – 341) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (60 – 800) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>24/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL intraoperative blood loss </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>306 (110) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375 (202) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL intraoperative blood loss </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (200–400) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (200–500) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL post‐operative blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>796 (523) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>897 (553) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL post‐operative blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650 (500–835) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>730 (543–980) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL total blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1103 (518) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1272 (588) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL total blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>913 (815–1230) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1185 (930–1398) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>78/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): complex cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL chest tube drainage volume at 6h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260.0 (155.0–410.0) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297.5 (200.0–455.0) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL chest tube drainage volume at 12h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405.0 (245.0–600.0) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>447.5 (320.0–700.0) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL chest tube drainage volume at 24h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>590.0 (400.5–839.5) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>682.5 (530.0–1050.0) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Wikkelso-2015" target="_blank">Wikkelso 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123/121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) lost to 6 weeks postpartum </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1700 (1500 to 2000) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1700 (1400 to 2000) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) chest drainage from intraoperative to 48 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320 (157 ‐ 750) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>410 (215 ‐ 510) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): valve replacement or repair</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) chest tube drainage at 12 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>925 (500 to 1693) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1315 (653 to 2965) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Godje-2006" target="_blank">Godje 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>25/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 6 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231 (113) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>278 (98) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 12 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371 (170) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>458 (160) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 24 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>649 (227) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>747 (222) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 36 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>798 (273) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>969 (309) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 48h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>958 (376) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1231 (175) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Korte-2009" target="_blank">Korte 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): gastrointestinal cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (ml) blood loss at completion of surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 (400 to 1000) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1050 (700 to 1800) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Levy-2009" target="_blank">Levy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>8/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of chest drainage at 8 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>358 (93.5) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>505 (301) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of chest drainage at 24h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>903 (738) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1155 (804) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of chest drainage at CT removal </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1007 (912) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1489 (1395) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PCC: prophylactic trials with inactive comparator</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>^ "Calculated total blood loss (%) was based on the estimated total blood volume (calculated as described by <a href="./references#CD010649-bbs2-0087" title="KearneyRA , RosalesJK , HowesWJ . Craniosynostosis: an assessment of blood loss and transfusion practices. Canadian Journal of Anaesthesia1989;36:473‐7. ">Kearney 1989</a> ) " <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> </p> <p>* "The visual assessment of the surgical field was performed by the senior surgical staff as follows: 0 = excellent haemostasis (dry field), 1 = mild bleeding (oozing), 2 = moderate bleeding (controllable with applied pressure) and 3 = severe bleeding (multiple diffuse bleeding sites)" <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> </p> <p>$ Findings are reported graphically, not numerically.</p> <p>(E) = elective surgery; h = hours; ICU = intensive care unit, IQR = inter quartile range; mL = millilitres; SD = standard deviation. </p> </div> </div> </section> <section id="CD010649-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>In the included trials the participant is the unit of analysis.</p> <p>We did not encounter unit‐of‐analysis issues. However, if in any future updates of this review we identify any cluster‐randomised trials we will treat these in accordance with the advice given in the <i>Cochrane Handbook</i> (<a href="./references#CD010649-bbs2-0085" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD010649-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors by email to request missing data or to clarify data that were presented. The list of authors we contacted and the information obtained is outlined below. </p> <p> <ul id="CD010649-list-0010"> <li> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> provided additional data about mortality. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> provided additional data about arterial and venous thromboembolic adverse events and the number of participants exposed to a red blood cell transfusion. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) and <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) provided additional data about the volume of red blood cell units transfused, the number of participants exposed to a red blood cell transfusion, mortality, bleeding mortality and arteriovenous thromboembolic events. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a> provided additional data on adverse events. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a> provided additional information on the number of participants in each study arm. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> provided additional data about outcome time points, mortality, adverse events and red blood cell transfusion. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a> provided additional information about the number of participants exposed to a red blood cell transfusion. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> provided additional data on the incidence of bleeding mortality, arterial and venous thromboembolic events and the volume of red blood cell units transfused. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>, <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>, <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a> and <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> were unable to provide any additional data that we could include in this review. </p> </li> <li> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; and <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> provided no response to our communication. </p> </li> <li> <p>The contact email addresses of <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a> generated an automatic failure‐to‐deliver email communication and no alternative contact details were available. </p> </li> <li> <p>There were no relevant or usable contact details provided in <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>, and no alternative contact details were available. </p> </li> </ul> </p> <section id="CD010649-sec-0047"> <h5 class="title">Method of analysis</h5> <p>Of the 31 included trials, 11 declared an intention‐to‐treat (ITT) analysis, 13 outlined per protocol analysis methods and seven studies did not identify their method of analysis. Due to this, and the paucity of data that could be usefully harmonised on participant cohort, intervention and outcome time point we have included per protocol data. </p> </section> </section> <section id="CD010649-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity based on the data extracted about the characteristics of the included trials. We have discussed possible explanations for the observed heterogeneity within the review. </p> <p>Where we considered trials to be clinically homogeneous, we conducted meta‐analysis and assessed statistical heterogeneity of treatment effects between trials by using a Chi<sup>2</sup> test with a significance level at P &lt; 0.1. We used the I<sup>2</sup> index to quantify the amount of possible heterogeneity (I<sup>2</sup> &gt; 30% as moderate heterogeneity and I<sup>2</sup> &gt; 75% as considerable heterogeneity). When we found heterogeneity, we explored its potential causes with prespecified subgroup and sensitivity analyses. </p> </section> <section id="CD010649-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>We made every effort to identify unpublished trials relevant to this review. We accept that funnel‐plot asymmetry, of which publication bias is one cause, is difficult to detect with the small number of trials (i.e. less than 10) often encountered in systematic reviews. In future updates, we will assess publication bias using funnel plots if we include 10 or more trials in any of our predefined comparison subgroups. </p> </section> <section id="CD010649-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analysis where trials were sufficiently homogeneous in terms of clinical setting and trial design and there were sufficient data of a suitable type. We used the Cochrane statistical software Review Manager 5 (<a href="./references#CD010649-bbs2-0092" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used a fixed‐effect model for combining data in the first instance. Where we identified heterogeneity in a fixed‐effect meta‐analysis, we noted this and repeated the analysis using a random‐effects model. We did not remove any study from any analysis due to a high risk of bias. We grouped outcome data into the outcomes listed earlier in the <a href="#CD010649-sec-0034">Types of outcome measures</a> section. </p> <p>As well as quantitative synthesis, the overall interpretation of the data incorporated insights from a qualitative summary. We based our conclusions on patterns of results identified across clearly‐tabulated results of included trials, as well as summary measures. We considered both the direction and magnitude of any effect. We document individual trial results in the 'Additional Tables' section of the review. </p> <p>For meta‐analysis, we log‐transformed blood loss outcome data and conducted the analysis using the transformed values. A meta‐analysis (using arithmetic means) of the differences in means using the transformed blood loss data corresponds to a meta‐analysis (using geometric means) of the ratio of means in the original scale. </p> </section> <section id="CD010649-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed one subgroup analysis due to heterogeneity, using the first of our predefined subgroups. </p> <p> <ul id="CD010649-list-0011"> <li> <p>Children versus adults (because different definitions of coagulopathy apply). We defined adults as being 18 years or older at the time of recruitment. </p> </li> <li> <p>Trials of participants with brain/neurological injuries. For example, acute intracranial injury versus no acute intracranial injury (in view of the added effect of central nervous system injury on coagulopathy and therefore the possibly different efficacy of interventions in this participant group). </p> </li> </ul> </p> <p>We did not use the second of our predefined subgroups as these data were sparse in the included studies. </p> </section> <section id="CD010649-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of our findings by performing sensitivity analyses for the trials where 1) allocation concealment was adequate, and 2) in which 25% of participants or fewer were lost in the one meta‐analysis with noted heterogeneity. </p> <section id="CD010649-sec-0053"> <h5 class="title"><i>'Summary of findings' tables</i> </h5> <p>We created 'Summary of findings' tables for each intervention, following guidance in the <i>Cochrane Handbook</i> (<a href="./references#CD010649-bbs2-0085" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from www.cochrane‐handbook.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We assessed the quality of the evidence for each outcome using GRADE (<a href="./references#CD010649-bbs2-0095" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Schünemann 2011</a>). The outcomes included in the 'Summary of findings' tables are: </p> <p> <ul id="CD010649-list-0012"> <li> <p>All‐cause mortality for trials in which the indication of use for the intervention was therapeutic; </p> </li> <li> <p>Arterial and venous thromboembolic complications for trials in which the indication of use for the intervention was prophylactic. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010649-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010649-sec-0054"></div> <section id="CD010649-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD010649-sec-0056"> <h4 class="title">Results of the search</h4> <p>The search strategy identified 4781 references with an additional 379 ongoing studies; these were reduced to 2770 references plus 319 ongoing studies once duplicates had been removed. Of these, 2681 references and 288 ongoing studies were ruled out for being clearly irrelevant to the scope of this review. We screened the remaining 89 references and 31 ongoing trials for eligibility. We included 31 studies (from 61 references) and identified 22 ongoing trials (from 25 references); we excluded 14 trials (from 28 references) and six ongoing studies (from six references). Full details are reported in the PRISMA flow diagram (<a href="#CD010649-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010649-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram." data-id="CD010649-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> </div> <p>We found four non‐English publications. Two papers required translation from German to assess eligibility for inclusion (<a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0045" title="SchererR , GilleA , ErhardJ , PaarD , KoxWJ . [The effect of substitution with AT III‐ and PPSB‐concentrates in patients with terminal liver insufficiency]. [German] [Substitutionseffekt von AT III‐und PPSB‐Konzentraten bei patienten mit terminaler leberinsuffizienz]. Anaesthesist1994;43(3):178‐82. ">Scherer 1994</a>). Following translation, we deemed one paper ineligible (<a href="./references#CD010649-bbs2-0045" title="SchererR , GilleA , ErhardJ , PaarD , KoxWJ . [The effect of substitution with AT III‐ and PPSB‐concentrates in patients with terminal liver insufficiency]. [German] [Substitutionseffekt von AT III‐und PPSB‐Konzentraten bei patienten mit terminaler leberinsuffizienz]. Anaesthesist1994;43(3):178‐82. ">Scherer 1994</a>), whilst we rated the second trial as eligible for inclusion (<a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>). A third paper was translated from Portuguese using Google translate and we included it in the review (<a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). The fourth paper was translated from Persian by a volunteer translator found through the Cochrane TaskExchange (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>), and was also included. </p> <p>One reference reported data from two distinct surgical groups: scoliosis surgery and craniosynostosis surgery (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a>). We report these data as two separate studies throughout the review: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) and <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C). </p> <p>The 31 included studies randomised a total of 2392 participants. There were 13 therapeutic trials that randomized 1057 participants (ranging from 20 to 249) and 18 prophylactic trials that randomised a total of 1335 participants (ranging from 20 to 479). Two trials had three arms (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>), and one trial had five arms (<a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>). All three were prophylactic trials. </p> </section> <section id="CD010649-sec-0057"> <h4 class="title">Included studies</h4> <p>We give further details about the included studies in the <a href="./references#CD010649-sec-0190" title="">Characteristics of included studies</a> table and <a href="#CD010649-tbl-0008">Table 3</a>; <a href="#CD010649-tbl-0009">Table 4</a>; <a href="#CD010649-tbl-0010">Table 5</a>; <a href="#CD010649-tbl-0011">Table 6</a>; <a href="#CD010649-tbl-0012">Table 7</a>; <a href="#CD010649-tbl-0013">Table 8</a> and <a href="#CD010649-tbl-0014">Table 9</a>. </p> <div class="table" id="CD010649-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Fibrinogen concentrate: prophylactic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Cui-2010" target="_blank">Cui 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(20/20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> <p>(17/14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (0.5‐1g) combined with traditional transfusion, guided by TEG </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE:</b> Traditional transfusion guided by clinical experience. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine,</p> <p>FFP, red blood cells, platelets.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to chest wall closure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paediatric population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Fenger-Erikson-2009" target="_blank">Fenger Erikson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> <p>(10/11 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (45mg/kg), administered intra‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> isotonic saline, administered intra‐operatively at a dose of 2.25 mL/kg). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intra‐operative FFP, red blood cells.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole blood maximum clot firmness as determined by thromboelastometry.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): radical Cystectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Karlsson-2011" target="_blank">Karlsson 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preoperative infusion of<b>fibrinogen concentrate</b> (2g) at 5 minutes following baseline measurements. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin,</p> <p>protamine,</p> <p>red blood cells, aspirin.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical adverse events, including graft occlusion on CT up to 3 to 4d post‐ operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Najafi-2014" target="_blank">Najafi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> <p>(15/15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> <p>(15/15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (30 mg/kg) infused after induction of general anaesthesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: normal saline administered in equal volume as fibrinogen. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of red blood cells transfused during and 24h post‐operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): total hip replacement arthroplasty</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> <p>(21/20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> <p>(21/20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (1g) infused after induction of general anaesthesia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): posterior spinal fusion.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> <p>(58/58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> <p>(58/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> with dose determined by the mean clot firmness test on the FIBTEM. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> Normal (0.9%) saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA during surgery, protamine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avoidance of allogeneic blood products transfusion during hospital stay up to 30d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> <p>(51/48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> <p>(48/44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> with dose calculated to reach a target plasma concentration of 2.9 g/L. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> Normal (0.9%) saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The percentage of patients requiring transfusion of red blood cell units during the liver transplant procedure. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): liver transplantation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Sadeghi-2014" target="_blank">Sadeghi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(30/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(30/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen</b> (1g) administered 30 minutes prior to anaesthesia induction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: saline administered 30 minutes prior to anaesthesia induction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of post‐operative haemorrhage 0, 12 and 24h post‐operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(36/36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(31/29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (2g) administered 15‐30 minutes before the start of surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 50ml normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding volume during and after surgery.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): transurethral resection of the prostate.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* For the outcomes bleeding and transfusion requirements, 1 patient from the Factor XIII, 1250 IE arm and 2 patients from the placebo arm were excluded from the analysis due to re‐operations following hints of early bypass occlusions. All patients were included in the analysis of the other outcomes. </p> <p>d = days; (E) = elective surgery; FIBTEM = is a ready‐to‐use ROTEM<sup>®</sup> system reagent for use with citrated whole blood and assesses the clot firmness of the fibrin clot, h = hours; PCC = prothrombin complex concentrate; mins = minutes; wks = weeks. </p> </div> </div> <div class="table" id="CD010649-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Fibrinogen concentrate: prophylactic trials with active comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Craniosynostosis surgery = 36</p> <p>(17/14).</p> <p>Scoliosis surgery = 26</p> <p>(10/9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Craniosynostosis surgery = 36</p> <p>(17/13).</p> <p>Scoliosis surgery = 26</p> <p>(10/9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> if FIBTEM MCF under 13mm (early substitution group). </p> <p>Total dose administered per subject in</p> <p>craniosynostosis surgery; median of 90mg kg<sup>‐1</sup> (IQR, 75 to 120 mg kg<sup>‐1</sup>); </p> <p>Scoliosis surgery = = median of 60mg kg<sup>‐1</sup> (IQR, 30 to 68 mg kg<sup>‐1</sup>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> if FIBTEM MCF under 8 mm (conventional). </p> <p>Total dose administered per subject in</p> <p>craniosynostosis surgery = median of</p> <p>90mg kg<sup>‐1</sup> (IQR, 60 to 90 mg kg<sup>‐1</sup>); Scoliosis surgery = median of 30mg kg<sup>‐1</sup> (IQR, 30 to 60 mg kg<sup>‐1</sup>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total volume of transfused red blood cells per kg bodyweight within 24h post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): craniosynostosis or scoliosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paediatric population</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CPB = cardiopulmonary bypass; (E) = elective surgery; FFP = fresh frozen plasma; FIBTEM = is a ready‐to‐use ROTEM<sup>®</sup> system reagent for use with citrated whole blood and assesses the clot firmness of the fibrin clot; h = hours; INR = International Normalised Ratio, IQR = inter quartile range; PCC = prothrombin complex concentrate; (U) = urgent surgery/ treatment. </p> </div> </div> <div class="table" id="CD010649-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Fibrinogen concentrate: therapeutic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> <p>(60/60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(58/57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose calculated to provide a target plasma fibrinogen concentration of 2.5 g/L. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 2g of<br/> albumin diluted with 50ml 0.9% sodium chloride solution. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intraoperative blood loss measured between intervention and closure of the chest.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> <p>(29/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> <p>(28/27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose determined by FIBTEM to elevate A5 result above 22mm. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 50ml of normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of allogeneic<br/> blood products (red blood cell , FFP, cryoprecipitate, platelets) infused after study medication until hospital discharge. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> <p>(24/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> <p>(24/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> 6g infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 300ml of normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major haemorrhage therapy as per hospital protocol: red blood cells, platelets, FFP, tranexamic acid, cryoprecipitate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feasibility of delivery of FgC therapy within 45 minutes to adult trauma patients and the proportion of participants whose fibrinogen levels were maintained ≥ 2 g/L during active haemorrhage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> <p>(26/26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> <p>(24/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen</b> (2g) as an infusion over 5 minutes, immediately<br/> before surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 100ml of normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 units kg−1 of heparin, 1 mg protamine per 100 units of heparin. Red blood cells, platelets, FFP, additional fibrinogen. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mediastinal drain loss during the first 12 hours post‐operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> <p>(25/25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> <p>(21/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, 6g as a 3 minute infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 300ml of normal saline as a 3 minute infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, tranexamic acid, FFP,<br/> platelets and cryoprecipitate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The feasibility of providing the study intervention within 1 hour of hospital admission.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> <p>(38 /42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> <p>(29/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose determined by FIBTEM test: median (IQR range) dose: 8g (6 to 9g). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> normal (0.9%) saline. Median (IQR range) dose: 400ml (300 to 450ml). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA during surgery, platelets or FFP.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of units of allogeneic blood components given during first 24h post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): aortic valve replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> <p>(78/74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> <p>(78/74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose determined by FIBTEM testing to generate an MCF of 22mm. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 0.9% sodium chloride solution. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of units of allogeneic blood products (FFP, platelets and red blood cells) administered during the 24 hours after administration of study medication. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): complex cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> <p>(124 /125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> <p>(PPA: 123 /121)</p> <p>(ITT: 120 /119)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed dose of 2g of <b>fibrinogen concentrate</b> dispensed using a syringe pump infusion over 20 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> 100ml of isotonic saline (mean (standard deviation) dose =1.2 (0.2) mg/kg). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA, hydroxyethyl starch, intravenous fluids.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cell transfusion during a 6 wk follow‐up period postpartum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>d = days; (E) = elective surgery; FFP = fresh frozen plasma; FIBTEM = is a ready‐to‐use ROTEM<sup>®</sup> system reagent for use with citrated whole blood and assesses the clot firmness of the fibrin clot; h = hours; INR = International Normalised Ratio, IQR = inter quartile range; mins = minutes; PCC = prothrombin complex concentrate; TXA = tranexamic acid; (U) = urgent surgery/ treatment; wks = weeks. </p> </div> </div> <div class="table" id="CD010649-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Fibrinogen concentrate: therapeutic trials with active comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> <p>(30/33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> <p>(30/33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose of <b>Fibrinogen</b> concentrate (60mg/kg body weight, Haemocomplettan®) given at time of intra‐operative bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose of <b>Cryoprecipitate</b> (10ml/kg body weight) given at time of intra‐operative bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not Stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐operative blood losses during 48h after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paediatric population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(22/21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(22/21)</p> <p>(but only 16/16 for primary outcome analysis).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFP</b> ( 2 units) + <b>Fibrinogen</b> (2g) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFP</b> (4 units) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine, red blood cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐ and post‐transfusion ROTEM analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiovascular, abdominal or spinal column</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single dose (4g) of <b>Fibrinogen</b> (RiaSTAP®) given within 30 minutes of intervention decision. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One unit of apheresis <b>platelets</b> (median volume 230 ml) within 30 minutes of intervention decision. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, plasma, cryoprecipitate and fibrinogen if triggers met</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>i) Haemostatic condition in the surgical field post‐intervention;</p> <p>ii) Haemostatic blood product use over the first 24h;</p> <p>iii) Percentage of patients with thromboembolic events at 6‐8 weeks post‐operatively;</p> <p>iv) Mortality at 6‐8 weeks post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): valve replacement or repair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> <p>(52/48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> <p>(50/44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b><br/> (50 mg/kg of bodyweight) for abnormal ROTEM fibrin<br/> polymerisation (FibA10 &lt; 9 mm) or four‐Factor PCC<br/> (20 IU/kg of bodyweight) for delayed initial thrombin<br/> formation (ExCT &gt; 90s or prothrombin time index &lt; 35%). FXIII concentrate (20 IU/kg of bodyweight) was administered with each second fibrinogen dose. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFP</b> (15 ml/kg bodyweight). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranexamic acid 20mg/kg, FXIII concentrate (20 IU/kg of bodyweight),</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Occurrence of multiple organ failure during ICU stay as assessed by the daily SOFA score. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* 20 of the 47 patients had a 2nd dose of 20ml of PCC: in 3 because of continued bleeding and in 17 due to INR target not being met. 3 of the 47 patients received a 3rd dose of PCC due to an unmet INR level. </p> <p>^ 3 of the 46 patients had a 2nd dose of 20 ml PCC: 1 due to a continued bleed and 2 did not reach the target INR. </p> <p>d = days; (E) = elective surgery; FFP = fresh frozen plasma; h = hours; INR = International Normalised Ratio; mins = minutes; PCC = prothrombin complex concentrate; ROTEM<sup>®</sup> = rotational thromboelastometry; TXA = tranexamic acid; (U) = urgent surgery/ treatment; wks = weeks. </p> </div> </div> <div class="table" id="CD010649-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Factor XIII (FXIII): prophylactic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Godje-2006" target="_blank">Godje 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> <p>(25/25/ 25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> <p>(25/25/25)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infusion of Factor<b>XII</b>I1) 1250 units or2) 2500 units*immediately after administration of protamine (protamine was administered during the scheduled coronary artery bypass graft surgery)* This is the group that was included in this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b>: standard surgical and post‐operative care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine for heparin reversal</p> <p>FFP, red blood cells, platelets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Karkouti-2013" target="_blank">Karkouti 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>479</p> <p>(164/162/153)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>409</p> <p>(143/138/128)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single intravenous dose of Factor<b>XIII</b> 1) 17.5 IU/kg or2) 35 IU/kg*before the induction of anaesthesia.* This is the group that was included in this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> single dose of an unspecified placebo before the induction of anaesthesia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine, antifibrinolytics during cardiopulmonary bypass, blood products</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percentage of patients avoiding any allogeneic transfusions within 7d or discharge home. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Korte-2009" target="_blank">Korte 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (no further details stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (no further details stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> (30 U/kg) infused 15 minutes after the beginning of surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: albumin infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low molecular weight heparin,</p> <p>FFP, red blood cells, platelets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clot firmness over 195 mins of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): gastrointestinal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Levy-2009" target="_blank">Levy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(10/9/8/8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(10/9/8/8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single infusion of Factor<b>XIII</b> at 4 doses:1) 11.9 units/kg;2) 25 units/kg;3) 35 units/kg*;4) 50 units/kg.* This is the group that was included in this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: no further details given. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine for heparin reversal</p> <p>FFP, red blood cells, platelets</p> <p>Cryoprecipitate, Fibrinogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of adverse events from intervention administration to follow‐up at 5 to 7 wks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Rasche-1982" target="_blank">Rasche 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(29/31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(29/31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> (1000 units) on day 1 of treatment and a subsequent daily dose of 500 units plus normal care protocols. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b>: normal care products </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, whole blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Shirahata-1990" target="_blank">Shirahata 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> <p>(30/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> <p>(30/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> (dose of 70 to 100 units) administered slowly for at least 10 minutes intravenously within 6 hours of delivery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prematurity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infant population</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010649-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Factor XIII (FXIII): therapeutic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> <p>(17/11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(11/9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> as an i.v. injection (at 3750 units on Day 0 and 1250 units on days 1 through 9) as an addition to basic steroid treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: continuation of basic steroid treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA,</p> <p>platelets or FFP post‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to cessation of macroscopically visible intestinal bleeding within 14d of starting treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulceratice colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010649-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">PCC: prophylactic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Turner-1981" target="_blank">Turner 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> <p>(39/39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> <p>(39/39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PCC</b> (dose of 1ml/kg or 2ml/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b>: normal care protocols. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin K, heparin and clotting Factors for disseminated intravascular coagulation, red blood cells </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>i) Mortality (all‐cause)</p> <p>ii) Incidence of intraventricular haemorrhage (post‐mortem)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prematurity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infant population</p> </td> </tr> </tbody> </table> </div> <section id="CD010649-sec-0058"> <h5 class="title">Setting</h5> <p>Three trials were multicentre, multinational trials (<a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>) and six were multicentre trials, based in a single country: Germany (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>), the UK (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>), Spain (<a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>), Sweden (<a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>) and Denmark (<a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). The remaining 22 trials were single‐centre trials. Four trials were conducted in Iran (<a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), three trials were conducted in Germany (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>), three trials were conducted in Switzerland (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>) and the Netherlands (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>), whilst one trial was each conducted in Brazil (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>), Austria (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>), Canada (<a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>), China (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>), Denmark (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>), Great Britain (<a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), Italy (<a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>), Japan (<a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>), Sweden (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>), and the USA (<a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). </p> <p>The clinical setting varied across the trials: 22 were in an elective surgical setting (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) and (C); <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>; <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), five in an urgent medical setting (<a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>), and four in a non‐urgent medical setting (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). Definitions of elective and urgent have been taken from the trial manuscript. </p> </section> <section id="CD010649-sec-0059"> <h5 class="title">Participants</h5> <p>Three trials were undertaken in infants (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), and three in paediatric populations (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)); the remaining 25 trials enrolled adult participants. We considered and analysed the infant trials separately for all outcomes other than allergic adverse events, where they have been grouped with the adult studies. We have included the paediatric population trials in analyses alongside the trials with adult populations, as we consider the populations in the three paediatric trials (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>, mean age 38.4 months; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S), mean age of 12 years and <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>, participants under 15 years of age) to be physiologically comparable to the populations in the trials recruiting adults. </p> </section> <section id="CD010649-sec-0060"> <h5 class="title">Interventions</h5> <section id="CD010649-sec-0061"> <h6 class="title">Prophylactic trials</h6> <p>Eighteen trials addressed prophylactic use of pro‐coagulant factors, 16 in comparison to inactive agents (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), and two in comparison to an active comparator (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)). </p> <section id="CD010649-sec-0062"> <p><b>Inactive comparator trials</b></p> <p>Of the 16 inactive comparator trials, seven recruited participants undergoing cardiac surgery (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). The other trials focused on elective cystectomy (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>), gastrointestinal cancer (<a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>), acute leukaemia (<a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>), spinal fusion (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>), liver transplantation (<a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>), trans‐urethral prostatic resection (<a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), and elective hip replacement arthroplasty (<a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>). Both neonatal population trials used inactive comparators and focused on babies at risk of intracranial haemorrhage (<a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). </p> <p>Six of these prophylactic trials used factor XIII as the pro‐coagulant haemostatic intervention (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>), and nine used fibrinogen (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>). <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> used a range of agents, including a prothrombin complex concentrate supplied by the Scottish National Blood Transfusion Service Protein Fractionation Centre: fibrinogen, factor VIII and platelets. </p> <p>The inactive comparator agents were haemostatically inactive placebo products in 10 trials (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), or nothing other than normal care (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). </p> </section> <section id="CD010649-sec-0063"> <p><b>Active comparator trials</b></p> <p>The participants in the two trials with an active comparator were neonates undergoing craniosynostosis or paediatric patients undergoing scoliosis surgery: both compared two doses of fibrinogen concentrate (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)). </p> </section> </section> <section id="CD010649-sec-0064"> <h6 class="title">Therapeutic trials</h6> <p>Thirteen trials addressed therapeutic use of pro‐coagulant factors: nine in comparison to inactive agents (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>), and four compared to an active comparator (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). </p> <section id="CD010649-sec-0065"> <p><b>Inactive comparator trials</b></p> <p>The inactive comparator trials focused on cardiac surgery (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>), ulcerative colitis (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>), trauma (<a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>), and postpartum haemorrhage (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). The pro‐coagulant haemostatic interventions were fibrinogen in eight studies (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>), and factor XIII (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>). The comparators in all nine trials were haemostatically inactive placebo products. </p> </section> <section id="CD010649-sec-0066"> <p><b>Active comparator trials</b></p> <p>The active comparator trials addressed cardiac surgery (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>), trauma (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>), and major elective surgery (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>). The intervention in all these trials was fibrinogen compared with FFP (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>), cryoprecipitate (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>), platelets (<a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>), and as a partial replacement for FFP (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>). </p> </section> </section> </section> <section id="CD010649-sec-0067"> <h5 class="title">Co‐interventions</h5> <p>Most trials documented the use of blood products (red blood cells and platelets) as well as transfusion of clotting products (FFP, prothrombin complex concentrate, cryoprecipitate) to treat bleeding or clotting derangement during the course of the trial. </p> <p>Non‐blood product co‐interventions were reported by 26 trials. One trial reported routine administration of Vitamin K to all participants (<a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), 11 trials reported administration of protamine (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>), 14 trials reported the use of an antifibrinolytic agent (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) and two trials documented the use of post‐intervention low‐molecular weight heparin (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>). Five trials did not report details of co‐interventions administered or outline additional transfusion policies (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>). </p> </section> <section id="CD010649-sec-0068"> <h5 class="title">Primary outcomes of included trials</h5> <p>Twelve trials reported transfusion requirement, or the avoidance of transfusion, as a primary outcome (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). Four trials reported blood loss as the primary outcome (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), and two trials each had primary outcomes of adverse events (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>), or clot firmness following surgery (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>). Other primary outcomes were time to chest wall closure (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>), the incidence of multiorgan failure (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>), mortality (<a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), time to cessation of bleeding (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>), clotting time and clot formation time (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>) and bleeding complications (<a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>). Two trials were feasibility studies (<a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>), and three studies did not report their primary outcome (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). </p> </section> <section id="CD010649-sec-0069"> <h5 class="title">Funding sources</h5> <p>Seventeen trials received support from a commercial company for their study: CSL Behring (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>), Novo Nordisk (<a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>), and Centeon Pharma GmbH (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>). Eight of these trials also received support from an academic institution or charity (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>). </p> <p>Four studies were solely supported by grants from an academic institution or a charity (<a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). Eight trials did not report receipt of any funding (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), whilst in one trial it was unclear whether or not funding had been received to support the trial (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>). </p> </section> </section> <section id="CD010649-sec-0070"> <h4 class="title">Excluded studies</h4> <p>For the full list of excluded trials see <a href="./references#CD010649-sec-0191" title="">Characteristics of excluded studies</a>. </p> <p>We excluded six trials as the participants were ineligible: they were on warfarin and received the pro‐coagulant haemostatic factor for anticoagulation reversal (<a href="./references#CD010649-bbs2-0032" title="BoulisNM , BobekMP , SchmaierA , HoffJT . Use of factor IX complex in warfarin‐related intracranial haemorrhage. Neurosurgery1999;45(5):1113‐8. ">Boulis 1999</a>; <a href="./references#CD010649-bbs2-0034" title="DemeyereR , ArnoutJ , StrengersP , GasthuisbergUZ . Prothrombin complex concentrate versus fresh frozen plasma in patients on oral anticoagulant therapy undergoing cardiac surgery: a randomized study. Critical Care2006;10(Suupl 1):233. DemeyereR , GillardinS , ArnoutJ , StrengersPF . Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sanguinis2010;99(3):251‐60. ">Demeyere 2010</a>; <a href="./references#CD010649-bbs2-0036" title="An open label, randomized, multicentre, phase IIIb to assess the safety, efficacy and tolerance of BERIPLEX P/N (Kcentra) compared with plasma for rapid reversal of coagulopathy induced by vitamin K antagonists in subjects requiring an urgent surgical procedure (BE1116_3003). ClinicalTrials.gov NCT00803101. GoldsteinJN , RefaaiMA , MillingTJJr , LewisB , Goldberg‐AlbertsR , HugBA , et al. Four‐factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open‐label, non‐inferiority, randomised trial. The Lancet2015;385:2077‐87. MillingTJJr , RefaaiMA , SarodeR , LewisB , MangioneA , DurnBL , et al. Safety of 4‐factor prothrombin complex concentrate (4F‐PCC) versus plasma for vitamin K antagonist reversal: an integrated data analysis of two phase III clinical trials. American Journal of Haematology. 2014; Vol. 89 (6):E26. RefaaiMA , GoldsteinJN , LeeML , MillingTJJr , SarodeR . Increased risk of volume overload with plasma compared to four‐factor prothrombin complex concentrate for the emergency reversal of vitamin K antagonist therapy. Academic Emergency Medicine2014;21(5):S243. RefaaiMA , GoldsteinJN , MillingTJJr , LewisB , Goldberg‐AlbertsR , HugBA , et al. Randomized phase IIIb study of rapid vitamin K antagonist reversal in patients requiring an urgent surgical procedure: four‐factor prothrombin complex concentrate is superior to plasma. Blood. 2013; Vol. 122:21. ">Goldstein 2015</a>; <a href="./references#CD010649-bbs2-0042" title="PapakitsosG , KapsaliA , PapakitsouT , RoimbaA . Comparison of two dose‐regimens of prothrombin complex concentrate in urgent anticoagulation reversal: A prospective randomised study. Haematologica. 2014; Vol. 99:267. ">Papakitsos 2014</a>; <a href="./references#CD010649-bbs2-0044" title="LangE . 4F‐PCC was noninferior to plasma in patients with acute major bleeding who needed urgent VKA reversal. American College of Physicians [Journal Club]2014; Vol. 160, issue 8:JC6. MillingTJJr , RafaaiMA , GoldsteinJN , Goldberg‐AlbertsR , SchneiderA , HugB , et al. Thrombotic events after vitamin K antagonist reversal with 4‐factor prothrombin complex concentrate or plasma. Annals of Emergency Medicine. 2013; Vol. 62 (4s):S10. MillingTJJr , RefaaiMA , SarodeR , LewisB , MangioneA , DurnBL , et al. Safety of 4‐factor prothrombin complex concentrate (4F‐PCC) versus plasma for vitamin K antagonist reversal: an integrated data analysis of two phase III clinical trials. American Journal of Haematology. 2014; Vol. 89 (6):E26. RefaaiMA , GoldsteinJN , LeeML , MillingTJJr , SarodeR . Increased risk of volume overload with plasma compared to four‐factor prothrombin complex concentrate for the emergency reversal of vitamin K antagonist therapy. Academic Emergency Medicine. 2014; Vol. 21:5 (Suppl 1). RefaaiMA , GoldsteinJN , MillingTJ , FoehlH , HugB , SarodeR . Correction of INR and coagulation factor levels in a randomized clinical trial of a four‐factor prothrombin complex concentrate (PCC‐4) versus plasma for urgent vitamin K antagonist reversal. Annals of Emergency Medicine. 2012; Vol. 60 (4s):S10. SarodeR , MillingT , RefaaiMA , MangioneA , SchneiderA , GoldsteinJN . Randomized Phase IIIb study comparing the safety and efficacy of four‐factor prothrombin complex concentrate with plasma in subjects receiving Vitamin K antagonists with major bleeding. American Journal of Haematology. 2012; Vol. 87 (S1):S146. SarodeR , MillingTJ , RefaaiMA , MangioneA , SchneiderA , DurnBL , et al. Efficacy and safety of a 4‐factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma‐controlled, phase IIIb study. Circulation2013;128:1234‐43. [PUBMED: 23935011] ">Sarode 2013</a>; <a href="./references#CD010649-bbs2-0049" title="vanAartL , EijkhoutH , KamphuisJS , DamM , StrengersPFW , PloegerB . The use of prothrombin complex investigated [Gebruik van protrombinecomplex onderzocht [Dutch]. Pharmaceutisch weekblad2001;136(3):84‐7. vanAartL , EijkhoutHW , KamphuisJS , DamM , SchattenkerkME , SchoutenTJ , et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thrombosis Research2006;118:313‐20. [PUBMED: 16182346] ">van Aart 2006</a>). We excluded one trial after translation from German and review of the full text for not being a randomised controlled trial (<a href="./references#CD010649-bbs2-0045" title="SchererR , GilleA , ErhardJ , PaarD , KoxWJ . [The effect of substitution with AT III‐ and PPSB‐concentrates in patients with terminal liver insufficiency]. [German] [Substitutionseffekt von AT III‐und PPSB‐Konzentraten bei patienten mit terminaler leberinsuffizienz]. Anaesthesist1994;43(3):178‐82. ">Scherer 1994</a>). One study was excluded on review of the full text as it was a review of the literature (Maegele 2015). We excluded five studies as the study interventions did not meet the inclusion criteria for this review (<a href="./references#CD010649-bbs2-0033" title="CurryN , RourkeC , DavenportR , BeerS , PankhurstL , DearyA , et al. Early cryoprecipitate for major haemorrhage in trauma: a randomised controlled feasibility trial. British Journal of Anaesthesia2015;115(1):76‐83. ">Curry 2015</a>; <a href="./references#CD010649-bbs2-0035" title="GarrigueD , GodierA , GlacetA , LabreucheJ , KipnisE , ParisC , et al. French lyophilized plasma versus fresh frozen plasma for the initial management of trauma‐induced coagulopathy: a randomized open‐label trial. Journal of Thrombosis &amp; Haemostasis2018;16(3):481‐9. ">Garrigue 2017</a>; <a href="./references#CD010649-bbs2-0037" title="MasoumiSG , BigdelianH , MousavianSM , MirzaeiA , AbediH , ZiaeifardM . Comparing the efficacy of synthetic fibrinogen plus albumin to fresh frozen plasma in the prevention of coagulation disorders in pediatric heart surgery. Isfahan University of Medical Sciences2016;119:44. ">Masoumi 2016</a>; <a href="./references#CD010649-bbs2-0038" title="MiyataS , SasakiH , UedaY , TakamotoS , UsuiA , NishiwakiK , et al. Liberal versus restrictive transfusion strategy of platelet concentrate and cryoprecipitate in thoracic aortic surgery: A multicenter randomized trial. Abstracts of the HAA 2014 Annual Scientific Meeting. 2014:407. ">Miyata 2014</a>; <a href="./references#CD010649-bbs2-0043" title="QiuM , ZhangX , CaiH , XuZ , LinH . The impact of hemocoagulase for improvement of coagulation and reduction of bleeding in fracture‐related hip hemiarthroplasty geriatric patients: a prospective, single‐blinded, randomized, controlled study. Injury2016;48(4):914‐9. ">Qiu 2016</a>). One study was excluded as it was terminated early for feasibility reasons after recruiting only a single participant to each study arm (<a href="./references#CD010649-bbs2-0046" title="Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (TOP‐CLOT). www.ClinicalTrials.gov, registry number (accessed 05.02.2018); study terminated (feasibility issues prevent completion of recruitment). ">TOP‐CLOT Trial</a>). </p> <p>We identified 22 trials as ongoing studies. Full details of these trials are available in the <a href="./references#CD010649-sec-0193" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> <section id="CD010649-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD010649-fig-0002">Figure 2</a> for visual representations of the assessments of risk of bias across all trials and for each item in the included trials. See the 'Risk of bias' section in the <a href="./references#CD010649-sec-0190" title="">Characteristics of included studies</a> for more detailed information about the biases identified within the individual trials. </p> <div class="figure" id="CD010649-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. Thirty‐one trials are included in this review (Haas 2015 reports two trials)." data-id="CD010649-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. Thirty‐one trials are included in this review (Haas 2015 reports two trials). </p> </div> </div> </div> <section id="CD010649-sec-0072"> <h4 class="title">Allocation</h4> <section id="CD010649-sec-0073"> <h5 class="title">Random sequence generation</h5> <section id="CD010649-sec-0074"> <h6 class="title">Prophylactic trials</h6> <p>We considered nine trials to be at low risk of bias, as randomisation was done centrally by a Voice response system (<a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>), or was randomly generated (<a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). We judged nine trials to be at unclear risk of bias, as the method of randomisation was not adequately reported (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). </p> </section> <section id="CD010649-sec-0075"> <h6 class="title">Therapeutic trials</h6> <p>We considered seven trials to be at low risk of bias, as randomisation was done centrally (<a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>), or was randomly generated (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>). We judged six trials to be at unclear risk of bias, as the method of randomisation was not adequately reported (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). </p> </section> </section> <section id="CD010649-sec-0076"> <h5 class="title">Concealment of treatment allocation</h5> <section id="CD010649-sec-0077"> <h6 class="title">Prophylactic trials</h6> <p>We considered five trials to be at low risk of bias for allocation concealment, as assignment was done centrally (<a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>) or was randomly generated (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>). We considered two trials to be at high risk of bias due to incorrect methods being used to conceal treatment allocation (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>). We judged 11 trials to be at unclear risk of bias because no description of allocation concealment was provided (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). </p> </section> <section id="CD010649-sec-0078"> <h6 class="title">Therapeutic trials</h6> <p>We considered seven trials to be at low risk of bias for allocation concealment, as assignment was done centrally (<a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>) or was randomly generated (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>). We considered three trials to be at high risk of bias, due to incorrect methods being used to conceal treatment allocation (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). We judged three trials to be at unclear risk of bias, because no description of allocation concealment was provided (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>). </p> </section> </section> </section> <section id="CD010649-sec-0079"> <h4 class="title">Blinding</h4> <section id="CD010649-sec-0080"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <section id="CD010649-sec-0081"> <h6 class="title">Prophylactic intervention</h6> <p>We considered 16 trials to be at low risk of <b>participant</b> performance bias as, i) participants were under anaesthesia when their intervention was administered (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>), ii) were too young to appreciate the nature of their intervention (<a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), iii) were unaware of the intervention content (<a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), or iv) the plastic container vials used were covered and details of the contents not visible (<a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). We considered two trials, <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a> and <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a> to be at unclear risk of performance bias as insufficient information was provided to permit an alternative judgement. We did not consider any trials to be at high risk of participant performance bias. </p> <p>We considered nine trials to be at low risk of <b>personnel</b> performance bias as: i) staff independent from the trial team prepared the interventions (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>); ii) interventions were provided in visually identical containers (<a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>); iii) the plastic container vials used were covered and details of the contents were not visible (<a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>); iv) clinical staff were blinded to treatment allocation (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>); and v) outcome was not likely to be influenced by lack of blinding (<a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). We considered six trials to be at high risk of personnel performance bias due to: i) the availability of the allocation concealment device in the participant's notes (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>); ii) the apparent non‐concealment of the notably visual difference between the intervention and control (<a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>); iii) personnel being unblinded to treatment allocation (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)); and iv) a lack of information on blinding where knowledge of treatment allocation could introduce performance bias (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>). We considered three trials to be at unclear risk of personnel performance bias, as insufficient information was provided to permit an alternative judgement (<a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>). </p> </section> <section id="CD010649-sec-0082"> <h6 class="title">Therapeutic trials</h6> <p>We considered all 13 trials to be at low risk of <b>participant</b> performance bias because: i) intervention and placebo were identical in composition (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>); ii) participants were under anaesthesia when their intervention was administered with the trial personnel and clinicians blinded to treatment allocation (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>); and iii) participants had a low level of consciousness or were unconscious at the time of the study intervention, although the clinicians administering the intervention were not blinded to its nature (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>). </p> <p>We considered nine trials to be at low risk of <b>personnel</b> performance bias because the placebo was identical in composition to the intervention (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). We considered two trials to be at high risk of personnel performance bias as these were open‐label trial designs (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>), and we considered two trials to be at an unclear risk of performance bias, as insufficient information was provided to permit an alternative judgement (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>). </p> </section> </section> <section id="CD010649-sec-0083"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <section id="CD010649-sec-0084"> <h6 class="title">Prophylactic intervention</h6> <p>We considered six trials to be at low risk of detection bias, as outcome assessments were: i) made by trial personnel blinded to treatment allocation (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>); or ii) knowledge of treatment allocation would not affect assessment of objective outcomes (<a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). We considered two trials to be at high risk of detection bias due to lack of appropriate allocation concealment (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), as well as notable functional and visual differences between the intervention and control in <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>. We considered 10 trials to be at unclear risk of detection bias, as insufficient information was provided to permit an alternative judgement (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>). </p> </section> <section id="CD010649-sec-0085"> <h6 class="title">Therapeutic trials</h6> <p>We considered six trials to be at low risk of detection bias as outcomes were: i) measured by participants blinded to their treatment allocation and by an independent reference laboratory (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>); ii) trial personnel were blinded to treatment allocation (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>); and iii) knowledge of allocation would not influence assessment of the trial's objective outcomes (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>). We considered two trials to be at high risk of detection bias as these were open‐label trial designs (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). We considered five studies to be at unclear risk of detection bias, as insufficient information was provided to permit a judgement of high or low risk of detection bias (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>). </p> </section> </section> </section> <section id="CD010649-sec-0086"> <h4 class="title">Incomplete outcome data</h4> <section id="CD010649-sec-0087"> <h5 class="title">Prophylactic intervention</h5> <p>We considered 11 trials to be at low risk of attrition bias, with all participants accounted for within the study flow diagram and no withdrawals (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), or where participants were lost to follow‐up this was evenly spread across trial arms (<a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>). We considered two trials to be at high risk of attrition bias because no details were reported about the intervention groups of participants excluded from analysis (<a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>) and four participants were excluded at unclear phases of the study, but following recruitment and may have been excluded following randomisation and treatment administration (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>). We considered five trials to be at unclear risk of attrition bias because: i) the issue of participant dropout and post‐randomisation exclusion was not addressed (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>); and ii) the number of participants randomised to each treatment arm or analysed by outcome was not reported (<a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>). </p> </section> <section id="CD010649-sec-0088"> <h5 class="title">Therapeutic trials</h5> <p>We considered 11 trials to be at low risk of attrition bias, as all participants were accounted for within the study flow diagram and there were no withdrawals (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). We considered one trial to be at high risk of attrition bias, because a third of all participants were not available for the intention‐to‐treat analyses (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>). We considered one trial to be at unclear risk of attrition bias, because we determined that the missing data forms from participants in both study arms were unlikely to have an impact on outcome; as the data were balanced across study groups, this presented an unclear risk of bias (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>). </p> </section> </section> <section id="CD010649-sec-0089"> <h4 class="title">Selective reporting</h4> <section id="CD010649-sec-0090"> <h5 class="title">Prophylactic trials</h5> <p>We considered 14 trials to be at low risk of reporting bias, because all the outcomes were prespecified by the authors and provided in the results (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S); <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). We considered two trials to be at high risk of reporting bias, as the trials did not report data for all predefined outcomes (<a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>). We considered two trials to be at unclear risk of reporting bias, as outcomes were not predefined (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). </p> </section> <section id="CD010649-sec-0091"> <h5 class="title">Therapeutic trials</h5> <p>We considered nine trials to be at low risk of reporting bias, because all the outcomes were prespecified by the authors and covered in the results (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). </p> <p>We considered two trials to be at high risk of reporting bias (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>). In <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>, due to the early discontinuation of the study, data were not reported for a number of prespecified outcomes, including haemoglobin and haematocrit levels. In <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>, the published manuscript did not report findings from all the outcomes they purported to measure. We considered two trials to be at unclear risk of reporting bias, as there was no trial protocol and no clarity about the outcomes measured in the trial (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>). In <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>, the study protocol outlined the use of ROTEM data, but none were reported. </p> </section> </section> <section id="CD010649-sec-0092"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010649-sec-0093"> <h5 class="title">Prophylactic trials</h5> <p>We determined four studies to be at low risk of other potential sources of bias in study design; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a> appeared free of all concerns, while <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C), <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) and <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a> declared industrial funding and support, but reported no conflicts of interest or funder control over data or publication. We considered one trial (<a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>) to be at high risk of bias due to variations in transfusion practice, despite declared protocols and the fact that the company producing the product and sponsoring the trial oversaw the trial operations, audited all data, and conducted the statistical analyses. There is also unclear ownership of trial data, although the publication states full author access. </p> <p>We determined that 13 trials were at an unclear risk of other bias. In seven of these trials, the reasoning was: i) participants enrolled in <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a> appear to have been randomised prior to application of exclusion criteria with more participants excluded from the intervention arm of the study, although the allocation and exclusion numbers were not stated; ii) <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a> did not declare sources of funding or a statement of author interests; iii) <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a> declared industry funding with an industrial employee on the byline, but did not provide any indication of roles or independence of publication or data ownership; iv) <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> declared industrial funding of the study and three authors, including the senior author, were industrial employees. However there was no statement of data ownership, study independence or industrial control of data, manuscript content or publication; v) <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a> declared full author access to data and decision to publish, independent of industrial funding, but ownership of the data was unclear; vi) <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> provided a power analysis identifying that 66 participants were required in each study group, hence insufficient participants (99) were recruited for the study's primary outcome conclusions; and vii) the source of funding for <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> was unclear. In the other six trials there was insufficient information from which to determine the risk of any other forms of bias (<a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>, <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>). </p> </section> <section id="CD010649-sec-0094"> <h5 class="title">Therapeutic trials</h5> <p>We deemed six therapeutic trials to be at low risk of other sources of bias. Five trials (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>) appeared free of all concerns, whilst the sixth (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>) declared industrial support for the study but provided detailed information about involvement and low industrial influence. </p> <p>We considered two trials to be at high risk of bias, due to a declaration of funding by CS Behring and having industrial employees as authors without providing any information about data ownership or control, study, manuscript and publication independence (<a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>). Five trials did not provide sufficient information for us to determine risk of other potential sources of bias (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). </p> </section> </section> </section> <section id="CD010649-sec-0095"> <h3 class="title" id="CD010649-sec-0095">Effects of interventions</h3> <p>See: <a href="./full#CD010649-tbl-0001"><b>Summary of findings for the main comparison</b> FIBRINOGEN: Therapeutic trials: intervention compared to inactive Control for the prevention and treatment of bleeding in participants without haemophilia</a>; <a href="./full#CD010649-tbl-0002"><b>Summary of findings 2</b> FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</a>; <a href="./full#CD010649-tbl-0003"><b>Summary of findings 3</b> FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</a>; <a href="./full#CD010649-tbl-0004"><b>Summary of findings 4</b> FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</a>; <a href="./full#CD010649-tbl-0005"><b>Summary of findings 5</b> FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</a> </p> <p>We present the outcome data in the following way.</p> <p> <ul id="CD010649-list-0013"> <li> <p>by outcome.</p> </li> <li> <p>by type of intervention.</p> </li> <li> <p>by whether the intervention was used in a prophylactic or therapeutic setting.</p> </li> <li> <p>by whether the intervention was being compared with a haemostatically inactive comparator (for example, placebo or saline) or a haemostatically active comparator (whether a different dose of the same intervention or a different haemostatically active intervention). </p> </li> </ul> </p> <p>However, the paucity of quantifiable data that can be combined in a meta‐analysis is such that we cannot provide quantitative analysis for most comparisons. </p> <p>We analysed the three trials enrolling neonates separately from the other included trials (as previously described) (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). Due to the small volumes of the placebo agents and their inactive nature in two trials (<a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>), we have compared all trials in this group as if their comparators are equivalent. </p> <p>Three trials assessed the prophylactic use of factor XIII against an inactive comparator with multiple factor XIII dosing arms (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>). While we appreciate it is not possible to generate an exact comparison across these trials, to facilitate some meaningful analysis we have included the data for the 2500 unit (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>) and 35 unit/kg arms (<a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>), as these should correlate for a 'typical' 70 kg person. Each trial included only a single control arm and we have included them in full. </p> <p>In <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>, the average participant weight was 77 kg, and we have used this value to calculate total intervention doses given. </p> <p>In <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>, the breakdown of the 22 randomised participants was not reported by intervention group, but based on graphical data in the report we have been able to identify that 11 participants were included in each study arm. </p> <section id="CD010649-sec-0096"> <h4 class="title">Primary outcome: mortality (all‐cause)</h4> <section id="CD010649-sec-0097"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials: <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <p>Four trials comparing fibrinogen concentrate versus inactive comparators with 248 participants reported data on all‐cause mortality (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>), but we did not pool data due to differences in the timing of the outcome measurement. </p> <p>There was no evidence of a difference in the number of deaths between the fibrinogen and the inactive comparator arms: risk ratio (RR) 0.33, 95% confidence interval (CI) 0.04 to 3.11; in 116 participants up to 30 days post‐complex cardiac surgery (<a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>) and RR 0.31, 95% CI 0.03 to 2.83; in 92 participants prior to hospital discharge after liver transplantation (<a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>). <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a> and <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a> reported no events at up to four days after radical cystectomy amongst 20 participants and up to seven days after coronary artery bypass graft surgery amongst 20 participants, respectively (<a href="./references#CD010649-fig-0003" title="">Analysis 1.1</a>). </p> </section> <section id="CD010649-sec-0098"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two participant groups reported in 1 trial: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p>No mortality was reported by either <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) or <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S), with 49 participants in total when comparing two different thresholds for administering prophylactic fibrinogen concentrate in complex surgery (<a href="./references#CD010649-fig-0011" title="">Analysis 2.1</a>). </p> </section> <section id="CD010649-sec-0099"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials: <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>All‐cause mortality data from 724 participants was reported by seven trials comparing fibrinogen concentrate with an inactive agent in the management of active bleeding (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). Differences in the timing of the outcome measure and clinical setting of the trial prevented us from pooling data across the seven trials (<a href="./references#CD010649-fig-0018" title="">Analysis 3.1</a>). </p> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> did not demonstrate any evidence of a difference in in‐hospital mortality within 30 days of cardiac surgery between the fibrinogen and inactive comparator intervention arms: RR 5.00, 95% CI 0.25 to 102.00; 120 participants; low‐quality evidence (<a href="./full#CD010649-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Pooled data at 46 days following aortic valve surgery (<a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>) and complex cardiovascular surgery (<a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>) did not demonstrate any evidence of a difference in the number of deaths between the fibrinogen and inactive comparator intervention arms: RR 0.23, 95% CI 0.05 to 1.01; 213 participants; high‐quality evidence (<a href="./full#CD010649-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Two trials investigating the role of fibrinogen concentrate in the management of trauma haemorrhage (<a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>) did not demonstrate any evidence of a difference in the number of deaths between the fibrinogen and inactive comparator intervention arms at 28 days following admission: RR 1.46, 95% CI 0.71 to 2.99; 97 participants; moderate‐quality evidence (<a href="./full#CD010649-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In the management of postpartum haemorrhage no deaths were reported or recorded in two trials six weeks postnatally (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; 50 participants and <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>; 244 participants). </p> </section> <section id="CD010649-sec-0100"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>) </p> <p>Four studies comparing fibrinogen concentrate to haemostatically active comparators reported on all‐cause mortality in 220 participants at different time points (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). No studies reported comparable time points, hence we did not pool data in a meta‐analysis across the trials (<a href="./references#CD010649-fig-0026" title="">Analysis 4.1</a>). </p> <p>Following major elective surgery, there was no evidence of a difference in the number of deaths between fibrinogen and FFP at post‐operative day 30 (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>: RR 0.95, 95% CI 0.06 to 14.30; 43 participants, low‐quality evidence (<a href="./full#CD010649-tbl-0002">summary of findings Table 2</a>)) or 30 days after major trauma (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>: RR 2.20, 95% CI 0.45 to 10.78; 94 participants, very low‐quality evidence (<a href="./full#CD010649-tbl-0002">summary of findings Table 2</a>)). </p> <p>Following cardiac surgery there were no recorded deaths in either the fibrinogen or cryoprecipitate arms at post‐operative day seven or hospital discharge (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>: 63 participants) or when fibrinogen concentrate was compared to platelet infusion at 28 days post‐operatively (<a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>: 20 participants). </p> </section> <section id="CD010649-sec-0101"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(Six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>All‐cause mortality was reported for 414 participants in five trials comparing prophylactic factor XIII with a haemostatically inactive control in adult populations (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>) (<a href="./references#CD010649-fig-0033" title="">Analysis 5.1</a>). </p> <p>Following coronary artery bypass graft surgery there was no evidence of a difference in the number of deaths between the factor XIII and placebo intervention arms at five to seven weeks post‐operatively in <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>: RR 2.78, 95% CI 0.11 to 67.73; 266 participants. <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> reported no events in 16 participants who had undergone coronary artery bypass graft surgery. <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a> recorded no deaths prior to hospital discharge in 50 participants following cardiac surgery. </p> <p>In non‐cardiac scenarios there was no evidence of a difference in all‐cause mortality between factor XIII and haemostatically inactive control groups at an unspecified time point in acute leukaemia patients in <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>: RR 1.07, 95% CI 0.49 to 2.32; 60 participants; or at a median follow‐up of 340 days from elective gastrointestinal surgery in <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>: RR 1.00, 0.26 to 3.91; 22 participants. </p> </section> <section id="CD010649-sec-0102"> <h5 class="title">Factor XIII (FXIII): therapeutic trials with inactive comparator</h5> <p>(one trial: <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> did not report on all‐cause mortality. </p> </section> <section id="CD010649-sec-0103"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(one trial: <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>) </p> <p>In <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> there was no evidence of a difference in the number of deaths amongst pre‐term neonates (time point not stated) when PCC was compared to no treatment: RR 1.05, 95% CI 0.71 to 1.53; 78 participants (<a href="./references#CD010649-fig-0042" title="">Analysis 7.1</a>). </p> </section> </section> <section id="CD010649-sec-0104"> <h4 class="title">Primary outcome: arterial and venous thromboembolic events (VTE)</h4> <section id="CD010649-sec-0105"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials: <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <p>Seven trials reported the incidence of arterial events in 398 participants where fibrinogen concentrate was given prophylactically in comparison to an inactive control (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) (<a href="./references#CD010649-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD010649-fig-0005" title="">Analysis 1.3</a>). We did not combine data across all studies due to differences in the time point of measurement and the clinical settings of the trials. </p> <section id="CD010649-sec-0106"> <h6 class="title">Arterial events</h6> <p>In participants undergoing cardiac surgery, at four days post‐operatively <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a> reported no arterial events in either study arm while <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a> reported a single event in each arm (60 and 20 participants, respectively). At 30 days following cardiac surgery, there was no evidence of a difference in the number of arterial events in <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>: RR 0.33, 95% CI 0.01 to 8.02; 116 participants; low‐quality evidence (<a href="./full#CD010649-tbl-0003">summary of findings Table 3</a>). </p> <p>In studies that assessed fibrinogen concentrate in elective surgery, no arterial events were reported up to three days following radical cystectomy in <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a> (20 participants), up to one week after trans‐urethral prostatic resection in <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> (60 participants) or at 30 days following hip replacement surgery in <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a> (30 participants). In <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>, there was no evidence of a difference in arterial event incidence between the intervention arms 30 days after liver transplantation: RR 0.31, 95% 0.03 to 2.83; 92 participants, low‐quality evidence (<a href="./full#CD010649-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD010649-sec-0107"> <h6 class="title">Venous events</h6> <p>Following cardiac surgery, there was no evidence of a difference in the incidence of venous thromboembolic complications at four days between the intervention arms in <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>: RR 3.00, 95% CI 0.14 to 65.90; 20 participants, moderate‐quality evidence (<a href="./full#CD010649-tbl-0003">summary of findings Table 3</a>). </p> <p>No venous events were reported at four days following cardiac surgery in 60 participants in <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a> or amongst 116 participants at 30 days following cardiac surgery in <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>. Following elective surgery <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a> (20 participants), <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> (60 participants) and <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a> (30 participants) did not report any venous events at three, seven and 30 days, respectively. </p> <p>In <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> there was no evidence of a difference in the incidence of venous thromboembolic complications between the intervention arms 30 days following liver transplantation: RR 0.31, 95% CI 0.01 to 7.32; 92 participants, low‐quality evidence (<a href="./full#CD010649-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD010649-sec-0108"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two trials reported in 1 study: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p><a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) and <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) reported no arterial or venous thromboembolic events in either fibrinogen concentrate supplementation arms (total 49 participants) during the entire participant hospital stay. </p> </section> <section id="CD010649-sec-0109"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials: <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>Six trials reported both arterial and venous thromboembolic events at a single time point each in a total of 562 participants (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). Additionally, adverse event data from <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a> (45 participants) could be used to calculate the per capita event rate for arterial events but not venous events (<a href="./references#CD010649-fig-0019" title="">Analysis 3.2</a>; <a href="./references#CD010649-fig-0020" title="">Analysis 3.3</a>). </p> <section id="CD010649-sec-0110"> <h6 class="title">Arterial events</h6> <p>Neither <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> nor <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> found any arterial events at six weeks following postpartum haemorrhage in 50 and 244 participants, respectively. There were no reported arterial events in <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a> at 28 days following admission for trauma (45 participants). <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> found no evidence of a difference between the fibrinogen and control arms in the arterial events rate at 28 days following admission for trauma: RR 0.47, 95% CI 0.05 to 4.82; 39 participants. </p> <p>In the cardiac surgery studies, there was no evidence of any differences in the number of arterial events at post‐operative day 30 (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; RR 2.33, 95% CI 0.63 to 8.60; 120 participants), day 45 (<a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>: RR 1.10, 95% CI 0.07 to 16.85; 61 participants) and during hospital stay (<a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>: RR 0.33, 95% CI 0.01 to 7.80; 48 participants). </p> </section> <section id="CD010649-sec-0111"> <h6 class="title">Venous events</h6> <p>There were no recorded venous thromboembolic events following cardiac surgery in <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> (120 participants) or <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> (48 participants), or at six weeks following postpartum haemorrhage in <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> (244 participants). In the three trials recording venous thromboembolic events there was no evidence of a difference in the event rate between the fibrinogen and inactive comparator intervention arms: following cardiac surgery in <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>: RR 0.37, 95% CI 0.02 to 8.66; 61 participants; at six weeks following postpartum haemorrhage in <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>: RR 0.92, 95% CI 0.06 to 13.95), 50 participants; and 28 days after an admission with major trauma in <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>: RR 4.76, 95% CI 0.24 to 93.19; 39 participants. </p> </section> </section> <section id="CD010649-sec-0112"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>) </p> <p>Three studies reported on both arterial and venous complications in 126 participants receiving therapeutic fibrinogen concentrate or active comparator (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). Additionally <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> reported on the incidence of venous thromboembolic complications in a further 94 participants. We did not pool data collectively due to differences in the timing of the outcome measurement (<a href="./references#CD010649-fig-0027" title="">Analysis 4.2</a>; <a href="./references#CD010649-fig-0028" title="">Analysis 4.3</a>), the active comparator and the clinical setting of the trials. </p> <section id="CD010649-sec-0113"> <h6 class="title">Arterial events</h6> <p>There was no evidence of a difference in arterial event incidence between the fibrinogen and active comparator arms in <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> seven days after cardiac surgery: RR 0.44, 95% CI 0.09 to 2.10; 63 participants; or in <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> 28 days after cardiac surgery: RR 0.33, 95% CI 0.02 to 7.32; 20 participants; or in <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> 30 days after major elective surgery: RR 2.87, 95% CI 0.12 to 66.75; 43 participants. </p> </section> <section id="CD010649-sec-0114"> <h6 class="title">Venous events</h6> <p>No venous events were reported in either cardiac surgery trial (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). </p> <p>There was no evidence of a difference in venous thromboembolic event incidence between the fibrinogen and active comparator arm in <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> 30 days after trauma admission: RR 0.63, 95% CI 0.21 to 1.87; 94 participants; or following major surgery in <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>: RR 3.00, 95% CI 0.12 to 77.83; 43 participants. </p> </section> </section> <section id="CD010649-sec-0115"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>Four trials of factor XIII prophylaxis reported on thromboembolic complications in 338 participants in cardiac surgery (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>) and surgery for gastrointestinal cancer (<a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>) (<a href="./references#CD010649-fig-0034" title="">Analysis 5.2</a>; <a href="./references#CD010649-fig-0035" title="">Analysis 5.3</a>) </p> <section id="CD010649-sec-0116"> <h6 class="title">Arterial events</h6> <p>No arterial events were reported at up to seven weeks following cardiac surgery in <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> (16 participants). </p> <p>There was no evidence of a difference in arterial thromboembolic events in <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a> up to seven weeks following cardiac surgery: RR 0.67, 95% CI 0.28 to 1.62;, 266 participants; low‐quality evidence; or in <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a> at an unspecified post‐operative time point: RR 0.20, 95% CI 0.01 to 3.97; 50 participants; very low‐quality evidence; or <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a> following gastrointestinal surgery: RR 3.00, 95% CI 0.14 to 66.53; 22 participants; low‐quality evidence. </p> </section> <section id="CD010649-sec-0117"> <h6 class="title">Venous events</h6> <p>No venous events were reported at up to seven weeks following cardiac surgery in <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> (16 participants) or <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a> (50 participants). </p> <p>There was no evidence of a difference in venous thromboembolic events in <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a> up to seven weeks following cardiac surgery: RR 0.93, 95% CI 0.06 to 14.67; 266 participants; low‐quality evidence; or <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a> following gastrointestinal surgery: RR 3.00, 95% CI 0.14 to 66.53; 22 participants; low‐quality evidence. </p> </section> </section> <section id="CD010649-sec-0118"> <h5 class="title">Factor XIII (FXIII): therapeutic trials with inactive comparator</h5> <p>(<i>one trial</i>: <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> did not report the incidence of arterial or venous thromboembolic complications. </p> </section> <section id="CD010649-sec-0119"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(One trial; <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>) </p> <p><a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> did not report the incidence of arterial or venous thromboembolic complications. </p> </section> </section> <section id="CD010649-sec-0120"> <h4 class="title">Secondary outcome: mortality due to bleeding</h4> <section id="CD010649-sec-0121"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials: <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <p><a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>, <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; and <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> reported on this outcome in 248 participants. There was only a single death due to bleeding reported in the fibrinogen arm of <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>: RR 2.76, 95% CI 0.12 to 65.92; 92 participants (<a href="./references#CD010649-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD010649-sec-0122"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two participant groups reported in one trial: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p>No deaths due to bleeding were reported in <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) or <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) from 49 participants in either fibrinogen supplementation arm (<a href="./references#CD010649-fig-0014" title="">Analysis 2.4</a>). </p> </section> <section id="CD010649-sec-0123"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials: <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>Five studies reported data on death due to haemorrhage with a total of 539 participants. <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a> reported no deaths due to bleeding occurred following cardiac surgery in 152 participants up to post‐operative day 46 (<a href="./references#CD010649-fig-0021" title="">Analysis 3.4</a>). </p> <p>Following postpartum haemorrhage, no deaths due to bleeding were reported at six weeks postnatally in either <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> or <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> in 50 and 244 participants, respectively. </p> <p>Mortality due to bleeding following administration of therapeutic fibrinogen at 28 days following trauma admission was reported and pooled for <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> and <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>: there was no evidence of any difference in the number of deaths between the intervention arms: RR 2.45, 95% CI 0.38 to 15.76; 93 participants. </p> </section> <section id="CD010649-sec-0124"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). </p> <p>Four trials with 220 participants reported no incidents of mortality due to bleeding to post‐cardiac surgery day seven (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>: 63 participants) and day 28 (<a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>: 20 participants; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; 43 participants), or at 30 days following trauma (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>: 94 participants) (<a href="./references#CD010649-fig-0029" title="">Analysis 4.4</a>). </p> </section> <section id="CD010649-sec-0125"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(Six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>Four trials with 392 participants reported data for this outcome (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>) (<a href="./references#CD010649-fig-0036" title="">Analysis 5.4</a>). </p> <p><a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a> reported mortality due to bleeding at a median of 32 days following the study intervention: there was no evidence of a difference in mortality due to bleeding in people with acute leukaemia given factor XIII infusion compared to no intervention: RR 0.80, 95% CI 0.20 to 3.28; 60 participants. </p> <p><a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> reported on this outcome following cardiac surgery and reported that no deaths due to bleeding occurred (total 332 participants). </p> </section> <section id="CD010649-sec-0126"> <h5 class="title">Factor XIII (FXIII): therapeutic trials with inactive comparator</h5> <p>(One trial<i>:</i><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> did not report on this outcome. </p> </section> <section id="CD010649-sec-0127"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). </p> <p><a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> did not report on this outcome. </p> </section> </section> <section id="CD010649-sec-0128"> <h4 class="title">Secondary outcome: red blood cell (RBC) transfusion requirement</h4> <p>See <a href="#CD010649-tbl-0006">Table 1</a> for individual study data for this outcome, which was reported in a number of ways (means, median, total) across the included studies. </p> <section id="CD010649-sec-0129"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials<i>:</i><a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <section id="CD010649-sec-0130"> <h6 class="title">Mean red blood cell volume required per participant</h6> <p><a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>, <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a> and <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a> (110 participants in total) reported these data as mean red blood cell volume required per participant, but pooling of data was not possible due to the lack of common time points. Following cardiac surgery, fibrinogen concentrate reduced the red blood cell transfusion requirement at 12 hours post‐operatively (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; mean difference (MD) −150.00, 95% CI −205.72 to −94.28 mL; 20 participants; although this effect was not reproduced intra‐operatively (MD −90.00, 95% CI −281.13 to 101.13 mL; 60 participants). There was no evidence of a difference in red blood cell requirement between the intervention arms at 24 hours post‐cardiac surgery in <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a> (MD −150.00, 95% CI −401.53 to 101.53 mL; 60 participants) or in the perioperative period following hip replacement surgery (<a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; MD −78.00, 95% CI −317.29 to 161.29 mL; 30 participants) (<a href="./references#CD010649-fig-0007" title="">Analysis 1.5</a>). </p> </section> <section id="CD010649-sec-0131"> <h6 class="title">Receipt of a red blood cell transfusion</h6> <p>Nine studies (with 470 participants) reported the number of participants receiving a red cell transfusion (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>). </p> <p>Following cardiac surgery three studies provided a common time point at 24 hours post‐operatively and we pooled the data (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). The data showed a reduction in the number of participants receiving a RBC transfusion with the use of prophylactic fibrinogen in cardiac surgery with moderate heterogeneity: RR 0.53, 95% CI 0.37 to 0.76; P &lt; 0.001; 207 participants; I<sup>2</sup> = 31% (<a href="./references#CD010649-fig-0008" title="">Analysis 1.6</a>). This association was also present when we used a random‐effects model. We noted no change to the effect estimate, but an increase in heterogeneity (analysis not shown) when we restricted the analysis to: </p> <p> <ul id="CD010649-list-0014"> <li> <p>trials including adult participants only: RR 0.53, 95% CI 0.36 to 0.78, I<sup>2</sup> = 65%; 176 participants) (<a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>); </p> </li> <li> <p>trials where the number of participants who were not included in the analysis was unclear: RR 0.53, 95% CI 0.36 to 0.78, I<sup>2</sup> = 65%; 176 participants) (<a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). </p> </li> </ul> </p> <p>We noted a change in the effect estimate in that there was no difference in blood loss between the intervention arms and a reduction in heterogeneity when<br/> we restricted the analysis to to trials with a low or uncertain risk of bias: RR 0.67, 95% CI 0.44 to 1.01, I<sup>2</sup> = 0%; 91 participants) (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). </p> <p>We also found evidence for a reduction in the number of participants receiving a transfusion between the fibrinogen and inactive comparator arm at 48 hours post‐operatively in <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>: RR 0.59, 95% CI 0.38 to 0.92; 116 participants. Conversely, <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a> did not find any evidence for a reduction in the number of participants requiring a red blood cell transfusion at 12 hours following coronary artery bypass grafting: RR 0.33, 95% CI 0.04 to 2.69; 20 participants. </p> <p>We pooled data from the elective, non‐cardiac surgery trials (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), and found evidence of a reduction in the number of participants requiring a red blood cell transfusion following prophylactic fibrinogen at 48 hours post‐operatively: RR 0.23, 95% CI 0.07 to 0.68; P = 0.008; 80 participants; I<sup>2</sup> = 0%; <a href="./references#CD010649-fig-0008" title="">Analysis 1.6</a>). In the trial of participants undergoing spinal fusion surgery (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>) and liver transplantation (<a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>) there was no evidence of a difference in the number of participants requiring a RBC transfusion between the intervention arms at 24 hours following surgery: RR 1.01, 95% CI 0.76 to 1.33; 92 participants; and RR 0.07, 95% CI 0.00 to 1.22; 41 participants, respectively). </p> <p>Four studies reported data at a range of different time points, as medians with IQRs (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>). See <a href="#CD010649-tbl-0006">Table 1</a> for these values. </p> </section> </section> <section id="CD010649-sec-0132"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two participant groups reported in one trial: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p><a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) and <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) reported the mean and median quantity of red cells transfused (in 49 participants). This trial compared receipt of fibrinogen concentrate at two predefined intraoperative fibrinogen concentrations: early substitution and conventional substitution. In both surgical settings, participants in the conventional substitution arm received a greater quantity of red cells within the first 24 hours following surgery than participants in the early substitution arm (see <a href="#CD010649-tbl-0006">Table 1</a>), although there was no evidence of a statistically significant difference between the intervention arms in either trial (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C): MD −8.70 (95% CI −21.71 to 4.31) mL/kg; 30 participants; and <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a>(S): MD −3.50, 95% CI −9.99 to 2.99 mL/kg; 19 participants; (<a href="./references#CD010649-fig-0015" title="">Analysis 2.5</a>). </p> <p>All 30 participants in the craniosynostosis trial (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C)) received a RBC transfusion within 24 hours of surgery. There was no evidence of a difference in the number of participants requiring a transfusion at 24 hours following surgery in the scoliosis trial (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a>(S)): RR 0.60, 95% CI 0.25 to 1.46; 19 participants). </p> </section> <section id="CD010649-sec-0133"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials: <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>Six trials including 568 participants reported data for RBC transfusion requirement (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). All six trials reported the number of participants who received a RBC transfusion, although differences in the measurement time points and the clinical setting of the trials prevented us from pooling the data (<a href="./references#CD010649-fig-0022" title="">Analysis 3.5</a>). </p> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> and <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a> reported the incidence of receipt of a RBC transfusion within 24 hours of delivery of the study drug in the management of bleeding during cardiac surgery. There was evidence of a reduction in receipt of a RBC transfusion for the participants who received fibrinogen in comparison with the placebo group: RR 0.54, 95% CI 0.39 to 0.75; P &lt; 0.001; 178 participants; I<sup>2</sup> = 0%; <a href="./references#CD010649-fig-0022" title="">Analysis 3.5</a>). The investigators also reported the median number of red blood cell units transfused (within 24 hours of delivery of the study drug), which was less in the fibrinogen group than in the placebo group (see <a href="#CD010649-tbl-0006">Table 1</a>). This finding was not repeated at the later time point reported by <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>, who found no evidence of a difference in the number of participants requiring a RBC transfusion during their entire hospital stay: RR 1.00, 95% CI 0.38 to 2.66; 48 participants. </p> <p><a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> found no evidence of a difference in the receipt of a RBC transfusion in 244 women with a postpartum haemorrhage who received fibrinogen or placebo (saline) within four hours (RR 0.39, 95% CI 0.13 to 1.22), within 24 hours (RR 0.72, 95% CI 0.38 to 1.38), and within seven days (RR 0.95, 95% CI 0.58 to 1.54) of receipt of the study drug. The investigators also reported the number of women who received a transfusion of four units or more (time point unspecified), with no evidence of a difference between the fibrinogen and the placebo (saline) group: RR 2.74, 95% CI 0.71 to 10.57; 244 participants. Similarly <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> found no evidence of a difference in the number of participants receiving a red blood cell transfusion between the fibrinogen concentrate and placebo arms before hospital discharge for postpartum haemorrhage: RR 0.96, 95% CI 0.55 to 1.69; 55 participants. </p> <p><a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> found no difference in the incidence of RBC transfusion following admission for trauma at three hours (RR 1.05, 95% CI 0.86 to 1.29; 46 participants), at six hours (RR 1.05, 95% CI 0.84 to 1.30; 43 participants), or 24 hours (RR 1.11, 95% CI 0.91 to 1.36; 41 participants). </p> <p>Only <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> reported the volume of red blood cells transfused; during the hospital stay following cardiac surgery there was no evidence of a difference between participants in whom bleeding was managed with fibrinogen concentrate and those who received placebo: MD −210.00, 95% CI −608.81 to 188.81 mL; 48 participants (<a href="./references#CD010649-fig-0023" title="">Analysis 3.6</a>). </p> <p>Median values are reported in <a href="#CD010649-tbl-0006">Table 1</a>. These data were presented in seven studies (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>). </p> </section> <section id="CD010649-sec-0134"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>) </p> <p>All four trials (total of 220 participants) reported data for RBC transfusion requirement. <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> reported the volume of RBC transfusion required following major elective surgery when fibrinogen concentrate was used as a partial replacement for FFP in the management of bleeding, but found no evidence of a difference between the intervention arms (MD −120.00, 95% CI −546.93 to 306.93 mL; 43 participants (<a href="./references#CD010649-fig-0030" title="">Analysis 4.5</a>). </p> <p>Three trials (total of 177 participants) reported the number of participants receiving a RBC transfusion (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>), but due to differences in the haemostatically active control used and the time points reported we did not undertake any meta‐analyses. Following cardiac surgery <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> reported no evidence of a difference in red cell exposure by 24 hours post‐operatively between the study's fibrinogen and platelet arms: RR 1.00, 95% CI 0.75 to 1.34; 20 participants. <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> reported no evidence of a difference between fibrinogen and FFP for red cell exposure 24 hours after a trauma admission: RR 1.04, 95% CI 0.90 to 1.21; 94 participants, and <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> found no difference at post‐operative day seven between fibrinogen and cryoprecipitate: RR 0.86, 95% CI 0.72 to 1.02; 63 participants (<a href="./references#CD010649-fig-0031" title="">Analysis 4.6</a>). </p> <p>Median values are reported in <a href="#CD010649-tbl-0006">Table 1</a> for <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>. </p> </section> <section id="CD010649-sec-0135"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(Six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>Five trials (472 participants) reported data for RBC transfusion requirement (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>). </p> <p>One study (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>) reported the volume of red blood cells transfused and found no evidence of a difference between the intervention arms: −MD 0.70, 95% CI −1.63 to 0.23; 50 participants; <a href="./references#CD010649-fig-0037" title="">Analysis 5.5</a>). <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a> reported data for the number of participants who received a RBC transfusion following elective surgery; there was no evidence of a difference between factor XIII and placebo: RR 0.97, 95% CI 0.70 to 1.35; 266 participants (<a href="./references#CD010649-fig-0038" title="">Analysis 5.6</a>). <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> stated that this outcome was measured in their trial, but did not report their findings. </p> <p>Data were reported as medians with IQRs only for <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>, <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a> and <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>. In <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>, the surgical participants in the haemostatically inactive control (placebo) arm received more RBC units than participants in the haemostatically active arm. In <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>, people with acute leukaemia in the haemostatically active arm required more RBC units than those in the haemostatically inactive control (placebo) arm. Median values are reported in <a href="#CD010649-tbl-0006">Table 1</a>. </p> </section> <section id="CD010649-sec-0136"> <h5 class="title">Factor XIII (FXIII):therapeutic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> did not report on this outcome. </p> </section> <section id="CD010649-sec-0137"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>) </p> <p><a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> did not report on this outcome. </p> </section> </section> <section id="CD010649-sec-0138"> <h4 class="title">Blood loss</h4> <p>See <a href="#CD010649-tbl-0007">Table 2</a> for individual study data for this outcome, which was reported in a number of ways (means, median, total) across the included studies. </p> <section id="CD010649-sec-0139"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials: <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <p>Post‐operative bleeding was reported by eight trials with 378 participants (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>, <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) (<a href="./references#CD010649-fig-0009" title="">Analysis 1.7</a>). </p> <p>In three trials, there was evidence of a difference in blood loss between the treatment arms with more blood being lost in the inactive comparator group than in the group that received fibrinogen concentrate (<a href="./references#CD010649-fig-0009" title="">Analysis 1.7</a>). We pooled data for the two cardiac surgery trials which reported blood loss at 12 hours post‐operatively (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>): Ratio of Geometric Means 0.68, 95% CI 0.60 to 0.76; P &lt; 0.001; I<sup>2</sup> = 0%; 180 participants. <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> reported evidence of a 21% reduction in bleeding at 24 hours following spinal fusion surgery for prophylactic fibrinogen concentration in comparison to an inactive comparator: Ratio of Geometric Means 0.77, 95% CI 0.66 to 0.89; P &lt; 0.001; 41 participants. </p> <p>There was no evidence of a difference between the intervention arms:</p> <p> <ul id="CD010649-list-0015"> <li> <p>in intra‐operative (Ratio of Geometric Means 0.90, 95% CI 0.64 to 1.27; 30 participants) or 24‐hour blood loss during hip surgery (Ratio of Geometric Means 0.99, 95% CI 0.80 to 1.24; 30 participants) in <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; </p> </li> <li> <p>in intra‐operative (Ratio of Geometric Means 1.02, 95% CI 0.75 to 1.37; 60 participants); or 48‐hour blood loss following prostatic resection (Ratio of Geometric Means 0.85, 95% CI 0.57 to 1.27; 60 participants) in <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>; </p> </li> <li> <p>in blood loss at one hour following cardiac surgery (Ratio of Geometric Means 0.75, 95% CI 0.52 to 1.09; 31 participants) in <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; </p> </li> <li> <p>in blood loss during and up to 48 hours after radical cystectomy (Ratio of Geometric Means 0.94, 95% CI 0.67 to 1.33; 20 participants) in <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>. </p> </li> </ul> </p> <p><a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a> reported the median quantity of blood lost from chest drain in the first 12 hours following elective cardiac surgery in 116 participants: there was less blood loss in participants receiving fibrinogen compared to the placebo control (saline); see <a href="#CD010649-tbl-0007">Table 2</a>. </p> </section> <section id="CD010649-sec-0140"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two participant groups reported in one trial; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p><a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) and <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) reported the median calculated total blood loss at 24 hours following surgery. This trial compared receipt of fibrinogen concentrate at two predefined intraoperative fibrinogen concentrations: early substitution and conventional substitution. In both surgical settings, participants in the conventional substitution arm had a greater total blood loss 24 hours post‐operatively than those in the early substitution arm. Median values are reported in <a href="#CD010649-tbl-0007">Table 2</a>. </p> </section> <section id="CD010649-sec-0141"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials: <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>Five trials with 614 participants reported data for blood loss post‐intervention.</p> <p>The only trial that reported mean blood loss following use of fibrinogen concentrate as a treatment for bleeding (<a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>) found no evidence of a difference in bleeding volume during surgery (Ratio of Geometric Mean 0.87, 95% CI 0.68 to 1.11; 48 participants) or at 12 hours post‐operatively (Ratio of Geometric Mean 0.86, 95% CI 0.67 to 1.11; 48 participants), although blood loss was lower in the fibrinogen arm at all time points (<a href="./references#CD010649-fig-0024" title="">Analysis 3.7</a>). </p> <p>Median blood loss was reported in five trials (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> provided median blood loss data at seven time points following cardiac surgery up to 24 hours post‐operatively. Participants who received fibrinogen demonstrated lower bleeding volumes at all time points. <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> and <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> provided median haemorrhage volumes following postpartum haemorrhage. In the fibrinogen intervention arm, <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> found there was less blood loss at 24 hours following study intervention, while in <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> there was no difference at up to six weeks postpartum. <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> and <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> reported median blood loss after cardiac surgery. <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> found comparable bleeding volumes during surgery with lower volumes at 12 hours post‐operatively in the fibrinogen arm. <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> demonstrated lower blood loss at 6, 12 and 24 hours post‐operatively in the active intervention arm. </p> <p>Median values are reported in <a href="#CD010649-tbl-0007">Table 2</a>. </p> </section> <section id="CD010649-sec-0142"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>) </p> <p>Two trials with 80 participants reported median data for blood loss post‐intervention (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> reported median blood loss as chest drainage to 12 hours post‐cardiac surgery, and <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> reported median blood loss at 48 hours following cardiac surgery. In both trials those participants who received the fibrinogen concentrate lost less blood than participants who received the respective haemostatically active control: cryoprecipitate in <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>, and platelets in <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>. Median values are reported in <a href="#CD010649-tbl-0007">Table 2</a>. </p> </section> <section id="CD010649-sec-0143"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(Six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>Only two trials (total of 66 participants) reported mean blood loss following prophylactic administration of factor XIII, both in cardiac surgery (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>). Blood loss was reported at a range of time points; at all time points blood loss was lower in the haemostatically active arm. We pooled data for two common time points, eight and 24 hours post‐operatively. There was evidence of reduced blood loss in participants who received factor XIII when compared to an inactive comparator at eight hours (Ratio of Geometric Mean 0.79, 95% CI 0.65 to 0.97; P = 0.02; I<sup>2</sup> = 0%; 66 participants) but this did not persist at 24 hours post‐operatively (Ratio of Geometric Mean 0.85, 95% CI 0.72 to 1.00; 66 participants) (<a href="./references#CD010649-fig-0039" title="">Analysis 5.7</a>). </p> <p><a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a> reported data at three further time points, with evidence of a reduction in blood loss for participants who had received factor XIII, in comparison to placebo at 12 hours (Ratio of Geometric Mean 0.78, 95% CI 0.63 to 0.97; P = 0.02; 50 participants), at 36 hours (Ratio of Geometric Mean 0.82, 95% CI 0.68 to 0.98; P = 0.03; 50 participants), and at 48 hours (Ratio of Geometric Mean 0.73, 95% CI 0.62 to 0.86; P &lt; 0.001; 50 participants) post‐operatively. <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a> reported blood loss data at the time of drain removal and observed that there was no evidence of a difference in blood loss between the intervention arms at those time points (Ratio of Geometric Mean 0.68, 95% CI 0.32 to 1.47; 16 participants). </p> <p><a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a> reported median blood loss at the completion of surgery for gastrointestinal cancer and noted greater blood loss in the Factor XIII arm when compared to placebo, see <a href="#CD010649-tbl-0007">Table 2</a> for median values. </p> </section> <section id="CD010649-sec-0144"> <h5 class="title">Factor XIII (FXIII): therapeutic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> did not report on blood loss post‐intervention. </p> </section> <section id="CD010649-sec-0145"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>) </p> <p><a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> did not report on blood loss post‐intervention. </p> </section> </section> <section id="CD010649-sec-0146"> <h4 class="title">Secondary outcome: allergic adverse reactions</h4> <section id="CD010649-sec-0147"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials: <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <p>One cardiac surgery trial (<a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>), and two non‐cardiac surgery trials (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>), with 196 participants in total, provided data on the incidence of allergic or hypersensitivity events following fibrinogen concentrate administration. No adverse events were reported at any time point. </p> </section> <section id="CD010649-sec-0148"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two participant groups reported in one trial: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p>No allergic adverse events to fibrinogen concentrate were reported in either arm of <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C) or <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S) in a total of 49 participants up to 24 hours post‐operatively. </p> </section> <section id="CD010649-sec-0149"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials; <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>Four trials reported data on hypersensitivity reactions to fibrinogen concentrate or placebo in 470 participants. A single allergic event was recorded within 24 hours of placebo administration in the setting of postpartum haemorrhage (<a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>: RR 0.33 (95% CI 0.01 to 8.06); 244 participants). No allergic reactions were reported at any time point following cardiac surgery (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>), or trauma (<a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>). </p> </section> <section id="CD010649-sec-0150"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>) </p> <p>Two trials with 106 participants reported data on allergic adverse reactions and found no hypersensitivity reactions to fibrinogen concentrate or the active comparators cryoprecipitate (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>), and FFP (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>). </p> </section> <section id="CD010649-sec-0151"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(Six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>Five trials (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) reporting on 206 participants reported no incidents of allergy to factor XIII, although the time points were unclear in all of these studies. </p> </section> <section id="CD010649-sec-0152"> <h5 class="title">Factor XIII (FXIII): therapeutic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> found no evidence of hypersensitivity to factor XIII in 28 participants. </p> </section> <section id="CD010649-sec-0153"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>) </p> <p><a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a> reported no allergic reactions during administration of PCC prophylaxis in 78 participants. </p> </section> </section> <section id="CD010649-sec-0154"> <h4 class="title">Change to laboratory measures of coagulation, both standard laboratory tests and global measurements of coagulation </h4> <p>Due to the volume and heterogeneity of time points, definitions, reporting formats and tests performed, we did not undertake statistical analyses of these data. Instead we report the number of studies which reported on this outcome and the measures that they used to assess the outcome. </p> <section id="CD010649-sec-0155"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with inactive comparator</h5> <p>(Nine trials: <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>; <a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a>) </p> <p>Eight trials (410 participants) reported measures of coagulation (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). All studies reported standard laboratory measures (most commonly Clauss fibrinogen levels) except <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>, where only TEG results were reported. Three studies reported viscoelastic tests and standard laboratory measures (<a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>), and only one study reported additional global testing (thrombin generation: <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>). All studies took samples at baseline and five reported a coagulation outcome at 24 hours (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0017" title="Effect of prophylactic administration of fibrinogen concentrate on volume of transfused packed RBC during and after total hip arthroplasty in hospital during 2011‐12. IRCT trial number 201012264784N2. NajafiA , MoharariRS , OrandiAA , EtezadiF , SanatkarM , KhajaviMR , et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trials study. Acta Medica Iranica2014;52(11):804‐10. ">Najafi 2014</a>; <a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>). There was marked heterogeneity across the studies in timing and frequency of testing. </p> </section> <section id="CD010649-sec-0156"> <h5 class="title">Fibrinogen concentrate: prophylactic trials with active comparator</h5> <p>(Two participant groups reported in one trial: <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)) </p> <p>These two trials analysed standard coagulation tests (activated partial thromboplastin time, international normalised ratio (INR), Clauss fibrinogen and factor XIII) and ROTEM at baseline alone (<a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (C); <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> (S)). </p> </section> <section id="CD010649-sec-0157"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with inactive comparator</h5> <p>(Eight trials: <a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>) </p> <p>All eight trials (with 759 participants) reported standard clotting tests, including Clauss fibrinogen, with all studies reporting results from baseline. Three studies (<a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>) reported additional ROTEM measures, with all three using a FIBTEM test (a ready‐to‐use ROTEMsystem reagent for use with citrated whole blood, and assesses the firmness of the fibrin clot). The reporting of post‐intervention coagulation tests varied, particularly with timing of tests. Between two and 10 tests were performed between two hours and day 11 post‐intervention. The commonest reported time was 24 hours, which was conducted in six studies (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>; <a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a>). </p> </section> <section id="CD010649-sec-0158"> <h5 class="title">Fibrinogen concentrate: therapeutic trials with active comparator</h5> <p>(Four trials: <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>) </p> <p>All four trials (with 220 participants) reported standard clotting assays and viscoelastic measures (all used ROTEM). Three studies reported coagulation factor levels, which varied between trials: factors II, VII, IX, X and XIII (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>); factors II, VIII, IX, X, anti‐thrombin (<a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>); and factor XIII and anti‐thrombin (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>). All studies reported baseline results and three of the four reported 24‐hour results (<a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>; <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a>). </p> </section> <section id="CD010649-sec-0159"> <h5 class="title">Factor XIII (FXIII): prophylactic trials with inactive comparator</h5> <p>(Six trials: <a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>) </p> <p>Five trials reported FXIII levels at baseline and at one or more subsequent time points (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>), which varied widely between 30 minutes post‐intervention (<a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>; <a href="./references#CD010649-bbs2-0016" title="Safety of rFXIII in patients following first time myocardial revascularisation requiring cardiopulmonary bypass. ClinicalTrials.gov; reference number NCT02239146. LevyJH , GillR , NussmeierNA , OlsenPS , AndersenHF , BoothFV , et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A‐subunit homodimer. A preliminary report. Thrombosis &amp; Haemostasis2009;102(4):765‐71. ">Levy 2009</a>) to once a week testing (<a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>). One trial, with 58 neonates, reported only one set of coagulation tests (factor XIII, Clauss fibrinogen, plasminogen, anti‐thrombin, proteins C and S, alpha‐2 anti‐plasmin, plasmin‐anti‐plasmin and fibrinogen degradation products), taken within the first week of birth (<a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). Standard clotting tests (activated partial thromboplastin time, prothrombin time and Clauss fibrinogen) were reported in two studies (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0023" title="RascheH , HaghouF , GausW , DietrichM , HoelzerD , PfliegerH , et al. [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. [German]. [Blutgerinnungsfaktor‐XII‐Substitution bei akuter Leukämie]. Deutsche Medizinische Wochenschrift1982;107(49):1482‐6. ">Rasche 1982</a>), and two studies reported Clauss fibrinogen only (<a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>; <a href="./references#CD010649-bbs2-0026" title="NakamuraT , AriyoshiN , ShirahataA . Effect of prophylactic administration of factor XIII concentrate on intraventricular haemorrhage in premature infants. Thrombosis and Haemostasis2009;62(1989):287. ShirahataA , NakamuraT , ShimonoM , KanekoM , TanakaS . Blood coagulating findings and the efficacy of Factor XIII concentrate in premature infants with intracranial haemorrhages. Thrombosis Research1990;57:755‐63. ">Shirahata 1990</a>). Only one study reported ROTEM measures (<a href="./references#CD010649-bbs2-0014" title="KorteWC , SzadkowskiC , GahlerA , GabiK , KownackiE , EderM , et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology2009;110(2):239‐45. ">Korte 2009</a>). </p> </section> <section id="CD010649-sec-0160"> <h5 class="title">Factor XIII (FXIII): therapeutic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>) </p> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> reported FXIII measures at nine time points, including baseline and up to day 42 post‐therapy in 20 participants. No other coagulation parameter was reported. </p> </section> <section id="CD010649-sec-0161"> <h5 class="title">Prothrombin complex concentrate (PCC): prophylactic trials with inactive comparator</h5> <p>(One trial: <a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>) </p> <p>Standard clotting assays (activated partial thromboplastin time, prothrombin time, Clauss fibrinogen) were reported at two time points, baseline and post‐intervention, in the 78 neonates in this trial (<a href="./references#CD010649-bbs2-0029" title="TurnerT , ProwseCV , PrescottRJ , CashJD . A clinical trial on the early detection and correlation of haemostatic defects in selected high‐risk neonates. Bristish Journal of Haematology1981;47:65‐75. [PUBMED: 7002204] ">Turner 1981</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010649-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010649-sec-0162"></div> <section id="CD010649-sec-0163"> <h3 class="title" id="CD010649-sec-0163">Summary of main results</h3> <p>We identified 31 randomised controlled trials which involved a total of 2392 participants, and compared the use of intravenous pro‐coagulant haemostatic factors with either placebo or another haemostatically active agent. </p> <p>Unlike inherited bleeding conditions, where a person has a deficiency in one coagulation factor alone, acquired coagulopathy is more complex, often involving multiple deficiencies of coagulant factors, and which also evolves with time. For example, in trauma haemorrhage, when trauma coagulopathy is present it leads initially to a reduction in pro‐coagulant factors (i.e. including factors V, XIII and fibrinogen); an increase in fibrinolytic factors (i.e. tissue plasminogen activator (t‐PA) with low plasminogen activator inhibitor type 1 (PAI‐1) and alpha 2‐antiplasmin (A2‐AP)) as well as an alteration of anticoagulant factors (i.e. high activated protein C levels). These initial changes can be associated with a bleeding phenotype, although at later stages can shift towards a pro‐thrombotic state. This has implications for the management of acquired bleeding, as it suggests that single pro‐haemostatic therapies may have less effect. This review therefore was aimed at understanding the trial data to inform efficacy and safety of multiple pro‐coagulants, or in combination. </p> <p>Our review identified data on three different pro‐haemostatic agents as interventions: fibrinogen (23 trials), Factor XIII (7 trials) and PCC (1 trial). While the earlier studies focused on factor XIII, there has been an increase in the investigation of fibrinogen concentrate since 2010, as demonstrated by fibrinogen concentrate being the focus of most of the trials published in the last five years. Eighteen trials explored the use of these pro‐haemostatic agents as prophylaxis for bleeding and 13 trials explored their therapeutic use. Fibrinogen was the focus of 12 of the 13 therapy‐orientated trials whilst six of the factor XIII trials tested used it as a prophylactic agent. </p> <section id="CD010649-sec-0164"> <h4 class="title">Summary of primary outcomes</h4> <p>The primary outcomes were all‐cause mortality (reported by 21 trials), arterial thromboembolic events (reported by 22 trials) and venous thromboembolic events (reported by 21 trials). The results of meta‐analyses did not demonstrate an impact of pro‐haemostatic agents on mortality or the incidence of arterial or venous thromboembolic events. The overall quality of this evidence ranged from very low to high (<a href="./full#CD010649-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010649-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010649-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010649-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD010649-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD010649-sec-0165"> <h4 class="title">Summary of secondary outcomes</h4> <p>Data were available for all of our secondary outcomes: mortality due to bleeding, red blood cell transfusion requirement, blood loss and allergic reaction. We also reported on changes to laboratory measures of coagulation, both standard laboratory tests and global measurements of coagulation, but meta‐analysis of these data were limited by heterogeneity in the assays and reported results. </p> <p>Overall there was no evidence of a decrease in mortality due to bleeding in any of the 10 trials that contributed data for this outcome. Fibrinogen concentrate was associated with a reduction in the individual patient risk of being exposed to a red blood cell transfusion when compared to inactive comparators. This finding was evident in both cardiac and non‐cardiac surgery settings and in the prophylactic and therapeutic settings (<a href="./references#CD010649-fig-0008" title="">Analysis 1.6</a>, <a href="./references#CD010649-fig-0022" title="">Analysis 3.5</a>). Additionally, prophylactic fibrinogen concentrate was found to reduce post‐operative bleeding in two studies of cardiac surgery and one trial in orthopaedic surgery, when compared to a haemostatically inactive comparator (<a href="./references#CD010649-fig-0009" title="">Analysis 1.7</a>). Overall, the prophylactic use of fibrinogen concentrate almost halves the risk of a person requiring a blood transfusion following cardiac surgery and reduces it by 75% in non‐cardiac surgery compared to placebo (<a href="./references#CD010649-fig-0008" title="">Analysis 1.6</a>). Prophylactic factor XIII demonstrated efficacy at reducing the volume of post‐operative bleeding in cardiac surgery compared to placebo (<a href="./references#CD010649-fig-0039" title="">Analysis 5.7</a>). </p> <p>All studies that reported blood loss following surgery found greater blood loss in the haemostatically inactive arm (no use of pro‐haemostatic agents), irrespective of differences in the clinical setting, the intervention or how and when blood loss was measured. Across all trials only a single intervention‐related allergic adverse event was recorded in an inactive‐control study arm participant. </p> <p>Overall the data evaluating coagulation test results were highly variable, with data presenting a wide range of standard as well as global tests (viscoelastic and thrombin generation). There was no consensus on the timing or frequency of results which were used to evaluate the 'laboratory efficacy' of the intervention in each clinical trial. Of more importance is the overwhelming lack of any attempt by trialists to combine laboratory data with clinically meaningful endpoints; for example, if a pro‐haemostatic drug is being given with the aim of preventing or treating bleeding, laboratory data would be best presented in combination with clinical endpoints such as 'cessation of bleeding' or 'time to haemostasis'. </p> </section> </section> <section id="CD010649-sec-0166"> <h3 class="title" id="CD010649-sec-0166">Overall completeness and applicability of evidence</h3> <section id="CD010649-sec-0167"> <h4 class="title">Completeness</h4> <p>The interpretation of the findings of our review are limited by the individual trial data that contributed to meta‐analyses. Specifically, meta‐analysis of the data across trials was not possible for many outcomes, due to a lack of common time points or inadequate or inconsistent definitions of time points. We were only able to report data on our primary outcomes of mortality and thromboembolic events in 21 out of 31 trials. </p> <p>The identified studies recruited participants across a broad range of clinical settings in which pro‐haemostatic agents are likely to be used. These include trauma, postpartum haemorrhage and cardiac surgery, where clinical outcomes might be modified significantly by optimal use of pro‐haemostatic agents. However, other clinical areas of bleeding risk, such as gastro‐intestinal bleeding, were poorly represented in the included trials. </p> </section> <section id="CD010649-sec-0168"> <h4 class="title">Applicability</h4> <p>Applicability of the review findings is limited. None of the included studies was powered to detect harm or adverse events, and there is little documentation of adverse events to the 90‐day time point that is recommended for hospital‐associated thromboembolic complications. The poor quality of the evidence means that the results for outcomes assessed in this review cannot be applied in other clinical settings (See 'Summary of findings' tables). </p> </section> </section> <section id="CD010649-sec-0169"> <h3 class="title" id="CD010649-sec-0169">Quality of the evidence</h3> <p>We used GRADE to summarise the quality of evidence for the two primary outcomes: mortality and thromboembolic events in the 'Summary of findings' tables. We focused on mortality for the studies assessing the use of pro‐coagulant haemostatic agents as a treatment for bleeding and thromboembolic events to assess the prophylactic use of pro‐coagulant haemostatic agents. The overall quality of the evidence ranged from very low to high, with most trial outcomes being rated as low quality. We considered no trial to be at low risk of bias in all domains, but we downgraded half the outcomes by one level for risk of bias. Domains with high risk of bias included allocation concealment, blinding of study personnel and outcome assessors, incomplete outcome data and selective reporting. The small cohorts and rare mortality and thrombotic events introduced risks of imprecision. Lastly, the trials in this review represented most of the clinical areas in which bleeding is observed, but not all clinical areas were represented in each of the intervention comparisons. Moreover the trials did not set out to explore the outcomes of interest to this review, and this introduced inconsistency. Lastly, we did not downgrade any outcome due to inconsistency, perhaps as a consequence of GRADE assessments being based on outcome data for one or two studies due to diversity in the clinical setting and the timing of outcome measurements, which limited our ability to pool data across studies (as has been highlighted above). </p> </section> <section id="CD010649-sec-0170"> <h3 class="title" id="CD010649-sec-0170">Potential biases in the review process</h3> <p>The searches performed for this review were extensive and we have tried to identify all trials eligible for inclusion, regardless of their publication status or language of publication. We have also attempted to obtain missing data from all the included studies to provide a complete picture of the primary and secondary review outcomes, and were able to acquire this from eight authors. The review authors performed screening and data extraction in duplicate to minimise bias and were blinded to each other's results. </p> <section id="CD010649-sec-0171"> <h4 class="title">Included study bias</h4> <p>Determining the risks of bias of these studies highlighted a range of methodological issues. A significant number of studies were unclear in their randomisation methodology (15 studies) and allocation concealment (14 at unclear risk and five at high risk of bias). Any impairment of the randomisation process is known to generate an overestimation of the clinical efficacy of any intervention (<a href="./references#CD010649-bbs2-0094" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a>). Similarly the blinding status of outcome assessors was often not addressed (13 at unclear risk and five at high risk of bias), although most outcomes in these trials were objective and therefore not prone to observer bias. More important, however, is the frequency with which study personnel were either unblinded or where insufficient information was available to assess their level of blinding (five at unclear risk and seven at high risk of bias). This is concerning for outcomes such as transfusion, especially where no algorithm or threshold for transfusion was applied, where decisions are likely to be prone to bias. </p> </section> <section id="CD010649-sec-0172"> <h4 class="title">Limitations of this review</h4> <p>Most of the studies we identified that contributed to this review were small‐scale, with a mean of 78 participants (range 20 to 479). This review is clearly limited to the data published and provided by the trial authors. A surprising number of studies did not provide mortality data as an outcome (10 studies). Most outcomes of interest in this review are objective and have well‐defined criteria, although the definitions of thromboembolic events, allergy and blood loss provided were less robust. </p> <p>Sample sizes in future randomized trials powered on clinical outcomes of mortality (or even preferably mortality due to bleeding) would need to be greatly increased. Analogous examples for power calculations would be CRASH2 (<a href="./references#CD010649-bbs2-0077" title="CRASH‐2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial. Lancet2010;376:23‐32. [DOI: 10.1016/S0140‐6736(10)60835‐5] ">CRASH‐2 2010</a>), WOMAN (<a href="./references#CD010649-bbs2-0104" title="WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised, double‐blind, placebo‐controlled trial. Lancet 389;10084:2105‐16. [DOI: 10.1016/S0140‐6736(17)30638‐4] ">WOMAN 2017</a>) and HALT IT (<a href="./references#CD010649-bbs2-0093" title="RobertsI , CoatsT , EdwardsP , GilmoreI , JairathV , KerK , et al. HALT‐IT ‐ tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. Trials2014;15:450‐63. ">Roberts 2014</a>, <a href="./references#CD010649-bbs2-0073" title="BrennerA , ArribasM , CuzickJ , JairathV , StanworthS , KerK , et al. Outcome measures in clinical trials of treatments for acute severe haemorrhage. Trials2018;19(1):533‐9. ">Brenner 2018</a>), which recruited between 15,000 and 20,000 participants each. </p> <p>We have grouped the wide range of study clinical settings into the broad primary categories of therapy or prophylaxis. However, we recognise heterogeneity within these settings and at further levels. For example, trials within the cardiac group may include more routine coronary artery bypass graft surgery (<a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>), or complex aortic surgery (<a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>), presumably with different levels of bleeding risk. </p> <p>The study interventions, doses and administration regimens varied. However, several of these agents act through common pathways of coagulation (factor XIII and fibrinogen, for example, principally act to increase clot strength and reduce the susceptibility of clots to fibrinolysis), and in some recent trials these interventions were used in combination (<a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a>). Fibrinogen concentrate doses ranged from one gram (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>) to six grams (<a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a>; <a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a>), and factor XIII therapy ranged from a single dose (<a href="./references#CD010649-bbs2-0008" title="GodjeO , GallmeierU , CalatzisA , SchelianM , FriedlR , GrunewaldM , et al. Reduction of blood loss and blood transfusions after cardiac surgery by application of plasma coagulation factor XIII. Annals of Hematology. 2002. 2002; Vol. 81 (Suppl 1):A22. GodjeO , GallmeierU , SchelianM , GrunewaldM , MairH . Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thoracic &amp; Cardiovascular Surgeon2006;54(1):26‐33. ">Godje 2006</a>; <a href="./references#CD010649-bbs2-0012" title="KarkoutiK , vonHeymannC , JespersenCM , KorteW , LevyJH , RanucciM , et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo‐controlled, multicenter clinical trial. The Journal of Thoracic and Cardiovascular Surgery2013;146(4):927‐39. [PUBMED: 23820174] ">Karkouti 2013</a>) to nine daily doses (<a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a>). In this review we have not differentiated between the doses given, as at present there are no robust data to support any one dose or dose calculation as providing clinical efficacy in a given setting. However, the more recent fibrinogen concentrate papers have implemented fibrinogen‐dosing protocols based on fibrinogen levels or viscoelastic markers of clot strength (<a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a>; <a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a>; <a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>; <a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a>; <a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a>). While this approach might eventually permit individualised approaches to product dosing, it increases the difficulty of comparing these studies. Additionally it is likely that some studies reported here administered haemostatic agent doses below that required for clinical efficacy (<a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a>; <a href="./references#CD010649-bbs2-0025" title="Effect of prophylactic fibrinogen concentrate infusion on postoperative bleeding in coronary artery bypass graft surgery: a randomised, double blind clinical trial. IRCT trial registration number 201011085140N1. SadeghiM , AtefyektaR , AzimaraghiO , MarashiSM , AghajaniY , GhadimiF , et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery [Estudo randômico e duplo‐cego de profilaxia com fibrinogênio para reduzir o sangramento em cirurgia cardÍca]. Revista Brasileria de Anestesiologia2014;64(4):253‐7. ">Sadeghi 2014</a>), with the potential of false negative findings. </p> <p>The published data on markers and indices of coagulation status were very heterogeneous and it is difficult to offer a useful interpretation of these data. </p> </section> </section> <section id="CD010649-sec-0173"> <h3 class="title" id="CD010649-sec-0173">Agreements and disagreements with other studies or reviews</h3> <p>There are no other published reviews of this scope on factor XIII for comparison. The paucity of data for the use of pro‐thrombin complex concentrates may have precluded systematic reviews of randomised trials, although there are reviews of observational studies (<a href="./references#CD010649-bbs2-0106" title="ZengL , ChoonaraI , ZhangL , LiY , ShiJ . Effectiveness of prothrombin complex concentrate (PCC) in neonates and infants with bleeding or risk of bleeding: a systematic review and meta‐analysis. European Journal of Pediatrics2017;176(5):581‐9. ">Zeng 2017</a>). </p> <section id="CD010649-sec-0174"> <h4 class="title">Clinical findings and conclusions</h4> <p>The findings of this review are consistent with other systematic reviews of the use of fibrinogen concentrate. An analysis of one prospective and seven retrospective studies in trauma found no impact on overall mortality and recorded a broad range of recorded mortality time points and heterogeneity in the reported outcomes (<a href="./references#CD010649-bbs2-0090" title="MengoliC , FranchiniM , MaranoG , PupellaS , VaglioS , MariettaM , et al. The use of fibrinogen concentrate for the management of trauma‐related bleeding: a systematic review and meta‐analysis. Blood Transfusion2017;15(4):318‐24. ">Mengoli 2017</a>). Similarly, analysis of blood loss and transfusion was impaired by variation in the use of continuous and discrete data presentation. Another systematic review that included four studies (two RCTs and two non‐randomised controlled studies) concluded that fibrinogen concentrate in the perioperative and major haemorrhage settings was safe and reduced bleeding and the transfusion of blood components (<a href="./references#CD010649-bbs2-0080" title="FranchiniM , LippiG . Fibrinogen replacement therapy: a critical review of the literature. Blood Transfusion2012;10(1):23‐7. ">Franchini 2012</a>). A Cochrane Review of fibrinogen concentrate in bleeding patients was published in 2013 and contains six RCTs that compared fibrinogen to placebo or usual care in adults with bleeding (<a href="./references#CD010649-bbs2-0103" title="WikkelsøA , LundeJ , JohansenM , StensballeJ , WetterslevJ , MøllerAM , et al. Fibrinogen concentrate in bleeding patients. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008864] ">Wikkelso 2013</a>). We have included these RCTs in this review (<a href="./references#CD010649-bbs2-0004" title="CuiY , HeiF , LongC , FengZ , ZhaoJ , YanF , et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artifical Organs2010;34(11):955‐60. ">Cui 2010</a>; <a href="./references#CD010649-bbs2-0006" title="Fenger‐EriksenC , JensenTM , KristensenB , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen concentrate corrects dilutional coagulopathy: a prospective, randomized placebo controlled clinical trial. Blood2008;112(111):Abstract Number 1227. Fenger‐EriksenC , JensenTM , KristensenBS , JensenKM , TonnesenE , IngerslevJ , et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo‐controlled clinical trial. Journal of Thrombosis &amp; Haemostasis2009;7(5):795‐802. ">Fenger Erikson 2009</a>; <a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a>; <a href="./references#CD010649-bbs2-0013" title="BaghaeiF , KarlssonM , TernstrmL , HyllnerM , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery: A prospective randomized pilot study. Journal of Thrombosis and Haemostasis2009;7(S2):697. KarlssonM , TernstromL , HyllnerM , BaghaeiF , FlinckA , SkrticS , et al. Prophylactic fibrinogen infusion reduces bleeding after coronary surgery. A prospective randomised pilot study. Thrombosis &amp; Haemostasis2009;102(1):137‐44. KarlssonM , TernstromL , HyllnerM , BaghaeiF , SkrticS , JeppssonA . Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clinical &amp; Applied Thrombosis/Hemostasis2011;17(4):396‐404. ">Karlsson 2011</a>; <a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a>; <a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a>). In keeping with our conclusions, the authors found that fibrinogen concentrate reduced transfusion requirement, but there were insufficient data to draw conclusions about the impact on mortality or other clinical efficacy. </p> </section> <section id="CD010649-sec-0175"> <h4 class="title">Risk of bias and quality of included studies</h4> <p>The three reviews highlighted above reached comparable conclusions to this review about the poor quality of evidence and frequently indeterminate or high risks of bias in the included studies. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010649-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram." data-id="CD010649-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. Thirty‐one trials are included in this review (Haas 2015 reports two trials)." data-id="CD010649-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. Thirty‐one trials are included in this review (Haas 2015 reports two trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 1 All‐cause mortality." data-id="CD010649-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 2 Arterial thromboembolic events." data-id="CD010649-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 2 Arterial thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 3 Venous thromboembolic events." data-id="CD010649-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 3 Venous thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 4 Mortality due to bleeding." data-id="CD010649-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 4 Mortality due to bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 5 RBC transfusion requirement." data-id="CD010649-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 5 RBC transfusion requirement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 6 Receipt of a RBC transfusion." data-id="CD010649-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 6 Receipt of a RBC transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 7 Blood loss." data-id="CD010649-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 7 Blood loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 8 Allergic Adverse Events." data-id="CD010649-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Fibrinogen: prophylactic trials: intervention vs inactive control, Outcome 8 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 1 All‐cause mortality." data-id="CD010649-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 2 Arterial thromboembolic events." data-id="CD010649-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 2 Arterial thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 3 Venous thromboembolic events." data-id="CD010649-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 3 Venous thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 4 Mortality due to bleeding." data-id="CD010649-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 4 Mortality due to bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 5 RBC transfusion requirement." data-id="CD010649-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 5 RBC transfusion requirement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 6 Receipt of a RBC transfusion." data-id="CD010649-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 6 Receipt of a RBC transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 7 Allergic Adverse Events." data-id="CD010649-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Fibrinogen: prophylactic trials: intervention vs haemostatically active control, Outcome 7 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 1 All‐cause mortality." data-id="CD010649-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 2 Arterial thromboembolic events." data-id="CD010649-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 2 Arterial thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 3 Venous thromboembolic events." data-id="CD010649-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 3 Venous thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 4 Mortality due to bleeding." data-id="CD010649-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 4 Mortality due to bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 5 Receipt of a RBC transfusion." data-id="CD010649-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 5 Receipt of a RBC transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 6 RBC transfusion requirement." data-id="CD010649-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 6 RBC transfusion requirement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 7 Blood loss." data-id="CD010649-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 7 Blood loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 8 Allergic Adverse Events." data-id="CD010649-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Fibrinogen: therapeutic trials: intervention vs inactive control, Outcome 8 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 1 All‐cause mortality." data-id="CD010649-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 2 Arterial thromboembolic events." data-id="CD010649-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 2 Arterial thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 3 Venous thromboembolic events." data-id="CD010649-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 3 Venous thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 4 Mortality due to bleeding." data-id="CD010649-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 4 Mortality due to bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 5 RBC transfusion requirement." data-id="CD010649-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 5 RBC transfusion requirement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 6 Receipt of a RBC transfusion." data-id="CD010649-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 6 Receipt of a RBC transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 7 Allergic Adverse Events." data-id="CD010649-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Fibrinogen: therapeutic trials: intervention vs haemostatically active control, Outcome 7 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 1 All‐cause mortality." data-id="CD010649-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 2 Arterial thromboembolic events." data-id="CD010649-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 2 Arterial thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 3 Venous thromboembolic events." data-id="CD010649-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 3 Venous thromboembolic events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 4 Mortality due to bleeding." data-id="CD010649-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 4 Mortality due to bleeding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 5 RBC transfusion requirement." data-id="CD010649-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 5 RBC transfusion requirement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 6 Receipt of a RBC transfusion." data-id="CD010649-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 6 Receipt of a RBC transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 7 Blood loss." data-id="CD010649-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 7 Blood loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 8 Allergic Adverse Events." data-id="CD010649-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 FXIII: prophylactic trials: intervention vs inactive control, Outcome 8 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 FXIII: therapeutic trials: intervention vs inactive control, Outcome 1 Allergic Adverse Events." data-id="CD010649-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 FXIII: therapeutic trials: intervention vs inactive control, Outcome 1 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 PCC: prophylactic trials: intervention vs inactive control, Outcome 1 All‐cause mortality." data-id="CD010649-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 PCC: prophylactic trials: intervention vs inactive control, Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010649-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/urn:x-wiley:14651858:media:CD010649:CD010649-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_t/tCD010649-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 PCC: prophylactic trials: intervention vs inactive control, Outcome 2 Allergic Adverse Events." data-id="CD010649-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 PCC: prophylactic trials: intervention vs inactive control, Outcome 2 Allergic Adverse Events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/media/CDSR/CD010649/image_n/nCD010649-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010649-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FIBRINOGEN: Therapeutic trials: intervention compared to inactive Control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Therapeutic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN in therapeutic trials<br/> <b>Comparison:</b> Inactive control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactive control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fibrinogen in therapeutic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 28 days following admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/> (0.71 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>97<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>184 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>268 per 1000<br/> (130 to 549) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>In‐hospital mortality up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.00<br/> (0.25 to 102.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>120<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 6 weeks post‐natally</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>294<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 46 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.23<br/> (0.05 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>213<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (4 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level as neither study was designed to measure mortality.<br/> <sup>b</sup>We downgraded by one level, due to low event rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FIBRINOGEN: Therapeutic trials: intervention compared to inactive Control for the prevention and treatment of bleeding in participants without haemophilia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010649-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN in therapeutic trials<br/> <b>Comparison:</b> Haemostatically active control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haemostatically active control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FIBRINOGEN in therapeutic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 7 days post‐operatively or hospital discharge</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 28 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.06 to 14.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (3 to 681) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.20<br/> (0.45 to 10.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>94<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000<br/> (20 to 490) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level due to low event rate.<br/> <sup>b</sup>We downgraded by one level due to concerns about risks of bias both in the way that allocation of treatment was concealed at randomisation and whether blinding to treatment could be maintained for the duration of the trial in this "open‐label trial where adequacy of surgical field haemostasis reported as a subjective outcome".<br/> <sup>c</sup>We downgraded by one level as the study did not measure mortality as an outcome.<br/> <sup>d</sup>We downgraded by one level due to concerns about risks of bias in how blinding to treatment intervention could be maintained for the duration of the trial in this "open‐label trial where adequacy of surgical field haemostasis reported as a subjective outcome", and the non‐reporting of all outcomes that the investigators said they would measure (selective outcome reporting). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FIBRINOGEN: Therapeutic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010649-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN: prophylactic trials<br/> <b>Comparison:</b> inactive control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactive control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FIBRINOGEN in prophylactic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events in one trial</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thrombotic events</p> <p>Up to 4 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thrombotic events</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.01 to 8.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>116<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (0 to 138) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thrombotic events ‐ up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>122<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thrombotic events</p> <p>Up to 4 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level due to low event rate.<br/> <sup>b</sup>We downgraded by one level due to concerns about risks of bias in the non‐reporting of all outcomes that the investigators said they would measure (selective outcome reporting).<br/> <sup>c</sup>We downgraded by one level due to concerns about risks of bias in the way that allocation of the treatment was concealed at the time of randomisation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">FIBRINOGEN: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010649-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FIBRINOGEN: prophylactic trials<br/> <b>Comparison:</b> Haemostatically active control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with haemostatically active control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FIBRINOGEN in prophylactic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events ‐ Duration of hospital stay (whole population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events Duration of hospital stay (whole population)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level as the thromboembolic events (arterial or venous) in these participants given fibrinogen prophylactically were not an outcome of interest.<br/> <sup>b</sup>We downgraded by one level due to the small number of participants available for this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">FIBRINOGEN: Prophylactic trials: intervention compared to haemostatically active control for the prevention and treatment of bleeding in participants without haemophilia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010649-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> the prevention and treatment of bleeding in patients without haemophilia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> FXIII: prophylactic trials<br/> <b>Comparison:</b> inactive control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with inactive control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FXIII in prophylactic trials</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> <p>Up to 5 to 7 weeks post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/> (0.28 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>282<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (23 to 131) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> <p>Up to 30 days post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.14 to 66.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Arterial thromboembolic events</p> <p>Post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.20<br/> (0.01 to 3.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (1 to 318) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events ‐ Up to 5 to 7 weeks post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.06 to 14.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>282<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (0 to 108) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events<br/> Up to 30 days post‐operatively </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.00<br/> (0.14 to 66.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Venous thromboembolic events</p> <p>Post‐operatively</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded by one level due to concerns about attrition, reporting and selection bias across these trials.<br/> <sup>b</sup>We downgraded by one level as thromboembolic events (arterial or venous) in these participants given factor XIII prophylactically were not an outcome of interest.<br/> <sup>c</sup>We downgraded by one level due to low event rates.<br/> <sup>d</sup>We downgraded by one level due to risks of bias concerns in how concealment of treatment intervention was attempted (unsealed envelopes in the patients notes) and the subsequent impact this had on the level of blinding to treatment intervention that could be maintained for the duration of the trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">FXIII: Prophylactic trials: intervention compared to inactive control for the prevention and treatment of bleeding in participants without haemophilia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Red blood cell transfusion requirement</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>intervention / comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical condition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Transfusion Protocol?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>When was transfusion requirement measured</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>How were findings reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Findings: Intervention/ Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Cui-2010" target="_blank">Cui 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>17/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During ICU stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 0)/0 (0 ‐ 1.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) total red blood cell usage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1.5)/1.5 (0 ‐ 2.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Fenger-Erikson-2009" target="_blank">Fenger Erikson 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Surgery (E): radical cystectomy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0 ‐ 5) /</p> <p>2.5 (0 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 2)/1.5 (0 ‐ 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total transfused</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 (0 ‐ 5)/4.0 (0 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within 48 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) patients requiring a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (20%)/8 (80%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Karlsson-2011" target="_blank">Karlsson 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within 12 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 (0.13)/0.7 (0.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Najafi-2014" target="_blank">Najafi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): total hip replacement arthroplasty</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Perioperative period"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) "sum of transfused packed cells" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 (1.01)/1.06 (1.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): posterior spinal fusion</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number</b> (%) patients transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)/6 (30%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Ranucci-2015" target="_blank">Ranucci 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>58/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Duration of hospital stay until 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (33%)/32 (55%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/1 (0 ‐ 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Within 24 hours of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL of red blood cells infused for transfused patients only </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (178)/356 (488)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>From 24 to 48 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL of red blood cells infused for transfused patients only </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>420 (760)/218 (552)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>48/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Surgery (E): liver transplantation</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/0 (0 ‐ 0.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (52.9%)/11 (42.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During and up to 24 hours after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0 ‐ 6)/3 (0 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (68.8%)/30 (68.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Sadeghi-2014" target="_blank">Sadeghi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>30/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Within first 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell infusions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (1.8)/2 (1.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (50)/21 (70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): transurethral resection of the prostate.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (3.2%)/5 (17.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Haas-2015" target="_blank">Haas 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>10/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): scoliosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Over 24 hours from the start of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 15.3)/18.4 (0 ‐ 23.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7 (6.2)/7.2 (8.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (40%)/6 (67%)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>17/ 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): craniosynostosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Over 24 hours from the start of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.2 (21.2‐ 49.9)/55.5 (27.5 ‐ 61.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL/kg of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.1 (17.9)/41.8 (18.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (100%)/13 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>58/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Between study intervention and chest closure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)/3 (5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Between study intervention and 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (17%)/20 (33%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/0 (0 ‐ 4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>28/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>From study intervention to discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0 – 2)/1 (0 – 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number (%) of patients who received a red blood cell transfusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (46.6%)/13 (48.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number of red blood cell transfusions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>24/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Trauma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3hrs following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2 ‐ 6)/2 (2 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (91.3%)/20 (87.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>6hrs following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2 ‐ 6)/2 (2 ‐ 6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (90.5%)/19 (86.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24hrs following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2 ‐ 8)/2 (2 ‐ 5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (95.0%)/18 (85.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>During hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) units of red blood cell s transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63 (1.17)/1.33 (3.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 1)/0 (0 ‐ 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2 ‐ 5)/3 (2 ‐ 4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Rahe_x002d_Meyer-2013" target="_blank">Rahe‐Meyer 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>29/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): aortic valve replacement</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>24 hours after receipt of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (55)/32 (100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0 ‐ 3)/2 (2‐5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): complex cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 hours after receipt of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0 ‐ 3)/0 (0 ‐ 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Wikkelso-2015" target="_blank">Wikkelso 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>123/121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for a red blood cell transfusion up to 4 hours post study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (3)/10 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for a red blood cell transfusion up to 24 hours post study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (11)/19 (16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for a red blood cell transfusion up to 7 days post study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (20)/26 (21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the 6 week period postpartum"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (20)/26 (21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time‐point not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients who received a transfusion of &gt; 4 units of red blood cells. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (7)/3 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Galas-2014" target="_blank">Galas 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐operative day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 ( 83)/32 (97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Tanaka-2014" target="_blank">Tanaka 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): valve replacement or repair</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (90)/9 (90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiovascular, abdominal or spinal column</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Following study intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.98 (3.01)/5.38 (2.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>50/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Trauma</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>At 24 hours after injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (90%)/39 (89%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2 ‐ 7)/6 (4 ‐ 11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Godje-2006" target="_blank">Godje 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (1.875)/3.3 (1.397)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Karkouti-2013" target="_blank">Karkouti 2013</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>138/128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Until post‐operative day 7 or hospital discharge (whichever occurred first)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0‐1)/0 (0‐1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number (%) of patients receiving a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (33)/43 (34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Korte-2009" target="_blank">Korte 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): gastrointestinal cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear time point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL of red blood cells transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150 (0‐700)/200 (0‐800)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Levy-2009" target="_blank">Levy 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>8/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Until post‐operative day 7 or hospital discharge (whichever occurred first)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> number of patients requiring allogeneic blood products </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data was reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Percentage</b> of patients avoiding a red blood cell transfusion </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data was reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Rasche-1982" target="_blank">Rasche 1982</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute leukaemia</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) number of red blood cell units transfused </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (0 ‐ 34)/6 (0 ‐ 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PCC: prophylactic trials with inactive comparator</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>(E) = elective surgery; ICU = intensive care unit, IQR = inter quartile range; SD = standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Red blood cell transfusion requirement</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood loss</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses intervention/comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Transfusion Protocol?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>How the outcome was measured</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Findings: intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Findings: Comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Cui-2010" target="_blank">Cui 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>17/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL/kg/h) of chest drainage at 1 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 (2.0) mL/kg/h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5 (1.6) mL/kg/h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (ml/kg/h) of chest drainage at 6 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.1) mL/kg/h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5 (0.6) mL/kg/h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity ( mL/kg/h) of chest drainage at </p> <p>24 h post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6 (0.4 to 0.8) mL/kg/h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7 (0.6 to 0.9) mL/kg/h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Fenger-Erikson-2009" target="_blank">Fenger Erikson 2009</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): radical cystectomy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) blood loss at time of intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2682 (962) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2933 (1320) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Karlsson-2011" target="_blank">Karlsson 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD): "post‐operative bleeding" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>565 (150) mL/12 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>830 (268) mL/12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Najafi-2014" target="_blank">Najafi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): total hip replacement arthroplasty</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of intraoperative blood loss </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>744.6 (337) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>870 (498) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of post‐ operative bleeding to 24 hours post surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231.6 (67) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>236.6 (81) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): posterior spinal fusion</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL blood loss up to 24 hours post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>533.3 (157.9) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>679 (130) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Ranucci-2015" target="_blank">Ranucci 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) lost from chest drain in first 12 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (200 to 400) mL/12 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355 (250 to 600) mL/12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Sadeghi-2014" target="_blank">Sadeghi 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of blood lost in chest drain in first 12 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>477 (143) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>703 (179) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>31/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Surgery (E): transurethral resection of the prostate.</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of blood lost intraoperatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>521 (290) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557 (411) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of blood lost post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291 (270) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>341 (314) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: prophylactic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Haas-2015" target="_blank">Haas 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): scoliosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) "calculated total blood loss (%)" by 24 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.5 (14.9 to 54.3) %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.0 (38.5 to 69.2) %</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/ 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): craniosynostosis</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) "calculated total blood loss (%)" by 24 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.7 (77.7 to 112.9) %</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156.9 (110..5 to 187.3) %</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>58/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss from study intervention to chest closure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (29 ‐ 100) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (33 ‐ 145) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss from ICU arrival to 1hr </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 (35 ‐ 130) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90 (46 ‐ 149) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 1hr to 3h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (50 ‐ 156) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (40 ‐ 220) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 3h to 6h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (54 ‐ 169) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (60 ‐ 208) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 6h to 12h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (80 ‐ 160) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125 (83 ‐ 224) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss in ICU from 12h to 24h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130 (80 ‐ 180) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160 (90 ‐ 270) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) cumulative mL blood loss in 24 hours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570 (390 ‐ 730) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>690 (400 ‐ 1090) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL blood loss within 24h of study intervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>225 (100 – 341) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (60 – 800) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>24/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL intraoperative blood loss </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>306 (110) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375 (202) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL intraoperative blood loss </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (200–400) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 (200–500) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL post‐operative blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>796 (523) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>897 (553) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL post‐operative blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650 (500–835) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>730 (543–980) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) mL total blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1103 (518) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1272 (588) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL total blood loss (within 12h) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>913 (815–1230) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1185 (930–1398) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>78/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E): complex cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL chest tube drainage volume at 6h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260.0 (155.0–410.0) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>297.5 (200.0–455.0) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL chest tube drainage volume at 12h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405.0 (245.0–600.0) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>447.5 (320.0–700.0) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) mL chest tube drainage volume at 24h </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>590.0 (400.5–839.5) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>682.5 (530.0–1050.0) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Wikkelso-2015" target="_blank">Wikkelso 2015</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123/121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) lost to 6 weeks postpartum </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1700 (1500 to 2000) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1700 (1400 to 2000) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fibrinogen concentrate: therapeutic trials with active comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) chest drainage from intraoperative to 48 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320 (157 ‐ 750) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>410 (215 ‐ 510) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): valve replacement or repair</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (mL) chest tube drainage at 12 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>925 (500 to 1693) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1315 (653 to 2965) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): prophylactic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Godje-2006" target="_blank">Godje 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>25/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 6 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231 (113) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>278 (98) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 12 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371 (170) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>458 (160) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 24 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>649 (227) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>747 (222) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 36 h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>798 (273) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>969 (309) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) drain volume (ml) at 48h post‐operatively<sup>$</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>958 (376) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1231 (175) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Korte-2009" target="_blank">Korte 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 in total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): gastrointestinal cancer</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median</b> (IQR) quantity (ml) blood loss at completion of surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 (400 to 1000) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1050 (700 to 1800) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609071716460151587722039442086%26format=REVMAN#STD-Levy-2009" target="_blank">Levy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>8/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of chest drainage at 8 h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>358 (93.5) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>505 (301) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of chest drainage at 24h post‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>903 (738) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1155 (804) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> (SD) quantity (mL) of chest drainage at CT removal </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1007 (912) mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1489 (1395) mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Factor XIII (FXIII): therapeutic trials with inactive comparator</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PCC: prophylactic trials with inactive comparator</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>^ "Calculated total blood loss (%) was based on the estimated total blood volume (calculated as described by <a href="./references#CD010649-bbs2-0087" title="KearneyRA , RosalesJK , HowesWJ . Craniosynostosis: an assessment of blood loss and transfusion practices. Canadian Journal of Anaesthesia1989;36:473‐7. ">Kearney 1989</a> ) " <a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> </p> <p>* "The visual assessment of the surgical field was performed by the senior surgical staff as follows: 0 = excellent haemostasis (dry field), 1 = mild bleeding (oozing), 2 = moderate bleeding (controllable with applied pressure) and 3 = severe bleeding (multiple diffuse bleeding sites)" <a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> </p> <p>$ Findings are reported graphically, not numerically.</p> <p>(E) = elective surgery; h = hours; ICU = intensive care unit, IQR = inter quartile range; mL = millilitres; SD = standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood loss</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Fibrinogen concentrate: prophylactic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Cui-2010" target="_blank">Cui 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(20/20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> <p>(17/14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (0.5‐1g) combined with traditional transfusion, guided by TEG </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE:</b> Traditional transfusion guided by clinical experience. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine,</p> <p>FFP, red blood cells, platelets.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to chest wall closure.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paediatric population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Fenger-Erikson-2009" target="_blank">Fenger Erikson 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> <p>(10/11 )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (45mg/kg), administered intra‐operatively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> isotonic saline, administered intra‐operatively at a dose of 2.25 mL/kg). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intra‐operative FFP, red blood cells.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole blood maximum clot firmness as determined by thromboelastometry.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): radical Cystectomy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Karlsson-2011" target="_blank">Karlsson 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preoperative infusion of<b>fibrinogen concentrate</b> (2g) at 5 minutes following baseline measurements. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heparin,</p> <p>protamine,</p> <p>red blood cells, aspirin.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical adverse events, including graft occlusion on CT up to 3 to 4d post‐ operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Najafi-2014" target="_blank">Najafi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> <p>(15/15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> <p>(15/15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (30 mg/kg) infused after induction of general anaesthesia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: normal saline administered in equal volume as fibrinogen. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of red blood cells transfused during and 24h post‐operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): total hip replacement arthroplasty</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0019" title="PournajafianAL , GhodratyMR , MohesniM , GhamariAA , SadeghiF . Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. Journal of Isfahan Medical School2015;33(347):1370‐9. ">Pournajafian 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> <p>(21/20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> <p>(21/20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (1g) infused after induction of general anaesthesia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): posterior spinal fusion.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0022" title="The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery. www.ClinicalTrials.gov, registry number NCT01471730 (accessed 05.02.2018). RanucciM , BaryshnikovaE . Fibrinogen supplementation after cardiac surgery: insights from the Zero‐Plasma trial (ZEPLAST). British Journal of Anaesthesia2016;116(5):618‐23. Ranucci M. BaryshinikovaE , CrapelliGB , Rahe‐MeyerN , MenicantiL , FrigolaA . Randomized, double‐blinded, placebo‐controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. Journal of the American Heart Association2015;4:e002066. ">Ranucci 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> <p>(58/58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> <p>(58/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> with dose determined by the mean clot firmness test on the FIBTEM. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> Normal (0.9%) saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA during surgery, protamine.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avoidance of allogeneic blood products transfusion during hospital stay up to 30d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0024" title="SabateA , GutierrezR , BeltraJ , MelladoP , BlasiA , AcostaF , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double‐blind, placebo‐controlled trial. American Journal of Transplantation2016;16:2421‐9. ">Sabate 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> <p>(51/48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> <p>(48/44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> with dose calculated to reach a target plasma concentration of 2.9 g/L. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> Normal (0.9%) saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The percentage of patients requiring transfusion of red blood cell units during the liver transplant procedure. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): liver transplantation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Sadeghi-2014" target="_blank">Sadeghi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(30/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(30/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen</b> (1g) administered 30 minutes prior to anaesthesia induction. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: saline administered 30 minutes prior to anaesthesia induction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Volume of post‐operative haemorrhage 0, 12 and 24h post‐operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0027" title="MasoumiN , SoleimaniM , LashayA , NooraieN . Fibrinogen concentrate effect on perioperative bleeding in transurethral resection of the prostate: a double blind placebo‐controlled and randomized study. BJU International. 2017; Vol. 119:44. SoleimaniM , MasoumiN , NooraeiN , LashayA , SafarienejadMR . The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. Journal of Thrombosis and Haemostasis2017;15:255‐62. ">Soleimani 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> <p>(36/36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(31/29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> (2g) administered 15‐30 minutes before the start of surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 50ml normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None stated.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding volume during and after surgery.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): transurethral resection of the prostate.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>* For the outcomes bleeding and transfusion requirements, 1 patient from the Factor XIII, 1250 IE arm and 2 patients from the placebo arm were excluded from the analysis due to re‐operations following hints of early bypass occlusions. All patients were included in the analysis of the other outcomes. </p> <p>d = days; (E) = elective surgery; FIBTEM = is a ready‐to‐use ROTEM<sup>®</sup> system reagent for use with citrated whole blood and assesses the clot firmness of the fibrin clot, h = hours; PCC = prothrombin complex concentrate; mins = minutes; wks = weeks. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Fibrinogen concentrate: prophylactic trials with inactive comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Fibrinogen concentrate: prophylactic trials with active comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0009" title="Fibrinogen for treatment of paediatric dilutional coagulopathy FibPaed study. ClinicalTrials.gov NCT 01487837. HaasT , SpeilmannN , RestinT , SeifertB , HenzeG , ObwegserJ , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. British Journal of Anaesthesia2015;115(2):234‐43. HaasT , SpielmannN , CushingM . Dosing of fibrinogen concentrate during major paediatric surgery‐calculating the increase in clot firmness. Transfusion medicine. Conference: 18th annual NATA symposium on patient blood management, haemostasis and thrombosis. 2017; Vol. 27:63. HaasT , SpielmannN , CushingM , SchmuggeM , WeissM . Influence of factor XIII levels on clot firmness during major paediatric surgery. Transfusion Medicine. 2015; Vol. 25:45. ">Haas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Craniosynostosis surgery = 36</p> <p>(17/14).</p> <p>Scoliosis surgery = 26</p> <p>(10/9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Craniosynostosis surgery = 36</p> <p>(17/13).</p> <p>Scoliosis surgery = 26</p> <p>(10/9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> if FIBTEM MCF under 13mm (early substitution group). </p> <p>Total dose administered per subject in</p> <p>craniosynostosis surgery; median of 90mg kg<sup>‐1</sup> (IQR, 75 to 120 mg kg<sup>‐1</sup>); </p> <p>Scoliosis surgery = = median of 60mg kg<sup>‐1</sup> (IQR, 30 to 68 mg kg<sup>‐1</sup>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> if FIBTEM MCF under 8 mm (conventional). </p> <p>Total dose administered per subject in</p> <p>craniosynostosis surgery = median of</p> <p>90mg kg<sup>‐1</sup> (IQR, 60 to 90 mg kg<sup>‐1</sup>); Scoliosis surgery = median of 30mg kg<sup>‐1</sup> (IQR, 30 to 60 mg kg<sup>‐1</sup>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total volume of transfused red blood cells per kg bodyweight within 24h post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): craniosynostosis or scoliosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paediatric population</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CPB = cardiopulmonary bypass; (E) = elective surgery; FFP = fresh frozen plasma; FIBTEM = is a ready‐to‐use ROTEM<sup>®</sup> system reagent for use with citrated whole blood and assesses the clot firmness of the fibrin clot; h = hours; INR = International Normalised Ratio, IQR = inter quartile range; PCC = prothrombin complex concentrate; (U) = urgent surgery/ treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Fibrinogen concentrate: prophylactic trials with active comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0010"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Fibrinogen concentrate: therapeutic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0001" title="BilecenS , deGrootJAH , KalkmanCJ , SpanjersbergAJ , BruinsmaGJBB , MoonsKGM , et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High‐Risk Cardiac Surgery. JAMA2017;317(7):738‐47. ">Bilecen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120</p> <p>(60/60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> <p>(58/57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose calculated to provide a target plasma fibrinogen concentration of 2.5 g/L. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 2g of<br/> albumin diluted with 50ml 0.9% sodium chloride solution. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The intraoperative blood loss measured between intervention and closure of the chest.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0003" title="BruynseelsD , DickJ , EltonC , MallaiahS , CollisRE . International Journal of Obstetric Anesthesia. 2016; Vol. 26:S62016. CollinsPW , Cannings‐JohnR , BruynseelsD , MallaiahS , DickJ , EltonC , et al. Viscoelastometric‐guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2,a double‐blind randomized controlled trial. British Journal of Anaesthesia2017;119(3):411‐21. WeeksA , CollisR , MallaiahS , EltonC , DickJ , Canning‐JohnR , et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: A multicentre, prospective, double blind randomised control pilot study (OBS2). BJOG: An International Journal of Obstetrics and Gynaecology. 2016; Vol. 123:177. ">Collins 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> <p>(29/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> <p>(28/27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose determined by FIBTEM to elevate A5 result above 22mm. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 50ml of normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of allogeneic<br/> blood products (red blood cell , FFP, cryoprecipitate, platelets) infused after study medication until hospital discharge. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0005" title="A multi‐centre, randomised, double blind, placebo‐controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. ISRCTN registry ISRCTN67540073 (accessed 05.02.2018). CurryN , FoleyC , WongH , MoraA , CurnowE , ZarankaiteA , et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E‐FIT 1). Results from a UK multi‐centre, randomised, double blind, placebo‐controlled pilot trial and comparisons with two fibrinogen supplementation trauma trials. The primary author, Dr Nicola Curry. ">Curry 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> <p>(24/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> <p>(24/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b> 6g infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 300ml of normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major haemorrhage therapy as per hospital protocol: red blood cells, platelets, FFP, tranexamic acid, cryoprecipitate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feasibility of delivery of FgC therapy within 45 minutes to adult trauma patients and the proportion of participants whose fibrinogen levels were maintained ≥ 2 g/L during active haemorrhage. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0011" title="JeppssonA , WaldenK , Roman‐EmanuelC , Thimour‐BergstromL , KarlssonM . Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. British Journal of Anaesthesia2016;116(2):208‐14. ">Jeppsson 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> <p>(26/26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> <p>(24/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen</b> (2g) as an infusion over 5 minutes, immediately<br/> before surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 100ml of normal saline. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 units kg−1 of heparin, 1 mg protamine per 100 units of heparin. Red blood cells, platelets, FFP, additional fibrinogen. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mediastinal drain loss during the first 12 hours post‐operatively.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0018" title="NascimentoB , CallumJ , TienH , PegH , RizoliS , KaranicolasP , et al. Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. British Journal of Anaesthesia2016;117(6):775‐82. ">Nascimento 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> <p>(25/25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> <p>(21/24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, 6g as a 3 minute infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 300ml of normal saline as a 3 minute infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, tranexamic acid, FFP,<br/> platelets and cryoprecipitate. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The feasibility of providing the study intervention within 1 hour of hospital admission.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0020" title="Haemocomplettan®P during aortic replacement. www.ClinicalTrials.gov, trial identifier: NCT00701142 [accessed 05 January 2016]. Rahe‐MeyerN , HankeA , SchmidtDS , HaglC , PichlmaierM . Fibrinogen concentrate reduces intraoperative bleeding when used as first‐line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo‐controlled trial. Journal of Thoracic and Cardiovascular Surgery2013;145(3 Suppl.):S178‐85. [PUBMED: 23410777] Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , HaglC , PichlmaierM . Haemostatic therapy with fibrinogen concentrate for controlling major bleeding during complex cardiovascular surgery: results of a randomised, placebo‐controlled trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii75‐104. Rahe‐MeyerN , SolomonC , HankeA , SchmidtDS , KnoerzerD , HochleitnerG , et al. Effects of Fibrinogen Concentrate as First‐lineTherapy during Major Aortic Replacement Surgery. Anesthesiology2013;118:40‐50. [PUBMED: 23249928] SolomonC , HaglC , Rahe‐MeyerN . Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. British Journal of Anaesthesia2013;110(6):947‐56. SolomonC , Rahe‐MeyerN . Fibrinogen concentrate as first‐line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100X109/L. Blood Transfusion2015;13:248‐54. SolomonC , SchochlH , HaglC , Rahe‐MeyerN . Fibrinogen concentrate as first line haemostatic therapy during aortic replacement surgery. International Society of thrombosis and Haemostatsis. 2012; Vol. 10:e7. SolomonC , SchochlH , HankeA , HaglC , Rahe‐MeyerN . Fibrinogen concentrate causes a short lived increase in plasma fibrinogen and fibrin based clot quality when used as a first line haemostatic therapy during aortic replacement surgery: a randomized trial. British Journal of Anaesthesia. 2012; Vol. 108 (S2):ii276‐7. ">Rahe‐Meyer 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> <p>(38 /42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> <p>(29/32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose determined by FIBTEM test: median (IQR range) dose: 8g (6 to 9g). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> normal (0.9%) saline. Median (IQR range) dose: 400ml (300 to 450ml). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA during surgery, platelets or FFP.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of units of allogeneic blood components given during first 24h post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): aortic valve replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0021" title="Rahe‐MeyerN , LevyJH , MazerCD , SchramkoA , KleinAA , BratR , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double blind phase III study of haemostatic therapy. British Journal of Anaesthesia2016;117(1):41‐51. ">Rahe‐Meyer 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> <p>(78/74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>152</p> <p>(78/74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b>, dose determined by FIBTEM testing to generate an MCF of 22mm. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: 0.9% sodium chloride solution. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, FFP, tranexamic acid.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The number of units of allogeneic blood products (FFP, platelets and red blood cells) administered during the 24 hours after administration of study medication. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): complex cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0030" title="Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial (FIB‐PPH). www.ClinicalTrials.gov, registry number NCT01359878 (accessed 06 January 2016). WikkelsoAJ , EdwardsHM , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , et al. Pre‐emptive treatment with fibrinogen concentrate for postpartum haemorrrhage: randomised controlled trial. British Journal of Anaesthesia2015;114(4):623‐33. WikkelsoAJ , EdwardsHM , AfshariA , Stensballe Langhoff‐RoosJ , AlbrechtsenC , et al. Fibrinogen concentrate as initial treatment for postpartum haemorrhage: FIB‐PPH study. Transfusion Medicine. 2015; Vol. 25 (S1):7‐72. WikkelsoeAJ , AfshariA , StensballeJ , Langhoff‐RoosJ , AlbrechtsenC , EkelundK , et al. The FIB‐PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trial. Trials2012;13(110):1‐8. ">Wikkelso 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> <p>(124 /125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> <p>(PPA: 123 /121)</p> <p>(ITT: 120 /119)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fixed dose of 2g of <b>fibrinogen concentrate</b> dispensed using a syringe pump infusion over 20 minutes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> 100ml of isotonic saline (mean (standard deviation) dose =1.2 (0.2) mg/kg). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA, hydroxyethyl starch, intravenous fluids.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cell transfusion during a 6 wk follow‐up period postpartum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>postpartum haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>d = days; (E) = elective surgery; FFP = fresh frozen plasma; FIBTEM = is a ready‐to‐use ROTEM<sup>®</sup> system reagent for use with citrated whole blood and assesses the clot firmness of the fibrin clot; h = hours; INR = International Normalised Ratio, IQR = inter quartile range; mins = minutes; PCC = prothrombin complex concentrate; TXA = tranexamic acid; (U) = urgent surgery/ treatment; wks = weeks. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Fibrinogen concentrate: therapeutic trials with inactive comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0011"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Fibrinogen concentrate: therapeutic trials with active comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses</b> </p> <p><b>(N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0007" title="GalasF , HajjarL , SorensenB , AlmeidaJ , SundinM , GuimaraesV , et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in paediatric cardiac surgery (FICCS study). Critical Care2012;16(Suppl 1):S156‐7. [PUBMED: PMC3363856] GalasFRBG , deAlmediaJP , FukushimaJT , VincentJL , OsawaEA , ZeferinoS , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. The Journal of Thoracic and Cardiovascular Surgery2014;148(4):1647‐55. ">Galas 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> <p>(30/33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> <p>(30/33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose of <b>Fibrinogen</b> concentrate (60mg/kg body weight, Haemocomplettan®) given at time of intra‐operative bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose of <b>Cryoprecipitate</b> (10ml/kg body weight) given at time of intra‐operative bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not Stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>post‐operative blood losses during 48h after surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paediatric population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0015" title="LanceMD , NinivaggiM , HamulyakK , vanPampusEC , tenCateH , HeemskerkJW . Early transfusion with FFP or FFP plus fibrinogen concentrate in massive hemorrhage: A randomised intervention trial. Transfusion and Haemostasis2005;100(5):1416‐21. LanceMD , NinivaggiM , MarcusMAE , HamulyakK , vanPampusECM , tenCateH , et al. Partial pro‐hemostatic effect of transfusion of fibrinogen concentrate replacing fresh frozen plasma in massive hemorrhage. Journal of Thrombosis and Haemostasis2011;9(Suppl 2):S229. LanceMD , NinivaggiM , ScholsSEM , FeijgeMAH , OehrlSK , KuiperGJ , et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sanguinis2012;103:25‐34. ">Lance 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(22/21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(22/21)</p> <p>(but only 16/16 for primary outcome analysis).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFP</b> ( 2 units) + <b>Fibrinogen</b> (2g) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFP</b> (4 units) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine, red blood cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pre‐ and post‐transfusion ROTEM analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): cardiovascular, abdominal or spinal column</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0028" title="RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT). ClinicalTrials.gov Identifier: NCT01283321; terminated 2015 (insufficient funding to complete total projected enrolment; accessed 05.02.2018). TanakaAK , EganK , SzlamF , OgawaS , RobackJD , SreeramG , et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion2014;54(1):109‐18. [PUBMED: 23718572] ">Tanaka 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(10/10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single dose (4g) of <b>Fibrinogen</b> (RiaSTAP®) given within 30 minutes of intervention decision. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One unit of apheresis <b>platelets</b> (median volume 230 ml) within 30 minutes of intervention decision. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, plasma, cryoprecipitate and fibrinogen if triggers met</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>i) Haemostatic condition in the surgical field post‐intervention;</p> <p>ii) Haemostatic blood product use over the first 24h;</p> <p>iii) Percentage of patients with thromboembolic events at 6‐8 weeks post‐operatively;</p> <p>iv) Mortality at 6‐8 weeks post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): valve replacement or repair</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0010" title="Correction to Lancet Haematol 2017; 4: e258–71. The Lancet Haematology2017; Vol. 4, issue 6:e257. InnerhoferP , FriesD , MittermayrM , InnrhoferN , vonLangenD , HellT , et al. Reversal of trauma‐induced coagulopathy using first‐line coagulation factor concentrates or fresh frozen plasma(RETIC): a single‐centre, parallel‐group, open‐label, randomised trial. Lancet Haematololgy2017;4(6):e258–71. ">Innerhofer 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> <p>(52/48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> <p>(50/44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fibrinogen concentrate</b><br/> (50 mg/kg of bodyweight) for abnormal ROTEM fibrin<br/> polymerisation (FibA10 &lt; 9 mm) or four‐Factor PCC<br/> (20 IU/kg of bodyweight) for delayed initial thrombin<br/> formation (ExCT &gt; 90s or prothrombin time index &lt; 35%). FXIII concentrate (20 IU/kg of bodyweight) was administered with each second fibrinogen dose. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FFP</b> (15 ml/kg bodyweight). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranexamic acid 20mg/kg, FXIII concentrate (20 IU/kg of bodyweight),</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Occurrence of multiple organ failure during ICU stay as assessed by the daily SOFA score. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>* 20 of the 47 patients had a 2nd dose of 20ml of PCC: in 3 because of continued bleeding and in 17 due to INR target not being met. 3 of the 47 patients received a 3rd dose of PCC due to an unmet INR level. </p> <p>^ 3 of the 46 patients had a 2nd dose of 20 ml PCC: 1 due to a continued bleed and 2 did not reach the target INR. </p> <p>d = days; (E) = elective surgery; FFP = fresh frozen plasma; h = hours; INR = International Normalised Ratio; mins = minutes; PCC = prothrombin complex concentrate; ROTEM<sup>®</sup> = rotational thromboelastometry; TXA = tranexamic acid; (U) = urgent surgery/ treatment; wks = weeks. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Fibrinogen concentrate: therapeutic trials with active comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0012"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Factor XIII (FXIII): prophylactic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Godje-2006" target="_blank">Godje 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> <p>(25/25/ 25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> <p>(25/25/25)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infusion of Factor<b>XII</b>I1) 1250 units or2) 2500 units*immediately after administration of protamine (protamine was administered during the scheduled coronary artery bypass graft surgery)* This is the group that was included in this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b>: standard surgical and post‐operative care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine for heparin reversal</p> <p>FFP, red blood cells, platelets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Karkouti-2013" target="_blank">Karkouti 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>479</p> <p>(164/162/153)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>409</p> <p>(143/138/128)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single intravenous dose of Factor<b>XIII</b> 1) 17.5 IU/kg or2) 35 IU/kg*before the induction of anaesthesia.* This is the group that was included in this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO:</b> single dose of an unspecified placebo before the induction of anaesthesia. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine, antifibrinolytics during cardiopulmonary bypass, blood products</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percentage of patients avoiding any allogeneic transfusions within 7d or discharge home. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Korte-2009" target="_blank">Korte 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (no further details stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (no further details stated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> (30 U/kg) infused 15 minutes after the beginning of surgery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: albumin infusion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low molecular weight heparin,</p> <p>FFP, red blood cells, platelets</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clot firmness over 195 mins of surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E): gastrointestinal cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Levy-2009" target="_blank">Levy 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(10/9/8/8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(10/9/8/8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single infusion of Factor<b>XIII</b> at 4 doses:1) 11.9 units/kg;2) 25 units/kg;3) 35 units/kg*;4) 50 units/kg.* This is the group that was included in this review. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: no further details given. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protamine for heparin reversal</p> <p>FFP, red blood cells, platelets</p> <p>Cryoprecipitate, Fibrinogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incidence and severity of adverse events from intervention administration to follow‐up at 5 to 7 wks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgery (E) : cardiac</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Rasche-1982" target="_blank">Rasche 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(29/31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> <p>(29/31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> (1000 units) on day 1 of treatment and a subsequent daily dose of 500 units plus normal care protocols. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b>: normal care products </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Red blood cells, platelets, whole blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute leukaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Shirahata-1990" target="_blank">Shirahata 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> <p>(30/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> <p>(30/28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> (dose of 70 to 100 units) administered slowly for at least 10 minutes intravenously within 6 hours of delivery. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prematurity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infant population</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Factor XIII (FXIII): prophylactic trials with inactive comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0013"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Factor XIII (FXIII): therapeutic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010649-bbs2-0002" title="BregenzerN , CarsarI , AndusT , HämlingJ , MalchowH , SchreiberS , et al. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Zeitschrift fur Gastroenterologie1999;37(10):99‐104. ">Bregenzer 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> <p>(17/11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> <p>(11/9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factor<b>XIII</b> as an i.v. injection (at 3750 units on Day 0 and 1250 units on days 1 through 9) as an addition to basic steroid treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PLACEBO</b>: continuation of basic steroid treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TXA,</p> <p>platelets or FFP post‐intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to cessation of macroscopically visible intestinal bleeding within 14d of starting treatment. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ulceratice colitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adult population</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Factor XIII (FXIII): therapeutic trials with inactive comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010649-tbl-0014"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">PCC: prophylactic trials with inactive comparator</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number randomised (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number included in analyses (N = intervention/ N = comparator)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Co‐interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1609061425232344366300690364588%26format=REVMAN#STD-Turner-1981" target="_blank">Turner 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> <p>(39/39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> <p>(39/39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PCC</b> (dose of 1ml/kg or 2ml/kg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NONE</b>: normal care protocols. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin K, heparin and clotting Factors for disseminated intravascular coagulation, red blood cells </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>i) Mortality (all‐cause)</p> <p>ii) Incidence of intraventricular haemorrhage (post‐mortem)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prematurity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infant population</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">PCC: prophylactic trials with inactive comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/full#CD010649-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fibrinogen: prophylactic trials: intervention vs inactive control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to 4 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Prior to hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Arterial thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to 3 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to 4 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Up to 30 days post‐operatively in patients who have had cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Up to 30 days post‐operatively in patients who had undergone elective surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Venous thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Up to 3 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Up to day 4 post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Up to 30 days post‐operatively in patients who have had cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Up to 30 days post‐operatively in participants who had undergone elective surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality due to bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 3 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Prior to hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 RBC transfusion requirement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intra‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Up to 12 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 In peri‐operative period (unclear time‐point)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Receipt of a RBC transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Intra‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.75, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Up to 12 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.37, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 During surgery and up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.76, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Up to 48 hours post‐operatively in patients who have had cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.38, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Up to 48 hours post‐operatively in patients who have undergone elective, non‐cardiac surgery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.07, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intraoperative blood loss (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.77, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Chest tube drainage at 1 hour post operatively (ml/kg/hr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Chest tube drainage at 6 hours post‐operatively (ml/kg/hr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.76, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Chest tube drainage in first 12 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Bleeding up to 24 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Bleeding at up to 48 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Bleesing during surgery and up to 48 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Means (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.67, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Up to 2 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Up to 3 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fibrinogen: prophylactic trials: intervention vs inactive control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fibrinogen: prophylactic trials: intervention vs haemostatically active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Duration of hospital stay (whole population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Arterial thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Duration of hospital stay (whole population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Venous thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Duration of hospital stay (whole population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality due to bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Duration of hospital stay (whole population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 RBC transfusion requirement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Surgical time plus 24 hours post‐operatively ‐ Craniosynostosis (ml/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Surgical time plus 24 hours post‐operatively ‐ Scoliosis (ml/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Receipt of a RBC transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Surgical time plus 24 hours post‐operatively ‐ Craniosynostosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Surgical time plus 24 hours post‐operatively ‐ Scoliosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Up to 24 hours post‐operatively (whole population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fibrinogen: prophylactic trials: intervention vs haemostatically active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fibrinogen: therapeutic trials: intervention vs inactive control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to 28 days following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.71, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 In‐hospital mortality up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 102.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Up to 6 weeks postnatally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Up to 46 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Arterial thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 During hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to 28 days following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Up to 45 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Up to 6 weeks postnatally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Venous thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 During hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Up to 28 days following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Up to 45 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Up to 6 weeks postnatally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality due to bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 28 days following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.38, 15.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 6 weeks postnatally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Up to 46 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Receipt of a RBC transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Intraoperative: Between study medication and chest closure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Up to 3 hours following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Within 4 hours of receipt of the study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.13, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Up to 6 hours following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Up to 24 hours following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.91, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Within 24 hours of receipt of study drug in patients who have had cardiac surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.39, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Within 24 hours of receipt of study drug in women who have experienced a post‐partum haemorrhage </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Within 7 days of receipt of the study drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.58, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 From end of intervention to hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.55, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 During hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.38, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 RBC transfusion requirement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 During hospital stay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Intra‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Post‐operative (within 12 hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Intra‐ and post‐operative (within 12 hours)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Up to 24 hours from study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Up to 10 days from study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Up to 28 days following admission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Up to 30 days from study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fibrinogen: therapeutic trials: intervention vs inactive control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Fibrinogen: therapeutic trials: intervention vs haemostatically active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to 7 days post‐operatively or hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to 28 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Up to 30 days post‐operatively in patients who have undergone major elective surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Up to 30 days post‐operatively in trauma patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Arterial thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to 28 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Venous thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Up to 28 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Up to day 30 following trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality due to bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Up to day 30 following trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 RBC transfusion requirement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Receipt of a RBC transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Up to 24 hours post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Up to 24 hours following trauma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Up to 7 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Fibrinogen: therapeutic trials: intervention vs haemostatically active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">FXIII: prophylactic trials: intervention vs inactive control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to 5 to 7 weeks post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Up to 340 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Time point not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Arterial thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to 5 to 7 weeks post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Venous thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Up to 5 to 7 weeks post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Up to 30 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality due to bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to a median of 32 days from study intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Until hospital discharge</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Up to 5 to 7 weeks post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Up to 340 days post‐operatively</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 RBC transfusion requirement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 From the point of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Receipt of a RBC transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Up to 7 days post‐operatively (or discharge)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Blood loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Chest tube drainage at 8 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Chest drain volume at 12 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.63, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Chest tube drainage at 24 hours post‐operatviely (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.72, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Chest drain volume at 36 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.68, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Chest drain volume at 48 hours post‐operatively (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Chest drainage at drain removal (mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Ratio of Geometric Mean (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.32, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Unclear timepoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">FXIII: prophylactic trials: intervention vs inactive control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">FXIII: therapeutic trials: intervention vs inactive control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Timepoint not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">FXIII: therapeutic trials: intervention vs inactive control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010649-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PCC: prophylactic trials: intervention vs inactive control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Time point not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Allergic Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Timepoint not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">PCC: prophylactic trials: intervention vs inactive control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010649.pub2/references#CD010649-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010649.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010649-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010649-note-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD010649-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010649-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD010649-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010649-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010649\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010649\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010649\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010649\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010649\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PMzGcYGP&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010649.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010649.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010649.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010649.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010649.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719270163"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010649.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719270167"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010649.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de4a2fc0c9368',t:'MTc0MDcxOTI3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 